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ABSTRACT 
 
Two major issues hinder the application of microarray based gene expression profiling in 
clinical laboratories as a diagnostic or prognostic tool. The first issue is the sheer volume and 
high-dimensionality of gene expression data from microarray experiments, which require 
advanced algorithms to extract meaningful gene expression patterns that correlate with biological 
impact. The second issue is the substantial amount of variation in microarray gene expression 
data, which impairs the performance of analysis method and makes sharing or integrating 
microarray data very difficult. Variations can be introduced by all possible sources including the 
DNA microarray technology itself and the experimental procedures. Many of these variations 
have not been characterized, measured, or linked to the sources.  
In the first part of this dissertation, a decision tree learning method was demonstrated to 
perform as well as more popularly accepted classification methods in partitioning cancer samples 
with microarray data. More importantly, results demonstrate that variation introduced into 
microarray data by tissue sampling and tissue handling compromised the performance of 
classification methods.  
In the second part of this dissertation, variations introduced by the T7 based in vitro 
transcription labeling methods were investigated in detail. Results demonstrated that individual 
amplification methods significantly biased gene expression data even though the methods 
 iv
compared in this study were all derivatives of the T7 RNA polymerase based in vitro 
transcription labeling approach. Variations observed can be partially explained by the number of 
biotinylated nucleotides used for labeling and the incubation time of the in vitro transcription 
experiments. These variations can generate discordant gene expression results even using the 
same RNA samples and cannot be corrected by post experiment analysis including advanced 
normalization techniques.  
Studies in this dissertation stress the concept that experimental and analytical methods 
must work together. This dissertation also emphasizes the importance of standardizing the DNA 
microarray technology and experimental procedures in order to optimize gene expression 
analysis and create quality standards compatible with the clinical application of this technology. 
These findings should be taken into account especially when comparing data from different 
platforms, and in standardizing protocols for clinical applications in pathology. 
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PREFACE 
 
The successful application of DNA microarray based gene expression profiling in 
translational research makes it a potential tool for use in clinical laboratories for diagnostic, 
prognostic, and therapeutic applications in the era of molecular medicine. However, the DNA 
microarray must overcome two significant hurdles before it can be used use in clinical 
environment. First, the massive volume of the gene expression data from DNA microarray based 
experiments requires a set of reliable algorithms that can discover patterns of gene expression 
robustly with high sensitivity and specificity. Second, published results from many studies have 
demonstrated the existence of significant variations in the data introduced by both the technology 
itself and the experimental procedures utilized to produce gene expression data. These variations 
can significantly impair the utility of microarray data in identifying biologically meaningful gene 
expression patterns.  
This dissertation represents work over five years, a time span in which research in 
microarray data has migrated from statistical analysis of large high-dimensionality data set to the 
understanding and control of experimental data variation between platforms, laboratories, and 
experiments. For these reasons, this dissertation has two main objectives.  
The first objective is to test the usefulness of a decision-tree learning algorithm for 
classification using large high-dimensionality gene expression data sets from DNA microarray 
experiments. Results and implication of this work are discussed in Chapter II. The second 
objective is to study the experimental variation introduced by a particular RNA labeling method 
and discovery its source. Results from this study are described in Chapter IV of this dissertation. 
In addition, Chapter III reports results from an attempt to integrate gene expression data 
generated from different types of arrays at different institutions. This work contributes to our 
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overall understanding of other sources of variation in the DNA microarray technology and 
microarray based gene expression profiling experiments. 
Two other studies are included as appendixes. Appendix A is a study describing the gene 
expression patterns in different types of prostate tissue specimens, which was done in 
collaboration with others in the Becich laboratories and directly related to the theme of this 
dissertation. Appendix B is a manuscript submitted to the Intelligence System for Molecular 
Biology (ISMB) 2002 Conference as a student paper. It was presented at the conference as a 
poster. It reports the results of using decision-tree learning to detect the global gene expression 
changes in rat brain after cocaine treatment. This study was collaboration with Drs David G. 
Peter and Robert E. Ferrell from Department of Human Genetics and Dr. Vanathi 
Gopalakrishnan from the Center for Biomedical Informatics (CBMI). It also is the initial phase 
of applying the decision-tree learning algorithm on microarray data which was tested in Chapter 
II of this dissertation.      
Chapter I summarizes the background knowledge related to the results presented in 
Chapter II, III, and IV. Section 1.1 provides an overview of the DNA microarray technology and 
discusses in detail the strategies of probe design and selection used for producing the Affymetrix 
GeneChip® arrays. It will help better understand the platform-dependent strategy proposed in 
Chapter III (Section 3.3.2.2) for microarray data integration. It will also help to understand how 
gene expression intensity values from the Affymetrix GeneChip® arrays are calculated by 
various algorithms in Section 1.3.2. Section 1.2 reviews the experimental procedures of DNA 
microarray based gene expression profiling experiments. RNA labeling methods are discussed in 
detail because they are important to understand the results presented in Chapter IV. Section 1.3-
1.5 review the analysis of gene expression data from DNA microarray experiments. This 
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includes both low-level and high-level analysis, each of which involves different principles. Both 
low-level and high-level data analysis are applied for every study conducted in this dissertation. 
Finally, Section 1.5 provides a thorough discussion of experimental variation in gene 
expression data in DNA microarray based experiments. Awareness of the extreme importance of 
this topic has increased recently and many manuscripts have reported on sources of data 
variation in microarray experiments. This section provides a systematic review of the current 
understanding of the problem and the possible solutions proposed. In particular, variations 
related to RNA labeling methods, tissue sampling and handling are discussed in detail as they 
provide direct background for results in Chapter II, III, and IV respectively.  
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1. CHAPTER I Introduction 
The classical dogma of molecular biology[1] states that the genetic information stored in 
DNA flows to RNA and then from RNA to protein by means of transcription and translation 
respectively. Gene expression is the process by which genetic information at the DNA level is 
converted into functional proteins. The transcription of messenger RNA from DNA molecules is 
an important regulatory point in this process and may signal cascades of many other events. The 
complexity and abundance of the messenger RNA population in a cell or organ reflect the 
cellular events in response to the environmental changes. Therefore, the study of patterns of gene 
expression at the messenger RNA level under different physiological conditions will provide 
evidence for understanding of many biological systems and gene function.  
In general, the study of gene expression involves the comparison of mRNA populations 
between two samples taken under different conditions such as diseased versus healthy or treated 
versus untreated. In the past two decades, gene expression analysis has evolved from studying 
only one differentially expressed gene at a time to a detailed survey of the whole transcriptome. 
This rapid progress is in large part driven by the development and application of DNA 
microarray techniques.  
1.1.DNA microarray overview 
1.1.1. Overview 
What is a DNA microarray? 
A DNA microarray is a small analytical device that holds hundreds or thousands of DNA 
molecules for the simultaneous examination of fluorescently labeled samples (cRNA, cDNA, 
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 mRNA or total RNA) prepared from the messenger RNA population taken from cell cultures or 
tissue samples[2-6]. The DNA molecules on array surfaces are called ‘probes’; the fluorescently 
labeled samples are referred to as ‘targets’. Probes are manufactured in a high-density fashion on 
a small area (1.28cm × 1.28 cm for Affymetrix GeneChip® array and 3 inch × 1 inch for typical 
cDNA microarray) of a flat and solid glass surface. Probes are ordered in grid and each probe on 
an array has a unique ‘address’ (or X-Y coordinate) on a two-dimensional surface. This ensures 
the correct identification of each probe by computer-controlled robots used in microarray 
production and by software tools for data analysis purpose. Each probe is also highly specific to 
identify only one sequence in the transcriptome. DNA microarray technology allows sifting 
through and analyzing genomic information with exceptional speed and precision compared to 
other existing methods such as Northern blot analysis, differential display or serial analysis of 
gene expression(SAGE)[2-4]. 
History about the development of DNA microarray technology  
Early forms of DNA arrays were initially generated by spotting the bacterial colonies on 
filter membranes for gene identification and DNA sequencing studies. Subsequent improvements 
in laboratory automation enabled the creation of high-density filter arrays[7, 8]. Beginning in the 
1980s, many studies used the high-density filter arrays for sequencing, analyzing different gene 
expression and identifying new genes[7-14]. These arrays are, in general, entitled as 
‘macroarrays’ because of the ‘gigantic’ size (usually 8cm to 22cm in diameter) of the nylon filter 
membranes. Along with the advent of automatic high speed spotting techniques for array 
manufacture were the introductions of glass surface for hybridization by several research groups 
in the late 1980s and early 1990s[15-19]. These experiments established the feasibility of 
hybridizing on glass surface and further founded the array fabrication techniques currently in use 
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 today. In 1995, Schena et al.[4] from Stanford University Medical Center was the first to report 
the usage of cDNA microarray for quantitative monitoring of gene expression patterns. Then in 
1996, Lockhart et al.[2] at Affymetrix Inc. (Santa Clara, CA) reported, for the first time, 
expression monitoring experiments by hybridization to high-density oligonucleotide arrays. 
Since then, cDNA microarrays and oligonucleotide arrays have become the major microarray 
platforms used for gene expression profiling.  Based on a database analysis of 2,000 microarray 
citations from 1995 to 2002[3], 65% of all the publications based on DNA microarrays 
experiments used cDNA microarrays and 26% of them applied oligonucleotide microarrays in 
their studies. In addition, 81.5% of microarray publications are for gene expression analysis. 
Type of DNA microarrays 
One major difference between cDNA and oligonucleotide microarrays is the type of 
DNA probe utilized. Probes on cDNA microarrays are typically 500~2500bp double-strand 
cDNAs produced by PCR amplification of cDNA libraries[3-5, 20]. In contrast, probes on 
oligonucleotide microarrays are single-strand 20~90 nucleotide molecules synthesized in vitro. 
In addition, microarrays can also be categorized based on array fabrication methods. For spotted 
arrays, DNA probes are mechanically deposited on the array surface[3-5, 20-26]. For in situ 
arrays, probes are synthesized in silico[2, 3, 6, 21, 22, 27-29], such as the GeneChip® arrays 
manufactured by Affymetrix Inc.. (Santa Clara, CA) DNA microarrays may also be categorized 
as one- or two-channel format where the difference is at the number of dyes used to label targets. 
For a DNA microarray using two dyes, two channels are needed in the image acquisition devices 
to gather signal from each dye.  
To date many species have been studied by microarray based experiments. Among all 
publications on microarrays from 1995 to 2002, more than half of microarray publications are 
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 from studies on human. Other popular species are mouse, yeast, and rat with decedent order of 
publications. E. coli, Arabidopsis, fruit fly, and C. elegans together account for 11.2% of all 
these publications. Other microarray-available species are zebra fish, B. subtilis, bovine, maize, 
P. aeruginosa, Plasmodium, Procine, S. aureus, soybean, sugar cane, wheat, Xenopus laevis etc. 
In theory, any organism/species can be studied by microarray; this is an attractive feature of 
microarray technology[3]. 
Applications  
DNA microarray based gene expression profiling has been widely applied to all kinds of 
research involving gene expression profiling. The use of this technology for non-human species 
is focused on gene function, development and expression survey of the whole genome[29-31]. 
The most common use of microarrays is gene expression profiling of human specimens and, 
among those, the most popular application is gene expression profiling of human cancers. Many 
studies have presented results on discovery of gene functions, drug targets, pathway dissection, 
etc… More importantly, DNA microarray base gene expression profiling has been successfully 
applied in clinical research on the classification of clinical samples, discovery of subclasses of 
disease, and prediction of disease outcome and patient survival (also see Section 1.4.3 and 
Section 104.4)[32-40].  
Other types of microarray 
In addition to DNA microarrays, other types of microarrays have also been developed 
more recently for high-throughput profiling other types of molecules or biological systems. 
Among these, tissue microarray is worthy to be summarized. 
Tissue microarray (TMA) technology[41] is used for high-throughput in-situ tissue 
analysis including immunohistochemistry (IHC), fluorescence in situ hybridization (FISH), 
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 mRNA in situ hybridization (mRNA ISH). A tissue microarray contains up to thousands of 
different tissue samples aligned in grid on a microscope glass slide.  Each tissue sample on a 
TMA is usually 0.1 to 0.6mm in diameter; adjacent tissue samples are 0.1mm apart[41, 42]. 
Tissue samples on a TMA are from representative regions of original tissue samples fixed by 
formalin and embedded in paraffin blocks or fixed by cold ethanol and embedded in Tissue 
Tek® O.C.T.™ compound for preserving intact DNA and RNA[43]. As pointed out by Simon et 
al.[42], the process of making a TMA involves handling many tissue specimens as well as 
associated data. These include the identification of relevant samples from a tissue bank, the 
collection of glass slides for selected cases, the selection of morphologically representative area 
on slides, the collection of paraffin blocks of the selected cases and the storage of histological 
and clinical information of selected cases. TMAs can be constructed manually or using semi-
automated devices with two needles. One needle punches a hole, 0.1 to 0.6mm in diameter, on 
the ‘recipient’ paraffin block at a specific coordinate. The other needle with inner diameter of 0.1 
to 0.6mm retrieves tissue samples from the selected region on the ‘donor’ paraffin embedded 
tissue specimen and then precisely arrays the core biopsy in the pre-made hole. A ‘donor’ tissue 
specimen can provide many tissue biopsies with negligible damage. A recipient paraffin block 
can hold hundreds, up to thousands of core tissues. Glass slides containing very large number of 
tissue samples are made from consecutive sections cut from the ‘recipient’ block, and are hence 
called tissue microarrays or TMAs. 
  There are many advantages of using TMAs. The key advantage is that molecular markers 
can be examined in the context of tissue morphology. TMA technology provides a platform to 
detect DNA, RNA, or protein targets on a large number of different tissue types using uniform 
methodologies and interpretation criteria. As the original tissue specimens remain intact, TMA 
5 
 allows intensive studying small tissue specimens as well as preserve precious tissues for future 
investigations. TMAs also allow possible automated analysis of arrayed tissue samples as each of 
them has relatively precise position on a TMA[42, 44]. 
Although TMAs can be used for any types of in situ tissue analysis, TMAs have been 
utilized mainly in cancer research. Applications of TMAs have been very well reviewed with 
great details by Simon et al.[42, 44] and summarized as follows. TMAs can be constructed to 
include tissue samples from multiple tumor types. This type of TMAs has been utilized to 
evaluate the prevalence of markers in different types of tumors. TMAs can contain different 
stages of a particular type of tumor for studying tumor progression and detect associations 
between tumor phenotype and genotype. There are also TMAs containing tumor tissue samples 
with clinical follow-up data for studying cancer prognosis and reveal association between genetic 
alteration and clinical outcome[45]. 
1.1.2. DNA microarray fabrication 
1.1.2.1. Overview  
DNA microarrays are fabricated by various techniques including techniques for in situ 
synthesis of oligo-nucleotide on an array surface[2, 6, 15, 27, 28, 46-48] and techniques for 
spotting pre-synthesized probes onto array surfaces[3, 4, 23, 25]. DNA microarrays created by in 
situ methods, such as GeneChip® arrays from Affymetrix Inc., are only available commercially. 
Spotted DNA microarrays are commercially available but also can be manufactured at 
microarray facilities in academic centers such as the Brown’s lab at Stanford University 
(http://brownlab.stanford.edu/).  
Microarray fabrication begins with the selection of a panel of appropriate probes that will 
be attached on the array surface. Two types of probes are currently in use for DNA microarray 
6 
 based gene expression profiling: cDNA probes and oligonucleotide probes. There are two 
approaches to prepare probes for DNA microarray manufacture: (1) cDNA probes and 
oligonucleotide probes can be prepared beforehand and then delivered onto the array surface; (2) 
Oligonucleotide probes can be synthesized in situ during array manufacture (refers to the in situ 
synthesis mentioned above). Accordingly, tasks related to probe preparation also vary. The major 
tasks in probe preparations include design, selection, and annotation of probes. Figure 1.1 
outlines the major steps/tasks for probe preparation based on probe type.  
Oligonucleotide probes may be synthesized in situ or fabricated prior array construction 
(Figure 1.1a). Either way, sequence information is required to design and prepare 
oligonucleotide probes. Since the recent completion of sequencing the whole genomes of human 
and other species[30, 31, 49], the availability of sequence information is no longer a factor that 
limits the production of oligonucleotide arrays. Probes are selected from established sequence 
databases, such as UniGene[50] and TIGR Gene Indices[51]. After a region on the sequence of a 
transcript is selected as a potential probe to represent the transcript on a microarray, this region 
needs to be validated by comparing it with all sequences, if available, in the transcriptome of the 
studied organism to minimize cross-hybridization using sequence similarity algorithms such as 
global BLAST. If the region is not unique enough to identify single transcript in the 
transcriptome, it is dropped and another region in the sequence of the same transcript may be 
selected and evaluated using the same strategy until a unique region is identified. Once probes 
are selected, precursors are prepared for microarray construction in situ, or probes are prepared 
using classical phosphoramidite chemistry[3, 52, 53] and purified before delivering to the array 
surface(Figure 1.1a).  
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Figure 1.1 Schematic of probe perpetration workflow for Oligonucleotide microarrays (a) and cDNA 
microarrays (b). 
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 cDNA probes are obtained by purifying PCR products of cDNA clones (Figure 1.1 b). In 
contrast to oligonucleotide probes, the availability of sequence information is not a prerequisite 
for cDNA probe preparation. cDNA clones usually can be obtained as pre-constructed, validated, 
and annotated clone sets from academic and commercial resources. Under certain circumstances, 
such as the lack of clone sets for the organism of interest, a cDNA library may need to be 
prepared from a specific cell type or tissue[54]. Before cDNA clones can be used for cDNA 
probe amplification by PCR, each individual clone in the library needs to be sequenced to verify 
the sequence itself and avoid possible redundancy. cDNA clones are selected to represent as 
many unique transcripts as possible to produce arrays with low redundancy of transcript 
representation to survey the broadest possible set of genes. 
1.1.2.2. Affymetrix strategies for probe design and selection 
Affymetrix has unique proprietary ways to design and selection probes for gene 
expression analysis. (Please refer to Lipshutz et al.[6] for a graphical illustration.) This design 
strategy determines that hybridization results using Affymetrix GeneChip® arrays need to be 
analyzed by specially designed algorithms (discussed in Section 1.3.2). On the other hand, this 
strategy provide means by which platform-dependent integration approach can be developed as 
presented Chapter III for the integration of microarray gene expression data from different 
generations of the Affymetrix GeneChip® arrays.  
When selecting probes from sequence databases, a set of heuristic rules and/or model-based 
approach is applied to identify candidate sequences as probes. Significantly, redundancy is 
applied to every single transcript surveyed by the array[2, 6, 29, 55, 56]. Multiple probes (11~20) 
are used for each transcript. This redundant set of probes is called a “probe set”. These 
approaches lead to the current set of GeneChip® arrays for gene expression analysis[6].
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 Probe redundancy 
A set of probes, named a “probe set,” is used to represent one transcript. A probe set 
comprises 11 to 20 independent pairs of probes/oligonucleotides. Each probe matches to a 
sequence region of the transcript with minimum, if not, overlapping to other probe sets. In the 
Affymetrix design, each probe is actually implemented as a probe pair. A probe pair consists of a 
perfect match probe (PM) and a miss match probe (MM) and both PM and MM probes are 25-
mer in length. The PM probe is 100% complementary to target sequence; the MM probe, on the 
other hand, has a single mismatch at the 13th base. Therefore, the only difference between PM 
and MM sequence is in the central position of the sequence[2, 6, 29, 55, 56].  
To summarize, in the Affymetrix GeneChip® arrays, redundancy is present at two levels: 
(1) the use of multiple oligonucleotides with different sequences (a probe set) to hybridize on 
different regions of a single transcript, (2) the use of MM probes in addition to the PM probe. 
These redundancies may offer advantages in the context of gene expression detection. When 
multiple oligonucleotides are used for the same transcript, the signal is derived by taking an 
average of the set of individual hybridization signal from each oligonucleotide. This may provide 
a better signal, decrease the signal-to-noise ratio, and increase accuracy for RNA quantitation. 
MM probes can be used as a control for cross-hybridization and non-specific hybridization. 
When calculating intensity value for a target, intensity values from MM probes in its probe set 
will be subtracted. At low concentration of a target, hybridization to the PM and MM probe pair 
will help to distinguish true signal with background/noise, i.e. whether the signal is generated by 
hybridizing the right target on its probe set or from non-specific hybridization of any type[6]. 
Probe selection rules 
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 Each probe set representing a transcript is selected from 3’ end sequence region of its 
intended target. For example, regardless the length of the transcripts, the maximum distance of 
the 5’-most probe pair to the 3’ end of the transcript on the HG-U95Av2 array and HG-U133 set 
is about 600 base pair. This 3’-biased probe selection strategy ensures maximum number of 
targets are available for detection even when mRNA have been partially degraded because 
mRNA degradation usually starts from the 5’ end. Uniqueness of probes is assessed by 
comparing the candidate probe sequence first to all probes on the array and then to the full-length 
sequences of all transcripts in the surveyed species, if available. Probes were rejected if there 
were 22 or more base positions matched. Further selection is based on the performance of probes 
in hybridization experiments. A set of heuristic rules have been developed for probe set selection 
based on probe behavior as a function of certain sequence features[2]. Neural network algorithms 
are then used to assess probe characteristics. At the last step, probes were rejected if more than 
60 synthesis steps are needed to help minimize synthesis time and cost[2, 29].  
1.2.DNA microarray based gene expression profiling 
1.2.1. Experimental procedure 
The experimental procedure of a gene expression profiling study using DNA microarrays is 
summarized as follows (Figure 1.2 a). The first step in such a study is to identify the sources of 
RNA. This is usually done while designing the study and the source is determined by the study 
objectives. Most common sources of RNA are either cell cultures or tissue specimens from 
experiment animals or patients. Experiments start from collecting RNA samples by extracting 
them from the RNA sources. Targets are then prepared by labeling RNA samples with 
fluorescent dyes using different methods. Some RNA labeling methods also amplify RNA 
samples at the same time. At the hybridization step, each labeled nucleotide acid molecule 
11 
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(mRNA, cRNA, or cDNA) in targets hybridizes with a probe complementary to its sequence on 
the array surface and forms a probe-target hybrid. Depending on the type of DNA microarray, 
two targets from different sources can hybridize on one array or on two separated arrays. 
Fluorescent dyes on each probe-target hybrid glow when stimulating the array surface with light. 
The intensity of emission from each hybrid is proportional to the relative abundance of an 
expressed transcript. Florescent emissions are captured by optical devices, converted to digital 
signal, and saved in an image file. Signal intensities stored in image files can be transformed to 
numerical intensity values for every probe on the array by appropriate algorithms. 
 (a) experimental procedure starting from identifying the RNA sources and all the way to data analysis, (b) the possible sources of 
variation identified at each step of the experimental procedure, (c) data analysis including low-level and high level analysis.  
Figure 1.2 Schematic of the experimental procedures, data analysis and sources of variation in gene expression profiling using DNA microarrays.  
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 1.2.2. RNA quality 
The primary target for gene expression analysis is mRNA derived from cell cultures or 
tissue samples. The quality of RNA from these samples will determine the quality of the ultimate 
gene expression data from DNA microarray hybridization. Alternatively, the quality of RNA 
samples is determined by multiple factors in the tissue acquisition and storage procedures 
discussed in Section 1.5.3.1 and 1.5.3.2. There are several factors that affect RNA quality in the 
target preparation and labeling process worthy of discussion here. RNA is not stable and 
RNAases exist in abundance in cells and in laboratory environments, which may cause the 
degradation of RNA samples. Therefore, RNA samples should be handled with great caution. 
RNA samples should be purified before target preparation and labeling process to remove 
proteins, DNAs, etc… In addition, phenol which is a reagent used commonly for RNA 
purification should be removed as it interferes the labeling efficiency of cyanine fluorescent 
dyes[57]. 
RNA purity is usually checked by a UV spectrometer. RNA with good purity should have 
an OD 260/OD 280 ratio above 1.8. 260nm and 280nm are the wavelengths at which the 
absorbance of the RNA recorded. If RNA is contaminated with proteins, the ratio will be lower 
than 1.8. RNA quality can be accessed by electrophoresis on an agarose gel and recently by a 
Bioanalyzer from Agilent (Foster City, CA). Good-quality RNA on a Bioanalyzer output should 
have smooth baselines with no increase of small molecular weight fragments. The 28s and 18s 
(for eukaryotic RNA samples) rRNA ratios should be between 1.5 and 2.0. 
1.2.3. Target preparation and labeling 
This section describes the approaches to prepare targets from purified, high-quality RNA 
samples for DNA microarray hybridization. After hybridization of targets with their 
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 corresponding probes on a DNA microarray, a reporting system is needed to signal the detection 
of a target and the intensity of the hybridization. Therefore, like conventional Northern and 
Southern blots, targets are labeled for signal detection purpose. According to Schena [3] there are 
two major approaches for target labeling: (1) direct labeling where labeling tags are attached in a 
covalent manner directly to the target molecule using a enzymatic or chemical means; (2) 
indirect labeling in which labeling tags are attached in non-covalent and indirect way to the 
target molecule using dendrimers, antibodies or some other reagent. Because of recent 
improvement in labeling techniques, mRNA can also be directly labeled without “transferred” to 
cDNA or cRNA[58, 59].  
For DNA microarray based experiments, the most popularly used labeling reagents are 
various kinds of fluorescent reagents although there are other types of labeling reagents used. 
Fluorescent reagents can be used for both direct and indirect labeling. Most commonly used 
fluorescent reagents are cyanines including Cy3 and Cy5, and phycoerythrin (PE)[3].  
In addition to labeling, target mRNA may be converted to cDNAs or cRNA for several 
reasons: (1) labeling can be introduced during the conversion, (2) cDNA is more stable than 
mRNA and therefore it is easy to handle and store than mRNA, (3) the process of obtaining 
cDNA and cRNA involves mRNA amplification that provides means to obtain enough targets 
from minute amounts of mRNA.  
To generate good quality array data, a typical microarray experiment requires 5~20 
micrograms of labeled targets which correspond to milligrams of tissues or approximately 
106~107 cells from cell cultures[2, 4]. This requirement limits the use of microarray based gene 
expression analysis as most clinical tissue samples, for example biopsies and tissues from laser 
capture microdissection (LCM), are too small to provide enough starting materials. Therefore, 
15 
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enzymatic amplification methods have been applied to generate abundant targets for 
hybridization from limited amount of starting material[60-64]. 
In the following sections, target labeling and/or target amplification methods will be 
discussed. Table 1.1 summarizes these methods based on the amount of total RNA needed, 
signal amplification or target amplification, popular dyes used, array platform used, time and 
work intensity. For a graphical illustration of each method please refer to Richter et al.[65]. 
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Table 1.1 Comparison of target labeling methods. 
 
 
 Reverse Transcription 
RT with 
aminoallyl 
T7 RNA 
polymerase 
based in vitro 
transcription 
SMART PCR Dendrimer  TSA 
Direct labeling of 
mRNA 
(1) by Cole et al. 
(2) by Gupta et al. 
Start amount of 
total RNA 10~15 µg      10~15 µg 0.01~15µg 0.05~1 µg 1µg 0.5~2µg 10~15 µg 
Sequence sense Anti-sense  Sense
Probe sense Sense  Antisense
Signal 
amplification Yes.  No
Target 
amplification 
No 
Yes. Through 
passive target 
amplification 
Yes. Through 
passive target 
amplification No  Yes
Array platform 
used 
Affymetrix, 
Oligo, cDNA 
Oligo, 
cDNA 
Affymetrix, 
Oligo, cDNA cDNA arrays 
cDNA 
arrays 
cDNA 
arrays 
Affymetrix, 
cDNA array 
Time (hours) Several hours (4) 
Several 
hours  
(9) 
Several days Several hours (4) 
Several 
hours 
(6) 
Several 
hours  
(9) 
2 hours for (1) 
under 1hour for (2) 
Work intensity Low       medium High low low High low
RT: reverse transcription;  
TSA: tyramide signal amplification; 
 
 1.2.3.1. Labeling with reverse transcription (RT) 
The basic RT approach is as follows. An oligo-dT primer is used to hybridize with 
mRNA which serves as the template for RT. cDNA is reversely transcribed from mRNA by 
incorporating deoxynucleotides base-by-base, some of which are covalently linked by a 
fluorescent reagent, with reverse transcriptase[3, 66]. Therefore, in the cDNA sequences 
produced there are nucleotides labeled with fluorescent dyes. After RT, the mRNA or total RNA 
templates are degraded and cDNAs are then purified. Both mRNA and total RNA can be used 
for RT reaction, but only the mRNA molecules in a total RNA sample is reverse transcribed 
because of the primer. Random primers are used when reverse transcribing prokaryotic RNA 
samples or RNA without poly-A tails. Reverse transcription of mRNA was the first labeling 
method used in DNA microarray based gene expression analysis[2, 4]. It is also a simple and 
effective approach. Furthermore, many different types of fluorescent reagents can be used for 
labeling with reverse transcription.  
Aminoallyl nucleotide analogs have been developed recently for direct labeling using 
reverse transcription [3, 28, 67]. An aminoallyl nucleotide has aliphatic primary amine group 
which is subsequently labeled with an amine-reactive fluorescent dye. The labeling is 
accomplished in two steps. First, the aminoallyl nucleotide analogs are incorporated through 
reverse transcription. Then the amine-reactive fluorescent dye reacts with aminoallyl group of 
nucleotide incorporated to form covalent bounds. Compared to fluorescently labeled nucleotides, 
aminoallyl nucleotide analogs have higher incorporation rates because of its small size and 
therefore more effective labeling can be achieved.  
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 1.2.3.2. Labeling with T7 RNA polymerase based in vitro transcription 
 
The T7 RNA polymerase based in vitro linear amplification assay makes single stranded 
cRNAs that is antisense to the corresponding mRNA molecule by a multi-step enzymatic 
reaction [60, 61, 63]. An RNA polymerase promoter is integrated into 5’ end of each cDNA 
molecule by reversely transcribing mRNAs with a chimeric primer composed of oligo (dT) with 
the bacteriophage T7 RNA polymerase promoter. The 2nd strand of cDNA is then synthesized 
using the 1st as a template. Once double stranded, the T7 RNA polymerase promoter region 
becomes functional. The ds-cDNA molecules subsequently serve as the template for in vitro 
transcription of the single stranded antisense complementary RNA molecules by T7 RNA 
polymerase. Biotinylated labeled NTP molecules are introduced at this step. The degree of 
amplification depends upon the enzyme concentration and incubation time[61]. In a typical 
application of this method, more than 30 µg of cRNA can be generated from as little as 1µg of 
total RNA using an overnight incubation. When only minute amounts (less than 100ng) of total 
RNA are available, this method is modified to include an additional cycle of reverse transcription 
and in vitro transcription after the first in vitro transcription reaction in order to produce enough 
cRNA targets[60, 63]. Aminoallyl nucleotide analogs have also been used recently for direct 
labeling with the T7 RNA polymerase based in vitro amplification[68]. 
Fidelity and linearity of the approach have been well documented (Section 1.5.4). This 
approach provides a solution for the problem of insufficient amount of target mRNAs for 
microarray hybridization. However, this approach is quite time consuming and several studies 
have shown systematic biases introduced by this approach[64, 69, 70]. More details on 
comparisons studies of labeling approaches will be summarized and discussed in Section 1.5.4. 
The variations introduced by this method have also been investigated thoroughly in Chapter IV.   
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 1.2.3.3. Labeling with SMART™ PCR amplification 
 
Polymerase chain reaction provides a way to amplify bulk amount of nucleic acids from 
minute amount of starting material. However, the nature of PCR limits its use in target 
preparation for microarray based gene expression experiments. PCR amplification is exponential 
where short templates are amplified more efficiently than long templates and therefore will 
distort the abundance and complexity in the mRNA population studied[64]. Nevertheless, there 
are several studies used a modified version of PCR amplification, SMART™ PCR or template 
switch PCR (TS-PCR), for target amplification and labeling in microarray gene expression 
experiments[62, 64, 71]. Based on the report from Petalitis et al.[62], SMART™ PCR provides 
better linearity compared with traditional PCR and increase the sensitivity of microarray 
experiments by allowing the detection of more transcripts which are below the detection 
concentration using direct labeling. Saghizadeh et al.[71] showed SMART™ PCR and IVT 
amplification are comparable in reproducibility and reliability by comparing gene expression 
data from the two approaches to data form total RNA and mRNA. However, a comparison study 
of SMART™ PCR and the T7 based amplification method by Puskás et al.[64] demonstrated that 
gene expression data from the T7 based method had better correlation with nonamplified (labeled 
by RT reaction) data than data from SMART™ PCR even though, both approaches gave highly 
reproducible data. Nonetheless, PCR amplification methods have not been accepted as a safe, 
reliable target labeling and amplification approach. 
1.2.3.4. Tyramide signal amplification  
 
Indirect labeling using tyramide signal amplification (TSA) employs antibody-antigen 
binding and enzymatic reactions to label array spots of target-probe hybrids. Labeling with TSA 
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 labels target-probe hybrid and therefore labeling event takes place after hybridization. In 
addition, TSA labeling generates highly reactive fluorescent dyes which then couples with the 
array surface. Two components are critical to this assay: hapten (usually biotin) modified 
nucleotides and horseradish peroxidase (HRP) conjugated antibody (streptavidin). cDNA are 
incorporated with hapten modified nucleotides by reverse transcription of mRNA/total RNA and 
then hybridized on the array. After hybridization, the array is incubated with HRP conjugated 
antibodies, which bind to haptens on the target-probe hybrids. The binding of antigen and hapten 
brings HRP close to the array surface. The array is then incubated with hydrogen peroxide 
(H2O2) which is used by HRP to oxidize tyramide linked fluorescent reagents such as Cy5-
tyramide. Oxidized tyramide fluorescent reagents are highly reactive and can rapidly attach to 
the array surface. Therefore, at only the spots where hybridization takes place, fluorescent dyes 
will be incorporated[3, 65, 72].  
TSA approach amplifies fluorescent signal rather than the target. The advantage of using 
TSA compared to using the reverse transcription method is that it can provide hundred fold 
signal amplification and therefore minimizing the usage of precious RNA samples[3, 72]. One 
drawback of this protocol is that it is a little time consuming compared to other methods[3].  
Biotin labeling 
It is worthwhile to reveal the mechanism of biotin labeling approach which is adopted by 
several oligonucleotide platforms such as Affymetrix GeneChip® arrays[2] and CodeLink 
BioArray [25, 73] for gene expression from GE Healthcare. The biotin labeling method is similar 
to TSA as it also uses antigen and antibody binding (biotin and streptavidin) to link fluorescent 
dyes to the target-probe hybrids but there is no enzymatic reaction needed for the biotin labeling 
approach. Streptavidin molecules are coupled with fluorescent dyes, phycoerythrin (PE) for 
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 GeneChip® arrays and Cy5 for CodeLink bioarrays, and therefore the labeling is done once the 
antibody and antigen binds.  
1.2.3.5. Labeling with dendrimer 
 
A dendrimer is a complex nucleic acid structure created by specific annealing of multiple 
nucleotide oligomers together to form a highly-branched structure[65, 74-76]. When use for 
labeling in microarray experiments, some branches can be labeled with fluorescent reagents, 
other branches tagged with a specific sequence tag. 
The indirect labeling approach using dendrimer works as follows. At reverse transcription, 
a chimeric primer is use, which contains both the poly-dT primer sequence and a small piece of 
sequence called “capture sequence”. This capture sequence is integrated to the 5’ end of cDNA 
molecule. (The capture sequence is complementary to the aforementioned sequence tag in some 
dendrimer branches.) cDNA targets are then hybridized on the array. cDNA are incorporated 
with hapten modified nucleotides by reverse transcription of mRNA/total RNA and then 
hybridized on the array. After hybridization, the array is incubated with the dendrimer. The 
sequence tag on a dendrimer hybridize with the capture sequence at each target-probe hybrid and 
the fluorescent labels on the dendrimer will be used to report the target-probe hybridization[3, 
65, 76]. 
The advantage of dendrimer approach is that each dendrimer can carry hundreds (up to 
350) of fluorescent labels. Small amount of target molecules (as low as 1 µg) at hybridization 
will provide enough signal for detection with high signal-to-noise ratio. Labeling process does 
not depend on the incorporation of fluorescent dNTP in a RT or IVT reaction and therefore the 
labeling can be robust[3, 65, 76].  
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 1.2.3.6. Direct labeling of RNA 
 
There are labeling approaches developed to label RNA molecules directly without 
amplification or conversion in the second example. Two methods are worthy of discussion. 
Direct labeling of RNA with multiple biotins has recently been proposed by Cole et al. 
from Affymetrix Inc. (Santa Clara, CA)[58]. This approach uses T4 RNA ligase to attach a 3’-
biotinylated donor molecule to the target RNA[58]. mRNA targets are reverse transcribe to 
cDNA and then converted to cRNA by in vitro transcription without amplification. cRNA are 
then fragmented to small pieces, 50~200bp, and dephosphorylated to expose 3’-hydroxyl groups. 
T4 RNA ligase is then used to catalyze the addition of the biotinylated donor molecules to 3’-end 
of the fragmented cRNAs. This approach labels fragmented cRNAs uniformly and therefore can 
avoid any bias from sequence dependent incorporation. Gene expression data from this method 
has 90% agreement with data from T7 based labeling approach when studying gene expression in 
AML vs. ALL indicating its acceptable sensitivity for detecting differentially expressed 
transcripts[58]. 
Direct labeling of RNA with platinum-linked cyanine dyes was reported by Gupta et 
al.[59]. In this approach, the mRNA molecules are labeled in the total RNA by a single-step non-
enzymatic reaction. Platinum is attached with cyanine fluorescent reagents. The platinum reagent 
can react with the N7 of guanine (G) residues in a RNA sequence to form a stable coordinate 
bond[59]. The stability of the RNA molecule and its hybridization ability is not be affected by 
labeling.[59] By comparing to gene expression data from labeling with regular reverse 
transcription approach, Gupta et al.[59] demonstrated the high precision and low error for gene 
expression analysis. 
23 
 The advantage of direct labeling of RNA is that it does not require any amplification and 
has only minor enzymatic manipulations. The integrity of the RNA sample is maximally 
preserved and the labeling procedure is much simplified. In addition, the direct labeling of RNA 
is quite fast. On the other hand, the direct labeling of RNA requires large amount of RNA and 
therefore may not be realistic for studies using low volume or rare tissue samples[58, 59]. One 
important note is that targets from direct labeling of RNA approaches are sense sequences in 
reference to mRNA, i.e. the same sequence as mRNA, and therefore the DNA microarrays need 
to be constructed to contain antisense probes[58, 59].  
1.2.4. Hybridization, detection and image acquisition 
There are two major ways to perform hybridization experiments (Figure 1.2a). A target can 
hybridize on one DNA microarray alone or two targets of different origin can co-hybridize on 
the same DNA microarrays. When using co-hybridization, targets are typically prepared from 
RNA taken from either cell cultures under different conditions or two different tissue samples 
and the same transcripts/genes from the two targets will compete for probe binding on the DNA 
microarray. Therefore, targets need to be labeled with two different fluorescent reagents so that 
binding of transcripts from each target can be distinguished at each spot. For a transcript/gene, 
depending on the amount of the two targets, the hybridized spot will show mixed color. Co-
hybridization usually is used on spotted arrays; the most popular pair of fluorescent dyes is Cy3 
and Cy5. On the other hand, if hybridization is done one target per DNA microarray, targets can 
be labeled and prepared with an appropriate approach and the comparison of two samples is 
conducted afterwards using intensity data from the two DNA arrays. 
Hybridization of targets with probes on DNA microarrays typically takes place at certain 
temperature and requires a certain amount of time to ensure hybridization reactions approach 
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 equilibrium. A closed environment is needed to retain the hybridization solutions on the array 
surface. Affymetrix GeneChip® arrays use a closed plastic chamber; other DNA microarrays 
made on microscopic glass may need a lid with sealed edges to cover the array surface. 
Depending on the types of labeling approaches, extra work may be needed after hybridization 
process. For example, if targets were prepared using Dendrimer or TSA approaches, the actual 
labeling takes place after hybridization[3, 66, 72, 74]. Once all steps have been completed, DNA 
microarrays are subject to scanning and image acquisition.  
Hybridization signals are generated by using light to stimulate the emission of the 
fluorescent dyes. Light from a lamp with certain wavelength shires on the array surface and 
causes the fluorescent dyes at each feature/spot to emit. The amount of emission is determined 
by the amount of fluorescent dyes bound, which is correlated with the amount of targets-probe 
hybrids at the site. If co-hybridization takes place, two wavelengths are needed to stimulate 
emissions of the two different fluorescent dyes. The emission is passed through emission filters 
and captured by a charge-coupled devise (CCD) camera. A scanner walks through the entire 
array surface with precise positioning to capture the signal feature-by-feature. Signals will be 
stored in image files. Therefore, image files are the first set/level of data generated from 
microarray experiments. For Affymetrix GeneChip® arrays, the image files have “.dat” 
extension. For cDNA arrays, the images files are usually in TIFF format.  
1.2.5. Background subtraction and intensity calculation 
Images must be analyzed to identify the arrayed spots and to measure the relative 
fluorescent intensities for each element. Most scanners or array platforms provide software 
packages to handle image processing. Image processing involves three steps. First each spots or 
features must be identified and distinguished from noises and backgrounds on the array which 
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 may be due to target precipitation contaminants (dust, etc.), or hybridization artifacts. The 
background needs to be calculated locally and then eliminated from each spot or element. 
Followed by determination of local background, the background-subtracted hybridization 
intensity for each spot or element must be calculated.  
For cDNA microarrays, there are two major ways regarding the calculation of intensities: 
either using the mean or the median intensity for each spot[3, 5, 77]. The intensity values will be 
used for normalization and expression ratio calculation that will be discussed in Section 1.3.1. 
For Affymetrix GeneChip® arrays, the fluorescent intensity at each probe cell is calculated in 
several steps. First, a grid is applied to the array image. This grid divides the image into many 
probe cells. Each probe cell covers an area, measured by pixels, on the image file. Then, pixels at 
borders are eliminated from intensity calculation as background. The distributions of intensities 
from remaining pixels in a probe cell are plotted and the intensity value at 75% is used to 
represent the average intensity of this probe cell. Average intensity is calculated for each probe 
cell in the image. The resulted average intensities are stored in a text file with “.cel” extension. 
This file is then used for probe-level analysis and normalization to generate gene expression 
value for each gene on the array [78]. 
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 1.3.Low-level data analysis 
Data analysis includes both low-level data analysis and high-level data analysis (Figure 
1.2c) When analyzing a microarray data set, low-level analysis is performed first. The purpose of 
low-level data analysis or normalization is to adjust for any bias which arises from variation in 
the microarray technology rather than from biological differences between the RNA samples or 
the printed probes. 
1.3.1. Low-level data analysis for cDNA microarrays 
For cDNA microarrays, after image processing, it is necessary to normalize the relative 
fluorescent intensities in each of the two channels and normalize across arrays. Normalization 
adjusts for variations in labeling and detection efficiencies for the fluorescent labels and for 
possible variations in initial RNA. It is well known that Cy3 and Cy5 have different 
incorporation rates[79]. Three normalization methods are popularly used[3, 77, 79]. All methods 
assume that most of genes in the array, some subsets of genes, or a set of exogenous genes 
spiked into the RNA before labeling should have an average expression ratio equal to one.  
The first normalization method simply uses the total measured fluorescence intensity on an 
array. The assumptions are: (1) equal amounts of two samples were hybridized on the array; (2) 
the overall intensity across all spots in the array should be equal for two channels. Under these 
assumptions, a normalization factor can be calculated and then used to scale the intensity for 
each spot in the array.  
The second approach uses linear regression techniques. For closely related samples, the 
expression levels of many genes are assumed constant across samples. Therefore, a scatter plot 
of measured intensities from Cy3 and Cy5 should have a theoretical slope of one. Under this 
assumption, regression techniques can be used to compute the real slope and adjust it to one. 
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 Usually, in many experiments, the measurements are not linear. Under this circumstance, local 
regression techniques can be used such as LOWESS regression (Locally Weighted Scatter plot 
Smoothing regression)[79, 80]. 
The last approach, developed by Chen et al.[81], relies on the assumption that intensities of 
a subset of house keeping genes have constant mean values and standard deviation independent 
of samples. The measured Cy5 to Cy3 ratio for these genes can be modeled and adjusted to one. 
In Chen et al. study[81], the authors developed an iterative procedure to perform normalization 
using this approach. 
After normalization, the data for each gene is reported as expression ratio of the two 
samples hybridized on the same cDNA array and ratios are usually in log scale. This ratio for 
each gene is simply calculated by dividing the normalized intensity from one channel with its 
normalized value from the other channel. Expression ratios will be used for high-level analysis 
for class discovery, class comparison, or cancer classification and/or predication. 
1.3.2. Low-level data analysis for Affymetrix GeneChip® arrays 
1.3.2.1. Probe level analysis  
 
As discussed in Section 1.1.2.3, Affymetrix GeneChip® arrays for gene expression apply 
a unique probe design. A transcript is represented by a set of probe pairs (11 pairs or 20 pairs) 
and each pair of probes contains a perfect match (PM) probe and a mismatch (MM) probe. Both 
PM and MM probes are 25mers oligonucleotides. The PM probes complement exactly to the 
corresponding transcript sequences; the MM probe has a mismatch nucleotide at the 13th 
position. When measuring gene expression, each probe will give an intensity measurement 
corresponding to the hybridization between the probe itself and the targeted sequences in the 
hybridization solutions. Therefore, analysis of gene expression data from Affymetrix 
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 GeneChip® arrays should start at the probe level in order to yield a single numerical value for a 
transcript by summarizing the intensity values from all probes in the probe set for this transcript. 
There are three algorithms used popularly to perform probe level analysis of expression results 
from Affymetrix GeneChip® arrays. The following paragraphs will summarize these three 
methods. 
Affymetrix Statistical Algorithm 
Affymetrix Statistical Algorithm is embedded into the GeneChip® Operating Software 
(GCOS) package. Early versions of the package are called Microarray Suite, MAS. Version 5.0 
(MAS 5.0) also employs the Affymetrix Statistical Algorithm for data analysis. Version 4.0 
(MAS 4.0), however, applied empirical analysis algorithms which were proved to perform 
inferiorly compared with the Statistical Algorithm discussed below. GCOS provides automated 
operation and control of instruments (fluidics and scanner), management of experiments and 
sample information, data acquisition, and data analysis. The Affymetrix Statistical Algorithm is 
the component in this software package that performs data analysis[82, 83]. This algorithm 
provides two types of analysis, ‘single array analysis’ and ‘comparison analysis’. 
Single array analysis  
For the single array analysis, there are two components, the detection algorithm, and the 
signal algorithm. The detection algorithm tells if a transcript is present or not in the hybridization 
solution. Using probe pair intensity values (which is stored in the “.cel” files) in a probe set it 
generates a detection p-value and assigns a detection call to the probe set. Detection calls can be 
“Present”, “Absent” or “Marginal”[82, 83]. The signal algorithm in single array analysis is used 
to derive numerical expression intensity values from probe pairs in a probe set. Signal is 
calculated using the One-Step Turkey’s Biweight Estimate. Briefly, for each probe pair, the 
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 intensity values of MM probe or an estimated value, if MM probe has higher intensity value than 
PM probe, is subtracted from the intensity value of the PM probe. The adjusted intensity of PM 
probe is log transformed and then assigned a weight based on the differences of this value to the 
median of all probe pairs in the probe set. For example, if the log transformed, adjusted intensity 
of PM probe in a probe pair is equal or very close to the median of all log transformed and 
adjusted intensities from all probe pairs in the probe set, it will be assigned a high weight. The 
mean of the weighted intensity values for a probe set is determined and becomes the quantative 
expression intensity value for the probe set[82, 83]. For single array analysis, probe-level 
analysis is performed first then data is normalized using the method discussed in section 1.3.2.2. 
Comparison analysis  
Comparison analysis compares expression from two arrays, hybridized with two distinct 
samples usually experiment and control, to detect changes in gene expression. Similar to single 
array analysis, the comparison analysis also has two components, a ‘change algorithm’ and a 
‘signal log ratio algorithm’[82, 83]. Before results from two arrays are compared, they need to be 
normalized or scaled to correct variations between the two arrays. Normalization and scaling will 
be discussed in 1.3.2.2. For the discussion of comparison analysis, assume results from the two 
arrays have been normalized or scaled.  
The ‘change algorithm’ detects the ratio of gene expression for each probe set between 
the experiment array and the baseline array. It also calculates a Change p-value. A change call is 
assigned to each probe set after comparison based on the Change p-value. The change calls can 
be “Increase”, “Marginal Increase”, “No Change”, “Decrease”, or “Marginal Decrease”[82, 83]. 
The “signal log ratio” algorithm calculates ratios of gene expression between experiment and 
control arrays. The signal log ratio represents the level and direction of the change of a probe set. 
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 To get this ratio, the log ratio between the two arrays is first calculated for each probe pair. Once 
log ratios for all probe pairs in a probe set are gathered, the signal log ratio is computed using a 
one-step Tukey’s Biweight method by taking a mean of these log ratios[82, 83]. 
Model-based Expression Analysis 
The model-based expression analysis algorithm calculates Model-based expression 
indexes (MBEI) for each probe set based on probe level intensity values across multiple 
Affymetrix GeneChip® gene expression arrays[84, 85]. It has been implemented in the DNA-
Chip Analyzer (dChip) software package[86]. Model-based expression analysis performs 
normalization first and then calculates the expression intensity values. The normalization method 
used in this model will be discussed in section 1.3.2.2. For the following discussion, please 
assume normalization has been performed.   
Model-based expression analysis builds a model to estimate the expression of a gene in 
each sample of a multiple-sample study based on the responses of probe intensity values on the 
arrays to gene expression changes across samples. It assumes that each probe, PM or MM 
probes, in a probe pair will have different sensitivity in responding to the expression change of 
the gene corresponding to the probe set. Therefore, a probe-sensitivity index is estimated for a 
probe across all arrays in the study. The (PM-MM) difference of each probe in an array is the 
product of MBEI in the array and the probe-sensitivity index of the probe plus an error term. 
Here the (PM-MM) deference is known for each probe pair and the probe-sensitivity index can 
be estimated by surveying the intensity value of the probe across all arrays in the analysis. As a 
result, the MBEI can be calculated and it is reported as the intensity for that probe[85, 86].  
In the newer version of the MBEI algorithm, the authors proposed a revised model that 
calculates the MBEI using only the intensity value of the PM probes. The reason for using only 
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 PM probes is that some MM probes are not sensitive enough to the changes of expression of a 
transcripts between samples[84]. The inclusion of intensity of MM probe, therefore, may impair 
the MBEI on faithfully representing the expression level of a transcript in each sample. The PM-
only model[84, 86] is similar to the PM-MM model but it changes the (PM-MM) difference term 
in the algorithm with intensity of PM probe. 
Compared to the MAS5.0 algorithm, MBEI reduces the variability of expression intensity 
estimate of the low expressor or rare transcripts. The PM-only model also provides a better 
estimation compared to either (PM-MM) model or MAS5.0[84, 85, 87]. 
Robust Multi-array Average (RMA)  
Robust multiple average (RMA) [87, 88] is implemented in the Bioconductor software 
package [89].  RMA also requires normalized data before probe-level analysis using quantile 
normalization discussed in section 1.3.2.2. RMA estimates the expression intensity values for 
each probe on an array using a log scale linear additive model. The model calculates the log 
transformed PM intensity values that are normalized and background corrected. The expression 
intensity value of a probe set is obtained by fitting a linear model with the intensity values from 
each the transformed PM probes (background corrected and normalized)[87, 88].  
In a comparison of the three probe-level analysis methods discussed above by Irizarray et 
al.[87], results demonstrated that RMA outperformed of both MAS5.0 and dChip on the 
precision of estimating gene expression intensities for low expressor by effectively reducing 
variations within replicate arrays, the consistency of fold change estimation and on detection of 
differentially expressed genes (increased sensitivity and specificity of the detection). 
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 1.3.2.2. Data normalization 
Probe-level analysis algorithms and/or software packages usually have normalization 
strategies implemented as well.  
Normalization methods used GCOS software 
GCOS software package provides two normalization procedures, normalization, and 
scaling, for the gene expression data Affymetrix GeneChip® arrays. Both methods maneuver 
either the average intensity value of all transcripts on each array or the average intensity values 
from selected probe sets/transcripts on the array. If all probe sets are used, the normalization is 
considered global. The assumption for global normalization is that most of genes in a 
transcriptome will not have changes in expression in both control and experiment samples, or 
under disease and normal states. However, under certain circumstances, for example treating cell 
culture with a drug, transcription levels of many, if not most, genes in a transcriptome will 
change. Therefore, only the group of genes known with no differential expression can be used in 
the calculation of average intensity value in normalization procedure. By doing so, the real gene 
expression change due to drug treatment will be preserved and only the experimental variations 
are eliminated by normalization. In addition, both methods are considered linear as the average 
intensity values of all arrays are normalized by multiplying a factor. The factor is calculated by 
comparing the average intensity value to either an arbitrary number or the average intensity value 
of a baseline array. 
When scaling, a numerical value, which is user defined and adjustable, is set arbitrarily as 
the target intensity value. The average intensity value of each array is set to this target intensity 
value by multiplying it with a factor, called scaling factor. If the average intensity value is larger 
than the targeted value, the scaling factor for this array is less than 1.0. Conversely, scaling factor 
is larger than 1.0. Scaling makes it possible the comparison of multiple arrays in a study since 
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 scaling, presumably, removes possible technical variations across arrays. Scaling can be used 
independent of the comparison analysis. Therefore, in a multi-array study, even though there 
may not be a baseline array, the arrays can still be compared for changes in gene expression after 
scaling[82, 83, 90].  
Normalization, on the other hand, can only be used in the comparison analysis 
(mentioned in Section 1.3.2.1) where gene expression between an experimental array and a 
baseline array are compared. At normalization step in the comparison analysis, the average 
intensity value of the experimental array is brought up or down to the average intensity value of 
the baseline array by multiplying the average intensity value of the experimental array with a 
factor called normalization factor. If the baseline array is changed, the normalization factor of an 
experimental array changes as well[82, 83, 90].  
Normalization method used dChip – Invariant set normalization 
For model-based expression analysis, probe intensities on an array need to be normalized 
before calculating MBEI. The normalization strategy used here is called “invariant set 
normalization” [84, 86]. This method normalizes the average intensity value of each array in a 
study (except the baseline array) to the average intensity value of the baseline array. The baseline 
array usually is the array with the median average intensity value across all arrays in the study. 
Alternatively, if a baseline experiment/sample is included in the study, the array from the 
baseline experiment/sample is used. 
This normalization strategy depends on genes of which expression intensities do not 
change across arrays (i.e. not differentially expressed). However, it is usually not possible to 
identify such group of genes. The assumption for this method is that probes of a gene with no 
change in expression between an array and the baseline array will have similar intensity ranks. 
34 
 Therefore, in this normalization method, for each array, intensity values of probes (only PM 
probes are used) are ranked. Then the rank from an array is compared to the rank from the 
baseline array. The probes that have the similar rank on both arrays are considered to belonging 
to the genes with no differential expression across the two arrays. An iterative approach is used 
to compare the ranks and select the set of invariant probes across all arrays in the study in the 
end. Each array is normalized to the baseline array based on the comparison of intensity values 
of probes in the invariant set across the two arrays. For each study, the invariant set of probes is 
different[84, 86]. 
Normalization method used in RMA -- Quantile normalization 
The normalization method used in RMA (Robust Multi-array Average, Section 1.3.2.1) is 
called quantile normalization. Performing quantile normalization makes the distribution of 
intensity values of all probes the same for all arrays in an analysis. In order to do so, first, data 
from all probes are projected to a high-dimensional space where each array is represented as a 
column of intensity values. If there are n arrays in the analysis, after the transformation, there 
will be n columns of data. Intensity values in a column are then sorted from small to large. 
Average is taken for all intensity values in a row and this average is used to replace the original 
value in each cell (i.e. the row in each column). After replacing each cell with the row average, 
the column is sorted again from small to large. The value in each cell becomes the normalized 
intensity value for a particular probe in an array[87, 91].   
Bolstad et al.[91] compared the three normalization methods aforementioned. Their 
results show that the quantile normalization method outperformed both the scaling normalization 
(a linear normalization) and the invariant set normalization (non-linear normalization) in terms of 
the ability to reduce variations of a probe set across all arrays in an analysis and speed.  
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 1.4.High-level data analysis 
1.4.1.  High-level analysis overview 
Many data analysis methods have been developed or adapted from other fields of research 
and then applied to DNA microarray technology for gene expression profiling. These methods 
are usually considered high-level analysis approaches in contrast to the low-level data analysis 
methods. The development and application of an analysis method is determined mainly by the 
study objective.  
Typical research in biological or biomedical field is hypothesis-driven because it 
investigates the mechanisms of a specific gene by manipulating the experimental conditions. 
Microarray based gene expression profiling, on the other hand, provides global/comprehensive 
survey of gene expression in a transcriptome by monitoring the expression levels of tens of 
thousands of genes simultaneously. Therefore, most microarray based gene expression profiling 
studies are typically considered descriptive research[92, 93]. Nonetheless, a gene expression 
profiling study using DNA microarrays will always at least have clear objectives and answer 
well-defined questions.  
In the following paragraphs, analysis methods will be summarized in the context of study 
objectives. Since there are a large number of analysis methods available and usually only a small 
number of them have been accepted and widely used in the research community, only those 
methods will be mentioned in the discussion. Before discussing the specific analysis objective 
and methods, it is worthy to describe the gene expression data sets from DNA microarray 
experiments.  
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 1.4.2. Characteristics of microarray gene expression data 
As mentioned before, the power of microarray based analysis is to make possible the 
simultaneous monitoring of tens of thousands of genes, in a massively parallel fashion and across 
many samples at the same time. Gene expression data resulted from microarray experiments 
have unique features which are different from results of all other means of gene expression 
profiling analysis such as Northern Blot, SAGE or RT-PCR. Let us assume there is a study using 
microarray experiment to survey gene expression of m samples with an array of n probes/probe 
sets. The number of data points or expression intensity values in the results will become m × n. 
Such a study may survey gene expression in a number of samples (several hundreds) and a DNA 
microarray typically contains thousands of probes. Therefore, microarray data always has large 
volume and high dimensionality. These features make the analysis of gene expression data from 
DNA microarray experiments with classical statistical method almost unfeasible. In addition, as 
multiple samples and genes are surveyed at the same time in a microarray experiment, there may 
be uncover networks or patterns of gene expression which can not be detected by classical 
analysis methods.  
1.4.3. Study objective and high-level analysis methods 
1.4.3.1. Class discovery 
 
Class discovery studies aim to discover previously unknown subtypes of samples or 
specimens using gene expression profiles from microarray experiments. The main idea for this 
type of studies is that, although some samples or specimens may share similar morphological 
features, they have distinct patterns of gene expression. Therefore, a global survey of gene 
expression will help to discover specific patterns, which can be used to identify this new 
subgroup of samples or specimens. Class discovery is usually combined with class comparison 
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 and prediction to perform cancer classification with microarray gene expression profiling results. 
Many studies in cancer research have been able to identify new subtypes of cancer using 
microarray gene expression data[33, 94, 95]. For example, Alizadeh et al.[95] conducted studies 
to characterize gene expressions in B-cell malignancies systematically. In their study, gene 
expression patterns identified from microarray data were able to distinguish diffuse large B-cell 
lymphoma into two clinically significant groups that had not been identified previously using 
classical morphological criteria and/or cellular markers.   
Alternatively, class discovery can also be used to discover groups of co-expressed genes 
and some of them may be novel genes or expression sequence tags with no known function. By 
grouping unknown genes with known genes, inferences can be possibly made on the functions 
and family of a novel gene based on its expression pattern. 
Data analysis involved in class discovery is not supervised with predefined class 
memberships or gene function groups. The resultant clusters or groups of samples or genes are 
derived based solely on gene expression data with no prior information about the samples. 
Therefore, methods used in class discovery are “unsupervised”[96, 97]. The most popularly used 
methods in class discovery are clustering methods including hierarchical clustering,[96, 98] K-
means clustering,[96, 99] self-organizing maps[96, 100], etc. In addition, methods for data 
visualization using multidimensional scaling, such as principle component analysis[96], have 
been used in class discovery. 
Clustering algorithms group similar objects (tissue specimens or genes) by calculating the 
similarity or distance (dissimilarity) between objects and grouping similar objects together[96]. It 
is useful to partition genes or tissue specimens into clusters based solely on microarray gene 
expression results. On the other hand, clustering algorithms can find clusters even in random data 
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 sets. Therefore, it is critical to validate the clusters resulting from clustering analysis[96, 97, 
101]. Many cluster validation approaches are available[96, 101] but most of them are not trivial 
to implement and use. When clustering is used in class discovery, researchers should be aware of 
its limitations and be cautious on any conclusive statements based on clustering results, unless 
appropriate validation is performed.  
1.4.3.2. Class comparison, class prediction and prognostic prediction 
 
Class comparison studies compare gene expression profiles from different classes of cancer 
specimens and identify gene expression patterns uniquely associated with a particular class or 
subclass of a certain type of cancer. Class comparison involves two aims. First, gene expression 
profiles from different classes or subclasses are compared to investigate if there are differences 
in patterns of gene expression. Secondly, analysis of gene expression is focused on specifying 
the group of genes differentially expressed between classes if they have distinct gene expression 
patterns. Most of these studies also attempt to develop a predictor or classifier based on the 
expression values of selected genes. This last aim, class prediction, may also be listed as a 
distinct objective. However, most likely, to achieve a possible prediction, studies have to have 
class comparison completed first.  
There are many examples for class comparison studies in the literature. The work from 
Golub et al.[32] is likely the first publication on class comparison and class prediction. In their 
study, the authors proposed the classification of human acute leukemia using solely DNA 
microarray data. They built a class discovery procedure to identify differentially expressed genes 
between two types of acute leukemia, ALL and AML. Then a predictor is built, using only gene 
expression results, which can distinguish ALL and AML without prior knowledge of the class 
membership of a specific sample. This study sets an example for molecular classification using 
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 microarray data, which combines class comparison and class prediction to achieve better 
classification of cancer. Many more studies have followed this work and attempt to molecularly 
classify of many different types of human cancers[33, 36, 45, 102]. A number studies are also 
focused on the classification of multiple cancer types using microarray gene expression 
results[33, 34, 39, 40, 103, 104]. 
In addition to classification, recent studies focused on linking gene expression patterns from 
microarray results to the prediction of cancer prognosis and clinical outcomes. This kind of study 
aims to investigate whether there is a relationship between gene expression and clinical 
outcomes. Usually a prognostic predictor is built using solely the expression levels of the 
selected genes to predict the clinical outcome. Studies have focused on predicting outcomes, 
such as metastasis and patient survival, of many types of human cancers[34-36, 38, 105-108]. By 
comparing predictions based on classical histologic criteria, predictors built on gene expression 
results have been proved more powerful in predicting the outcome of the cancer from a patient 
and therefore will help to improve therapeutics and patient care. 
Van’t Veer et al.[106] reported the prediction of the clinical outcome of breast cancer using 
microarray data. The authors were able to identify a 70-gene prognosis signature or poor 
prognosis predictor of distant metastases of breast cancer with high accuracy even though the 
primary cancer was lymph node-negative disease, i.e. no lymph node metastasis at the time of 
diagnosis. Van De Vijver et al.[107] further evaluated this “poor prognosis predictor” on its 
ability to predict the survival of 295 breast cancer patients with and without lymph node 
metastases. Their results demonstrated that the predictor/prognosis signature built using only 
gene expression data performed best on predicting the appearance of distant metastases in first 
five years after treatment. The predictor was also highly predictive of the risk of distant 
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 metastases of patients with or without lymph node metastases at the time of diagnosis. Results 
from these two consecutive studies proved the predictive power of gene expression signature in 
clinical outcome studies.  
The prerequisites for successful cancer classification and prognosis prediction are 
comprehensive information related to clinical outcomes including patient demographics, 
pathological and histological information such as disease stage and grade, treatment, prognosis 
related information such as lymph node metastases and survival after treatment, etc... Gene 
expression signatures with high predictive ability can only be identified when informative and 
sufficient clinical information is provided along with the gene expression profiles from 
microarray experiments. The collection of cancer tissue specimens and the management of the 
patient and disease related information requires tremendous effort over a long periods of time 
and rely on tissue banking informatics tools such as disease-specific databases or comprehensive 
data warehouses.   
If a study involves class comparison, significance tests should be used to identify 
differentially expressed genes between samples belonging to different classes. Significant tests 
are usually considered supervised since data analysis is conducted using the known knowledge 
of sample class memberships. This is in contrast to unsupervised methods such as clustering.  
Though many statistical tests are available (and more are being developed), the most popularly 
used methods are nonparametric tests such as Mann-Whitney rank sum test or multiple testing 
with controlling for false positives such as Welsh’s t-test with the Bonferroni correction. 
ANOVA can also be used to compare the multiple conditions. Alternatively, Significance 
Analysis of Microarrays (SAM)[109] and the Signal-to-Noise metric with Permutation[32] allow 
the estimation of variation in experimental error between replicates and therefore estimate the 
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 false discovery rate at various levels of stringency. In general, the success of significance testing 
is dependent on the size of the difference one wishes to detect, the variation in the data, and the 
number of replicates available. Because the variation in the data is a function of expression level 
(with greater variation at lower expressions), it is difficult to estimate the level of differential 
expression that will be found to be significant in an experiment. Hence, gene lists from 
significance tests should be interpreted carefully.  
Classification and class prediction also use supervised methods, which can detect patterns 
of gene expression and build classifiers or predictors. The classifiers or predictors are built based 
on the expression data of some differentially expressed genes. The selection of differentially 
expressed genes is called “feature selection”. It is the first step toward developing the classifier 
or predictors. Methods for feature selections can be the methods used for class comparison, 
which identify significantly expressed genes between samples. Another method, principle 
component analysis[110], can also be used for feature selection. The popularly used methods for 
building classifiers or predictors from microarray data are Discriminant Analysis[111], Nearest 
Neighbor classifiers[38], the Weighted Gene Voting method[32], Support Vector Machines[112, 
113], Shrunken Centroids[114], Fishers Linear Discriminant Analysis (FLDA)[111] and 
Decision Tree Based Methods using Recursive Partitioning[115]. 
It is difficult to compare the performance of different methods and to identify the best 
method. Dudoit et al.[111] performed a direct comparison of several methods (Weighted Gene 
Voting method, Decision-Tree learning method with or without boosting, Nearest Neighbor 
classifier, standard and diagonal discriminant analysis) on their ability to classify three 
microarray data sets. Their results showed that the diagonal discriminant analysis and Nearest 
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 Neighbor classifier had the best performance; the standard discriminant analysis performed 
poorly. For their study, decision-tree learning methods had intermediate performance.      
An issue associated with class prediction studies is the validation of the classifiers or 
predictors. It is usually accomplished by two ways. Cross-validation is performed for almost 
every study. In doing so, usually a portion of the samples or specimens is left out when building 
the classifier or class predictor. Subsequently it is used to predict the class membership of the 
left-out samples. The set of left-out samples is referred to as the ‘test set’; the set of samples used 
in the classifier is called the ‘training set’. Leave-one-out cross-validation (LOOCV) is a special 
case of the cross-validation method. In LOOCV, one sample is left out at a time and a classifier 
is built using the training set of samples (all samples – the left-out sample). This classifier is 
tested on its ability to predict the class membership of the left-out sample. This process is 
repeated until each sample is left out once. The performance of classification or class prediction 
is measured by the overall error rate in LOOCV[32, 96]. It is important to note that, at cross-
validation or LOOCV, feature selection is only performed using the training set. The test set is 
remained unseen by the classifier so that the accuracy on predicting the test set reflects the “true” 
performance of the classifier[96, 97].  
Alternatively, the performance of a classifier or a class predictor can be validated by 
classifying or predicting the class memberships of samples in another microarray data set. 
Samples from this new data set should not be used either in feature selection or in developing the 
classifier. Such a data set can be obtained from the published articles that carried out studies 
using similar RNA samples as we did in Chapter II[38]. Alternatively, if there are a large number 
of samples in an analysis, the original data set can be divided into two portions; the larger portion 
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 of samples is used to build the classifier and the smaller portion is used to validate its 
performance[96].  
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 1.5.Variations in gene expression data from DNA microarray experiments  
1.5.1. Overview 
It is common for multiple groups to conduct similar studies using different types of DNA 
microarrays and/or clinical tissue specimens. These studies may also ask very similar, if not the 
same, questions; however, gene expression results from DNA microarray based experiments 
often give quite different answers due to the lack of control of variation.  
For example, the contest data sets for the Critical Assessment of Microarray Data Analysis 
(CAMDA) 2003 conference came from four studies on lung cancer. The four data sets were 
created by four research groups from different institutions, Michigan[35], Harvard[33], 
Stanford[34], and Ontario[36]. Data sets from Harvard and Michigan groups were generated 
from two generations of Affymetrix GeneChip® arrays; and data sets from Stanford and Ontario 
used cDNA microarrays. The goals of their studies were: (1) to perform molecular classification 
and staging of lung cancer specimens for diagnosis purpose, (2) to help predict cancer prognosis 
and patient survival.  
Each study reported either (1) a molecular classification of lung cancer with a panel of 
differentially expressed genes or (2) linkage of patient survival to gene expression. There was 
little or no overlap between the differentially expressed gene lists from the four studies. This 
makes true meta-analysis very challenging. Furthermore, only 4% (2499) of the total transcripts 
(62029) surveyed by the four DNA microarrays—Harvard 12600, Ontario 19200, Michigan 
7129, Stanford 23100—were present on all four of the arrays used in these studies[116]. Other 
limitations on cross-platform integration were related to inherent differences between types of 
DNA microarrays (cDNA probes vs. oligonucleotide probes or one channel vs. two channel), 
tissue sampling and handling, clinical parameters (tumor stage/grade, percentage of tumor cell in 
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 the specimen, etc.), demographic differences of the patients etc. Each of these factors may 
introduce variations and/or systematic biases into gene expression data. Results in Chapter III 
reported our efforts on attempting to integrate data sets from Harvard and Michigan using two 
different integration strategies. Although integration can be achieved to certain degree in our 
results, complete integration is not possible due to the variations in microarray data sets.    
Studies on the molecular classification of prostate cancer showed similar observations[37, 
38, 40]. Independent groups at University of Pittsburgh[37, 40] and MIT[38] compared prostate 
cancer to non-cancerous prostate tissue using two versions of the Affymetrix GeneChip® human 
genome arrays, HG_U95av2 and HG_U95A arrays respectively. The study carried out by the 
MIT group identified a group of genes strongly correlated with the grade of prostate tumor 
differentiation measured by Gleason score, and a model built solely on microarray gene 
expression data was able to predict patient outcome[38]. The study by our laboratories at the 
University of Pittsburgh, on the other hand, built a gene expression model using 70 differentially 
expressed genes to predict the aggressive behavior in prostate cancer[40]. Both studies provided 
strong evidence for the concept that the clinical behavior of prostate cancer are linked to the 
differences in gene expression patterns which could be detected at the time of diagnosis[38, 40].  
On the other hand, although the tumor and non-tumor samples used in the two studies had 
very similar clinical features and DNA microarray data were generated using very similar arrays, 
classifiers built based on data from University of Pittsburgh could not classify correctly tissue 
samples from the MIT study[117]. (Ma, et al. submitted to BMC bioinformatics and please see 
Chapter II in this thesis for details). Further investigations[37] on the data set from University of 
Pittsburgh revealed that the non-tumor tissue samples were dissected from regions close to the 
cancer and therefore carried genetic changes similar to or mimic of morphologic cancer. 
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 Therefore, in this example, tissue sampling likely affected the performance of the classifier built 
based on data from University of Pittsburgh. This underlines the importance of selecting the 
correct “baseline” or control tissue in the design of microarray based gene expression 
experiments[37, 117]. 
Many more studies in every field of research where DNA microarray is used as the major 
analysis tool for gene expression face similar challenges for cross-platform comparison. Many 
other factors, in addition to those aforementioned, influence microarray based gene expression 
studies profoundly and the resulting gene expression data may suffer from variations or biases 
caused by these factors (Figure 1.2b). As the awareness of the problem and pitfalls in microarray 
data has increased dramatically for the last 5 years, cross-platform comparison studies have been 
used to investigate the types, sources, and extent of variations, and potential methods to 
minimize these variations. The following section will review these studies and summarize the 
current knowledge on the sources of variation, which interferes with cross-platform comparison 
and data integration.   
1.5.2. Overall levels of variations indicated by cross-platform comparison studies 
Almost all available DNA microarray platforms have been compared with each other in 
various studies[118-121]. Comparisons were focused on: (1) the concordance of intensity levels 
detected for each transcript surveyed on an array; (2) the concordance of differential expression 
ratios between experimental samples and controls or under two conditions; (3) the biological 
themes identified in gene expression data. Concordance is often measured by the correlation of 
intensity values or ratios over a group of overlapped transcripts. The group of transcripts 
overlapped among DNA microarray platforms compared in a study is usually identified by 
finding transcripts with the same UniGene identifier or by matching the sequences of transcripts 
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 targeted by probes. Biological themes are usually assigned to differentially expressed genes from 
a study by studying their categories in Gene Ontology[122] using software tools such as 
EASE[123]. In addition to the relative comparisons among arrays, Northern blot analysis, and 
(quantitative) RT-PCR (qRT-PCR) results of a number of transcripts provide a standard for the 
assessment of the degree of agreements among various array platforms and further allow 
calibration of microarray data.  
Early comparisons in 2002 and 2003 were rather discouraging as comparison results 
showed there was lack of concordance between the available microarray platforms that were 
designed to survey biological relevant patterns[119, 124-126]. The correlations of the intensity 
values and the ratios/fold changes of the differentially expressed genes across platforms ranged 
from significantly low (<0.5) to moderate (0.5~0.6)[124, 126]. The subsets of differently 
expressed genes identified by different platforms had limited overlap[119]. However, it is 
important to note that for the genes that do overlap, the ratios/fold changes showed good 
agreement with fold changes from Northern blot analysis or qRT-PCR[124]. On the other hand, 
these independent validation approaches failed to validate transcripts with disparate expression 
intensity values across platforms[125]. 
Over the past several years, cross-platform concordance has improved significantly as both 
the technology and experiences with the technology advanced. In 2004, Yauk et al.[118] 
compared six DNA microarray platforms used for gene expression analysis including one with 
long oligonucleotide arrays, three with short oligonucleotide platforms, and two cDNA array 
platforms. Results showed rather reasonably high correlations (0.65~0.78) for the pair-wised 
cross platform comparison of the Affymetrix GeneChip array, the Agilent oligonucleotide array, 
the CodeLink Uniset I array, and the Agilent cDNA array using either a group of genes common 
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 in all platforms or the genes in common on a given pair of platforms. Similar or better levels of 
concordance have also been reported by other studies[127-129]. Using a two factor ANOVA 
analysis, results from Larkin et al.[130] in 2005 demonstrated that 90% of the overlapping genes 
(~5800) between the Affymetrix GeneChip® arrays and TIGR cDNA arrays was little affected 
by platforms on gene expression intensity values and that these genes had high correlation of 
intensity ratios across platforms (>0.80). For genes consistent across platforms, qRT-PCR results 
also showed robust correlations between platforms. While for genes with disparate expression 
ratio measurements between platforms, qRT-PCR results disagreed with both platforms and 
provided a third expression profile. 
Larger scale, comprehensive studies have been carried out in 2005 on comparing multiple 
DNA microarray platforms, taking into consideration not only the variations between microarray 
platforms but also the variability across different laboratories[120, 121].  
Irizarry et al.[121] published the first ever platform comparison study across different 
laboratories in Nature Methods, April 21, 2005. In this study, the authors compared gene 
expression results from three platforms--Affymetrix GeneChip® arrays, two-color cDNA arrays, 
and two-color oligonucleotide arrays--using the same RNA samples with a known number of 
differential expressed genes. Gene expression data were produced from a consortium of ten 
laboratories from the Washington DC and Baltimore areas with each array platform implemented 
in at least two laboratories. Their results showed laboratory effects typically influence the 
precision of gene expression data, and that precision varies across laboratories where the same 
array platform was used.  
In the same issue of Nature Methods, another cross-platform, between-laboratory study was 
conducted by the Toxicogenomics Research Consortium[120]. In this study, the authors 
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 investigated effects from many technical aspects, such as RNA labeling methods and data 
acquisition, as well as effects from various microarray platforms on the overall agreement of 
cross-platform comparisons. Gene expression data from a total of twelve DNA microarray 
platforms and across eight laboratories were compared. For most platforms in the comparison, 
reproducibility of gene expression data between laboratories was poor but could be dramatically 
improved by standardizing RNA labeling and hybridization, microarray processing, data 
acquisition and normalization. This result highlights the importance of standardization in 
improving the concordances across array platforms. ANOVA analysis of this data demonstrated 
that the microarray platform is the most prominent source of variability in microarray data and 
contributes to more than half of the variability observed in the data. Other sources of variations 
are laboratory, tissue, array replicates, tissue × platform, tissue × laboratory, and dye. Overall, 
the results showed that good concordances (correlation coefficient >0.90) were achieved across 
commercial DNA microarray platforms and between laboratories. The best reproducibility came 
from commercial DNA microarrays with standardized protocols. In summary, within the limits 
investigated to this point, microarray data sets can be comparable across platforms and between 
laboratories when known sources of variation have been controlled for or eliminated.  
Although reasonably good agreement across platforms can be achieved, it is still far from 
perfect. In all cross-platform comparison studies, there have been a number of genes which have 
disparate expression profiles across platforms. For example, a gene can be differentially 
expressed with a large fold change in expression data from one platform but show no difference 
across the same biological samples in data from another platform. Northern blot or qRT-PCR 
may verify none of the results from any of the array platforms but may generate yet another gene 
expression profile for this gene[121, 130]. This may be due to other sources of variation that 
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 have not been identified or more likely it is because transcript sequence information and 
annotation have not been fully understood or optimized. Either way, the concordance can still be 
improved.  
Regardless of the level of concordance achieved in various comparison studies, there are a 
number of common findings worthy of discussion. Commercial DNA microarrays typically show 
lower variances in array replicates and higher sensitivity in detecting differentially expressed 
genes than custom made/academic center DNA microarrays[118, 120]. Therefore concordances 
between commercial DNA microarray platforms are better than the agreement between custom 
made arrays or between custom made arrays and commercial arrays[118, 120, 131]. 
Concordances across platforms are better when using fold changes/ratios of gene expression 
instead of intensity measurements[130]. Even when there is low level of concordance across 
array platforms and/or between laboratories, the biological themes identified in gene expression 
data from different platforms may have significant agreement with each other[119]. 
Reproducibility of gene expression data across platforms can be improved by applying 
“superior” analysis algorithms such as probe level analysis algorithms and normalization 
techniques[130]. Agreements across platforms can be improved by removing noise in the gene 
expression data for example by using only transcripts identified as present by preliminary DNA 
microarray analysis in the initial RNA samples[128] or by applying standardized protocols[120, 
121, 130]. Finally, tissue heterogeneity, cell type difference, or biological treatments influence 
much more significantly the gene expression data than technical variations among different 
platforms[118, 130, 132]. 
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 The most important sources of variation investigated in platform comparisons studies 
(mentioned above) are summarized as follows (also depicted in Figure 1.2b side-by-side with 
steps in the experimental procedure Figure 1.2a).  
(1) Inherent differences among various platforms such as probe type, probe 
length, features of probe sequences, probe quality, annotation, and surface 
substrate, 
(2) Tissue sampling and handling, 
(3) Technical aspects such as RNA labeling, hybridization, and data handling as 
demonstrated in the between laboratory comparisons.  
The following sections will focus on variations from tissue sampling and handling, and RNA 
labeling. These discussions will provide background knowledge for Chapters II, III, and IV.  
1.5.3. Variation introduced by tissue sampling and tissue handling 
The purpose of gene expression analysis is to detect relative changes in gene expression in 
order to make inferences regarding the underlying biological mechanisms or states. Therefore, 
gene expression profiles should reflect either the biological or the physiological state of a tissue 
sample or cell culture or relative differences in gene expression between two tissue samples or 
cell cultures under different treatments. It is not surprising to discover that biology is the major 
driving force in cross platform comparisons. For example, results from the study by Yauk et 
al.[118] showed that, despite the different types of arrays used, gene expression data formed 
major clusters based on the cell types and tissue origin indicating that biological differences 
influence gene expression data more significantly than technical variations among different 
platforms. As mentioned above, Larkin et al.[130] demonstrated that gene expression intensity 
values of 90% of the overlapping genes (~5800) between the two platforms were not affected by 
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 array platforms but rather represent the true states of gene expression in the original RNA 
samples. A number of comparison studies on RNA preparation and labeling approaches also 
proved the same idea by demonstrating that RNA amplification and labeling approaches can 
introduce non-negligible amount of biases/variations but these biases do not significantly impair 
gene expression profiles[64, 133, 134]. 
On the other hand, as pointed out above, sampling and tissue handling have significant 
impact on accuracy and reproducibility of microarray based gene expression analysis. This is of 
particular importance for microarray based gene expression studies on human diseases such as 
the breast cancer studies in the CAMDA workshop[33-36] and the prostate tumor classification 
studies[38, 40] discussed at the beginning of this section. Careful sampling is important because 
human tissues are very heterogeneous by nature. Tissue handling, on the other hand, ensures the 
quality of the initial RNA samples obtained from a tissue specimen.  
1.5.3.1. Tissue sampling 
 
Human tissues, normal or diseased, are very heterogeneous, comprising many cell types 
including epithelial cells, stromal cells, muscle cells, nervous tissue, fat cells, immune cells. 
Different regions of a tissue may also have distinct composition of cell populations (cell type + 
the number of cells in each type). This results in variation even between very similar tissue 
samples. This inter-sample heterogeneity (tissue heterogeneity) is in addition to differences 
between individuals (the inter-patient heterogeneity). For example, individuals may have 
different single nucleotide polymorphism at a particular site in the sequence of a transcript. In 
cancer studies, even though tissue samples dissected in a surgery are rich in cancer cells, the 
population of cancer cells may be “contaminated” by non-cancerous cells. Cancerous tissues 
removed by surgery typically contain normal appearing tissues to remove completely the 
53 
 cancerous tissues. Therefore, most tumor tissues are “contaminated” with normal appearing 
tissues. There is also heterogeneity of cellular populations such as multifocality and different 
degrees of malignancy (grade). Furthermore, as a large tissue specimen usually is dissected into 
small blocks and each block used for a study is different from all others.[57, 135, 136] Giving 
this level of heterogeneity, it is quite challenging to obtain consistent tissue samples with a 
somewhat consistent number of cells affected by the disease or biological state, for gene 
expression analysis in a study.  
One example of the effects of sampling on microarray based gene expression profiling is 
the study on molecular classification of prostate cancer at University of Pittsburgh[37, 40, 117]. 
Three types of tissues were collected, cancerous tissues (tumor), normal appearing tissues 
adjacent to the cancer (adjacent normal), and normal tissues from disease-free (free of any 
prostate related diseases) organ donors (donor). Each type of tissues produced unique gene 
expression profiles. Yu et al.[40] reported a cancer field effect because the gene expression 
profile of the adjacent normal tissues is changed substantially (and, to certain degree, it 
resembles the profile from cancer). Chandran et al.[37] conducted in depth analysis to compare 
the gene expression profiles from the three types of tissues with the same data set. Profiles from 
adjacent normal tissues correlate better with profiles form tumor than those of the donor tissues. 
The comparison of tumor vs. donor detected many more differentially expressed genes than the 
comparison of tumor vs. adjacent normal at a similar stringency level (false discovery 
rate<0.025). These results suggested that the normal appearing tissues adjacent to prostate 
cancers undergo tumor-like changes in gene expression. The authors also speculated on which 
type of tissue, normal appearing tissue adjacent to cancer or normal tissue from disease free 
organ donor, serve as a better baseline in an study for detecting differentially expression genes in 
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 prostate cancer. Alternatively, Ma et al.[117] performed classification studies using the same set 
of data using various machine learning algorithms. Classifiers constructed from profiles of tumor 
and donor performed better than classifiers built form profiles of tumor and adjacent normal both 
in leave-one-out validation and in classification of gene expression data sets of prostate cancer 
from other institutes. These results reinforced the hypothesis of the choice on baseline tissues for 
prostate cancer studies which should include “true normal” controls.  
Interestingly, Stamey et al.[137] conducted a study to investigate what is the best prostate 
control tissue. Three potential control tissues were collected, peripheral zone, central zone, and 
benign prostate hyperplasia (BPH). Gene expression profiles were generated from each type of 
tissues. Profiles were compared to each other for efficiency in detecting present 
transcripts/genes. Each profile was then compared with expression profile from Gleason grade 
4/5 prostate cancer for detecting differential expression genes. Their results showed that there 
was substantial overlap of the present genes in each profile. However, very little overlap of the 
differentially expressed genes detected using each “normal” type of tissues as control. 
Expression profiles of the morphologically normal appearing peripheral zone tissues shared 
many genes with Gleason grade 4/5 cancer, suggesting a possible field effect similar to that 
described in the Pittsburgh study. Their results demonstrated the variations introduced by 
inappropriate sampling and, once again, emphasized the importance of using the right controls 
for any study on detecting differential gene expression and therefore eliminated from the study. 
Several approaches have been proposed and implemented in daily practice to provide 
good/correct sampling in gene expression analysis. First, pathological evaluations should always 
be used at the time of collecting tissue samples. Pathological evaluations can help ensure the 
tissue blocks obtained for a study do contain enough of the tissues (such as tumor tissues) of 
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 interest. Pathological evaluations will also provide cell composition information in the tissue 
samples. For example, pathological evaluation can tell that tumor cells may only be 10% of all 
cells in a tissue specimen used for gene expression profiling. 
Intra- and inter-patient heterogeneity can be diminished by increasing sample size so that 
appropriate statistical analysis and normalization can be applied to expression profiles. 
Alternatively, Bakay et al.[132] first demonstrated that intra-patient tissue heterogeneity and 
differences between individual patients (inter-patient) are the major source of variability in gene 
expression data when a single DNA microarray platform is used. Then, the authors tested a 
strategy for eliminating the intra-patient and inter-patient variations by pooling/mixing of patient 
cRNA samples before hybridization. Pooling was done with cRNA samples from different 
region of a tissue to help minimizing intra-patient variations. It was also done with cRNA 
samples from different patients with matched age, gender, disease stage, etc. to diminish inter-
patient variations. Results from hybridizations using pooled cRNA samples demonstrated that 
gene expression profiles from pooled samples were able to detect differential gene expression 
between target tissue and control with high specificity comparable to the profiles generated from 
individual cRNA samples, while at the same time, intra- and inter-patient variations were 
effectively normalized. Their results suggested that pooling or mixing a rather small number of 
RNA samples from multiple regions of a piece of tissue from an individual and from multiple 
individuals matched for most variables (age, gender, disease, etc.) can help eliminate variations 
owing to tissue heterogeneity and provide stringent and robust gene expression data. 
Laser capture microdissection (LCM) is also used to help improve sampling[138-141]. 
LCM is a process by which individual cells can be dissected from a tissue specimen. A typical 
LCM procedure is as follows (Please refer to Emmert-Buck et al. [138] for a graphical 
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 illustration.). A thin, transparent film is applied to the surface of a microscopic slide, which holds 
a piece of tissue. The film is a thermoplastic film made of ethylene vinyl acetate polymer. Under 
the microscope, selected areas of film on top of the cells (or tissues) of interest are activated by 
laser pulse. The activated film has strong focal adhesion power which allows the selected regions 
to be procured from the tissue. The film with the procured cells is then removed from the slide 
and cells/tissues adhered are sent to further treatments in DNA, RNA or enzymatic assays. 
Multiple regions can be procured on a single film in one procedure. The transferred cells or 
tissues retain their morphological features which can be verified under microscope.
 
LCM offers an efficient means to isolate cells of interest from other cell types in a tissue. 
It has been applied successfully to collect samples for DNA microarray based gene expression 
analysis[139, 141, 142]. One issue associated with LCM is the limited amount of RNA from 
collected cells. But the problem has been mitigated by amplifying RNA with the T7 RNA 
polymerase based in vitro transcription method (Section 1.2.3.2)[63, 143]. Gene expression 
profiles from amplified cRNA from LCM have been validated to have high fidelity and 
reproducibility[139-141]. One potential drawback of LCM is that it uses morphological 
characteristics to identify cells of interest, and cells with similar morphological features may not 
have same gene expression profiles. For example, epithelial cells in the adjacent normal prostate 
tissues resemble normal epithelial cells but genetically their expression profiles share many 
characteristics with cancerous epithelial cells. This discrepancy may potentially introduce biases 
into gene expression profiles generated from LCM samples.  
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 1.5.3.2. Tissue handling 
 
Good tissue handling guarantees the quality of the initial RNAs extracted from the tissues 
and therefore provides an optimum start for target preparation (labeling and/or amplification) as 
mentioned in Section 1.2.2. For gene expression analysis, tissue handling is of special 
importance because RNA samples are very sensitive to degradation. Therefore, fresh tissues need 
to be handled and stored properly to preserve the transcriptomes intact. 
There are a couple of major problems in tissue handling which can potentially affect the 
quality of RNA samples. First, the length of processing time from surgical removal of tissues to 
collect samples for research use will affect gene expression greatly by inducing ischemia. 
Ischemia is caused by lack of blood flow to a tissue/organ. Without blood flow, the tissue/organ 
will be depleted of oxygen and therefore become hypoxic. In the state of ischemia, stress-specific 
response genes will be transcribed to protect tissues from damage. Prolonged processing time 
may cause tissues to be ischemic and therefore affect gene expression.  
Dash et al.[144] reported the effect of warm ischemia on differential gene expression of 
radical prostatectomy specimens. In this study, gene expression profiles of tissue samples 
collected at different time after radical prostatectomy were compared. A number of genes were 
identified with significant increase of expression at 1 hour after radical prostatectomy. Many of 
these genes have shown increased expression secondary to ischemic stress, hypoxia. Therefore, 
after surgical removal or biopsy, tissues should be collected as soon as possible and processed 
then stored properly if not used immediately.   
The means by which tissues are processed after surgical removal or biopsy is also an 
important factor affecting RNA quality. Typically, tissues are fixed in formalin and embedded 
into paraffin blocks, which can be preserved for many years and archived. However, RNAs will 
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 be degraded by forming cross-links with formalin[135, 136]. Alternatively, tissues can be snap-
frozen in liquid nitrogen to avoid RNA degradation. Tissues should be put into solutions, such as 
RNAlater and ethanol that inhibit RNase[57, 135]. 
1.5.4. Variations introduced by RNA labeling methods 
Various labeling and target preparation approaches have been used in DNA microarray 
based gene expression studies (Section 1.2.3). A well known recommendation[65, 70] on 
labeling approaches for DNA microarray based gene expression analysis is that one should never 
change/combine labeling strategies within a study as the data from more than one method may 
not be comparable. This indicates the possibility of profound, not yet fully characterized, 
differences introduced by labeling and/or amplification approaches. Systematic assessments of 
the performance of these methods[64, 65, 70, 74] have demonstrated that individual labeling 
methods can significantly influence the gene expression data and data using different 
amplification approaches on the same type of array may not be directly comparable[145]. In 
addition, many have pointed out that labeling and target preparation (including labeling and 
amplification) is one of the many technical variables that can profoundly influence the 
compatibility of gene expression data across platforms  and between laboratories[119, 120, 130]. 
This section will summarize the comparison studies conducted on various labeling and/or 
amplification approaches and their effects on gene expression data from DNA microarray based 
experiments.  
Most of the comparison studies use “controlled” studies/experiments where other 
experiment variables such as the source of total RNA and the type of DNA microarray are 
controlled to study the effects of different labeling and/or amplification methods on gene 
expression analysis. Gene expression data from total RNA /mRNA labeled using reverse 
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 transcription approach is usually used as the standard for the comparison studies. However, the 
reverse transcription labeling approach is not necessarily the best method to preserve the initial 
RNA abundance and complexity. There is significant variation during total RNA extraction or 
mRNA purification[70, 146]. Therefore, a small number of differentially expressed genes may 
have to be further verified by Northern blot or quantative RT-PCR. Performance of the labeling 
approaches is reported as the sensitivity of gene detection and the reproducibility of that 
detection. Labeling approaches may vary from each other at (1) the gene populations detected as 
present/differentially expressed in the RNA sample and at (2) the ratio of differential expression, 
which is expressed as fold change or a statistical metric such as signal-to-noise ratio or t-test 
value. 
A couple of labeling methods, including TSA[72] and the dendrimer approach[76] which 
cause signal amplification with no target amplification have been recently developed and have 
not yet been adopted as routine procedure for target labeling in DNA microarray based gene 
expression analysis. Variations from these methods have not been studied systematically. Stears 
et al.[76] and Manduchi et al.[74] reported that the dendrimer approach has low background, 
high signal-to-background ratio, comparable level of reproducibility and ability to detect 
expression, and requires much less targets for hybridization compared to reverse transcription 
approach using cDNA microarrays. However, in a comparison study carried out by Richter A et 
al.[65] using a cDNA microarray comprising genes in iron metabolism regulation, the dendrimer 
approach failed in detecting any differentially expressed genes. The TSA approach showed high 
background, moderate accuracy and sensitivity in the same report[65]. In summary, gene 
expression analysis using these two labeling approaches may be less capable of detecting 
differentially expressed genes and introduce more biases/variations into gene expression data. 
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 Furthermore, the signal amplification may not recapitulate relative differences in a linear 
fashion[72].  
Many more studies have been conducted on the variations introduced by labeling 
approaches with target amplification such as the T7 RNA polymerase based in vitro transcription 
method and SMART PCR method. PCR based methods employ exponential amplification that 
may distort the initial transcript levels. Therefore are not widely adopted for target preparation in 
DNA microarray based experiments (also see Section 1.2.3.3 for details)[64, 133].  
T7 RNA polymerase based in vitro transcription was developed by Gelder and 
Eberwine[60, 61, 63] and first applied for target preparation in gene expression analysis using 
Affymetrix GeneChip® arrays by Lockhart et al. in 1996[2]. This method has been adopted with 
modification as the major target preparation method for various types of DNA microarrays 
including cDNA arrays and long-and short-oligonucleotide arrays[2, 22, 25, 28, 147-149]. This 
method amplifies mRNA in a linear fashion and, in theory, introduces little distortion to the 
initial transcript level in mRNA samples. Therefore, the relative abundance and complexity of 
mRNA will be maximally preserved in the amplification products. Various studies[2, 61, 69] had 
proved the linearity of this method. Gelder and colleagues[61] have shown by electrophoresis the 
distribution of the antisense RNA amplified is similar to the cDNA population from which it was 
produced. By Northern blot and Southern blot analysis, their results also show that the 
abundance of the amplified antisense RNA is representative to the parent cDNA. Lockhart and 
co-authors[2], on the other hands, prove the linearity of amplification with array hybridization 
results. Poly-A tailed synthetic prokaryotic RNA molecules were spiked into eukaryotic total 
RNA samples at varies of known concentrations, from low to high, before amplification. The 
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 array intensities of each spiked control genes are quantitively related to its concentrations over 
the entire concentration range[2].  
High reproducibility of the T7 based method has been reported in almost every study 
regardless the type of DNA microarrays used with high correlation coefficients (>0.90) and low 
average coefficient of variances among replicates (<15%) [25, 64, 69, 73]. Correlations of 
amplified and non-amplified (total RNA/mRNA) data is in the range of 0.77~0.85[64, 150-152]. 
In a systematic study conducted by Richter et al.[65] using a custom cDNA array comprising 
known genes for iron metabolism regulation, the T7 based method yielded the largest number of 
genes as differentially expressed which is also close to the number of genes presented on the iron 
chips expected to be expressed in the cell line studied, indicating the T7 based method has the 
best sensitivity. The reverse transcription labeling method on the other hand detected the smallest 
number of genes as differentially expressed and therefore target amplification increases 
sensitivity. When compared to the gene expression data from unamplified mRNA and total RNA 
(labeled by reverse transcription), most studies show that the T7 driven amplification method 
detected 80% ~ 94% of genes identified by unamplified mRNA or total RNA as differentially 
expressed[64, 148, 152, 153]. Similarly to Ritcher et al.’s study [65], the T7 based amplification 
method usually identifies more differentially expressed genes than unamplified mRNA or total 
RNA[70, 152, 153]. Genes uniquely called present or differentially expressed in gene expression 
results from one type of method were further proved to be true by qRT-PCR verification, 
suggesting an increase of sensitivity using the T7 amplification method. Two-rounds of 
amplification[60, 63] is necessary to yield enough material for DNA microarray based gene 
expression analysis. Studies showed that gene expression data from two-round of amplification 
was relatively comparable (correlation is about 0.93~0.95) to data from standard T7 based 
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 method[133, 134, 145, 154]. However, certain variations are introduced by two-rounds of 
amplification (discussed bellow).  
In summary, within the limits investigated to this point, the T7 RNA polymerase based in 
vitro transcription method (one- or two- rounds) has been proven to amplify mRNA linearly and 
the gene expression profiles from T7 based method demonstrate acceptable/excellent fidelity and 
reproducibility as well as improved sensitivity. Therefore some scientists suggest the routine 
usage of RNA amplification for all array based gene expression profiling experiments.[152] 
However others suggest to use RNA amplification only when the starting material is limited[64] 
and to verify microarray gene expression results with other independent methods like Northern 
Blot and qRT-PCR.  
For the T7 RNA polymerase based linear in vitro transcription, selective sequence 
amplification could occur even in the case of linear amplification. Sequence specific efficiency 
of the T7 RNA polymerase may also introduce biases to the initial transcript level at in vitro 
transcription owing to the early termination of transcription because of a very long poly(A) tail 
or strong secondary structure in sequences[64]. 
Different variations introduced by the T7 RNA polymerase based amplification approach 
have been reported in a number of studies[69, 70, 133, 134, 145, 150, 154, 155]. Using an 
ANOVA model and multiple hypothesis testing, Nygaard et al.[155] reported that target 
amplification significantly affects differential expression ratio of 10% of the genes studied. 
Variations introduced by either sequence-dependent or sequence independent manner[69, 70]. 
Baugh LR et al.[69] reported a reduction of present calls in gene expression profiles of the 
amplified cRNA by the T7 method because of a high molecular weight product existing in the 
cRNA products. This product is produced by the T7 RNA polymerase in the presence of the 
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 carried-over oligo (dT)-T7 primers. Li Y et al.[94] reported that systematic biases can be 
introduced by RNA amplification method in a sequence-dependent rather than copy-number 
dependent fashion. The authors also reported sequence dependent biases and 5’ under 
representation introduced by T7 based RNA amplification.  
Variations are also observed in the amplification products where the distribution of cRNA 
products changed compared to the distribution of total RNA or mRNA, indicating the possible 
distortion of relative transcript abundance caused by amplification. For example, several reported 
showed that amplified products have smaller range than purified mRNA and there is a shift 
toward small transcript size in distribution (we also observed the shift of transcript size 
distribution in Chapter IV, Section 4.4.3)[153, 156]. More shifts were observed with two-round 
of amplification[134, 154]. Polacek et al. speculated that this shift is because of early termination 
of reverse transcription and/or in vitro transcription of the T7 based amplification method[153]. 
Spicess et al. on the other hand, thought this is owing to the cRNA degradation by T7 RNA 
polymerase and suggested that one should never compare gene expression results with cRNAs 
from different amplification times[156]. A number of studies also demonstrated the decreases of 
intensity values of certain transcripts in gene expression data caused by 5’ truncation at the T7 
target amplification process[69, 133, 145, 148]. For such a transcript, the 3’/5’ intensity ratio, if 
there are both probes designed from 5’- and 3’- end sequences, will subsequently increased. This 
is quite a prominent variation observed in gene expression results from two-round 
amplification[133, 145]. In addition, Gold et al. speculated the 5’ truncation in amplification is 
the cause of the observed decrease of sensitivity after two-round of amplification[134]. 
Efforts had been made to correct some of the variations aforementioned and to improve 
gene expression data from amplification. For example, a template switch strategy has been used 
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 to synthesize of second strand cDNA to ensure the generation of full-length ds-cDNA[148, 151]. 
However, Zhao et al.[151] demonstrated that template switch did not help to improve fidelity of 
gene expression data with target amplification. Baugh et al.[69] improved gene expression 
results from amplified targets by removing the template-independent, high molecular weight 
products which is caused by the excess amount of oligo-(dT)-T7 primer during amplification. 
However, variation can not be 100% removed from amplified products indicating there are 
uncharacterized sources responsible for the observed variations other than 5’-end truncation and 
template-independent high molecular weight products. Understanding the possible sources of 
variations and the impacts of the variations to gene expression results will also help on better 
study design and cross-platform comparison. 
In addition, there are many “versions” of the T7 RNA polymerase based in vitro 
amplification methods available, each of which is designed to produce optimized array 
hybridization results as claimed by its manufacture. It is intuitive to speculate that these methods 
may introduce variations into gene expression results even though they are all derived from the 
original T7 based method. However, up to now, there is no systematic comparison of different 
methods.  
Chapter IV in this thesis described a comparison study of three popularly used T7 based 
methods. Results from this comparison study demonstrated the existence of significant variations 
introduced across different T7 based target amplification methods. In addition, results also 
demonstrated that both the number of biotinylated nucleotides used for labeling and the reaction 
time of in vitro transcription are responsible for the observed variations.  
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2. CHAPTER II  Effects of analysis methods on the supervised classification of 
prostate tissue samples using microarray data: implications of variation introduced by 
sampling and tissue handling  
Resubmitted to BMC Bioinformatics 
2.1. Abstract 
Tumor classification and class prediction has become one important application of 
microarray technology. In this study, we examine the classification of prostate tumor tissue and 
normal (non-tumor) prostate tissue using three different classification methods (Boosted 
Decision Tree based on the C4.5 algorithm, Support Vector Machines and Weighted Gene 
Voting) at various levels of feature selection. In addition, we were able to divide the normal 
(non-tumor) samples into different types (normal prostate tissue from cancer prostatectomies and 
normal prostate tissue from tumor free organ donors), and examine the effect of using one or the 
other in the analysis. Our results indicate the boosted decision tree results were as good if not 
better as the classification produced by more accepted microarray classification methods such as 
support vector machines and weighted gene voting. Significantly, the type of ‘normal tissue’ 
used in the analysis had a significant impact on the accuracy of the classifiers, indicating that the 
sample selection and tissue processing may be much more important than the specific analysis 
method used in the interpretation of microarray data. 
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 2.2.Introduction 
Over the past several years, gene expression microarray technology has been successfully 
applied in prostate research. Numerous groups have reported the discovery of individual genes 
associated with prostate cancer[38, 45, 139, 157, 158], the reliable discrimination of tumor and 
benign samples[38], and the correlation of gene expression with traditional morphologic metrics 
of tumor progression such as Gleason grade[38]. In addition, the possible discovery of prostate 
cancer sub-types with varying degrees of aggressiveness has been reported[40].   
One of the most critical microarray applications is tumor classification and class 
prediction – the task of classifying samples into known diagnostic classes. Compared to 
unsupervised methods such as clustering[98], supervised classification methods are preferred for 
performing these tasks because such methods takes advantage of existing information and 
domain knowledge and therefore should create a more accurate (and reliable) classifier. 
Supervised classification methods take training sets in which the expression of each gene and 
diagnostic class (tumor, non-tumor, etc) of each sample is known and use that information to 
build a classifier that can predict the diagnostic class of new tissue samples based on their gene 
expression data.  
Supervised classification will be particularly important in the pathology laboratory, when 
they are faced with the task of classifying a clinical specimen into one or more diagnostic 
categories (for example, benign, pre-malignant, and malignant) based on microarray results. It 
will also be important for predicting progression and patient survival. This scenario is becoming 
more and more realistic, as an increasing number of hospitals (including the University of 
Pittsburgh Medical Center) are implementing clinical laboratories to use microarray technology 
for diagnostic, predictive and prognostic classification (on an experimental basis).  
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 There are however, a number of open questions surrounding the supervised classification 
of tissue samples in general and prostate samples in particular. For example:  
(1) There are multiple supervised classification methods in use including the Nearest 
Neighbor classifiers[38], the Weighted Gene Voting method[32], Support Vector 
Machines[112, 113], Shrunken Centroids[114], Fishers Linear Discriminant Analysis 
(FLDA)[111], and Decision Tree Based Methods using Recursive Partitioning[115]. 
There is limited information on which are most accurate and appropriate for prostate 
tissue classification. 
(2) Most microarray experiments measure a large number of genes (more than 10,000) on a 
few dozen tissue samples. This high dimensionality makes analysis and interpretation 
difficult. The expression of the great majority of genes (reported by a microarray) does 
not change between specimen classes. These genes therefore do not contribute a 
differential "signal" but do contribute "noise", making the classification process less 
effective and potentially more costly. For these reasons, there has been interest in "feature 
selection" as a pre-processing step before the application of classification algorithms. 
Numerous statistical methods[32, 109] have been developed to reduce the dimensionality 
of microarray data by selecting only genes that are significantly expressed between 
specimen classes. However, the effect of feature selection should be examined 
systematically.  
(3) The microarray experiment itself is difficult to perform and control. Numerous 
experimental factors such as sampling, tissue handling[144] and storage conditions can 
affect results. The adult human prostate is an architecturally complex, hormonally 
sensitive organ that continues to evolve over a person's lifetime. Significantly, different 
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 topological zones in the prostate manifest different biology - adenocarcinoma, a common 
finding in the organ's periphery seldom involves the central or transitional zones. Most 
intriguing, published studies using a variety of techniques as diverse as chromosomal 
analysis[159], SAGE[160], ploidy analysis[161, 162], and image analysis[163-165] have 
shown molecular and morphologic abnormalities in normal appearing prostate adjacent to 
adenocarcinoma. 
In this study, we evaluate the classification and prediction of prostate tissue samples from 
three independent data sets. We used three classification methods (Boosted Decision Tree 
(BDT)[166], Support Vector Machines (SVMs)[112, 113], and Weighed Gene Voting 
(WGV)[32]). We examined the results at different levels of feature reduction and, most 
importantly, compared tumor samples against different types of “normal” baselines. Our results 
indicate that the classification methods performed in a fairly similar manner (both well or poorly 
depending on the samples compared), feature selection can have an important impact on 
accuracy of BDT and, in these prostate data sets, tissue sampling and processing methods may be 
much more important than the specific statistical methods used in the analysis process.  
2.3.Materials and methods 
2.3.1. Data sets 
Three data sets were used in this study. The data sets had in common the use of tumorous and 
normal appearing human prostate tissue. However, the data sets were generated at different 
institutions using different populations and different sampling techniques. These differences 
were particularly significant in the selection of normal tissue. While tumor samples were taken 
from prostate cancer patients, normal samples were taken from both the normal appearing 
regions of prostatectomy specimens (Patient Normal), and from normal appearing areas of tumor 
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 free prostates taken from organ donors (Donor Normal). Table 2.1 gives the clinical and 
pathologic features of patients, donors, and specimens. 
The Primary Data set 
The primary dataset (Table 2.1) used in this study was generated by scientists at University of 
Pittsburgh Medical Center (UPMC)[40]. There were three sample types used in this data set. 
Eighteen “Donor Normal” samples were taken from prostates harvested from eighteen organ 
donors. These prostates were certified to be free of tumor by UPMC pathologists and the samples 
were felt to be histologically “normal” (no prostatic hyperplasia, inflammation, etc.) Samples 
were also taken from patients undergoing radical prostatectomy for prostate adenocarcinoma. 
From sixty-three patients, 60 tumor samples and 63 samples of normal appearing prostate 
adjacent to tumor (Patient Normal) were analyzed. In all, 141 samples (18 Donor Normals, 60 
Tumors and 63 Patient Normals) were run on the Affymetrix U95Av2 chip. The raw expression 
data was then analyzed using MAS5.0 software (Affymetrix Inc.) and normalized using a global 
normalization approach. This data is referred to as the “PITT” data set in the following 
discussions. Please also refer to Appendix A for a related study on this data set.  
The Two Independent Test Data sets 
Two previously published prostate tumor datasets (Table 2.1), referred as “Singh” data 
set[38] and “Welsh” data set[39], were obtained from public domain or given kindly by the 
authors respectively. The Singh data set was generated from patient prostatectomy specimens. 
There were 52 histologic tumor samples and 50 samples taken from normal appearing areas of 
the prostatectomy adenocarcinoma (Patient Normals) using Affymetrix U95Av2 chip. The 
Welsh data set was generated by using Affymetrix U95A chip (12600 probe sets are overlapped 
between U95A and U95Av2 chips) from 24 histologic tumors and 8 normal tissue samples 
70 
 (Patient Normals). Normal samples were obtained from 8 of the specimens with tumor. The raw 
expression data (".dat" files and ".cel" files) of these two datasets were reanalyzed using MAS5.0 
software and normalized by the same global normalization method as that used for PITT data set. 
This procedure makes the three data sets comparable for the subsequent analysis. 
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 Table 2.1 Clinical and pathological features of the prostate tissue samples in the three data sets. 
 
 
 PITT Singh Welsh 
Tumor Samples 
No. of Tumor Samples 60 52 25 (24 unique samples) 
Features of Tumor Samples 
T2a 2 3.3% 7 13.5% 5 20.0%
T2b 21 35% 25 48.1% 6 24.0%
T3 0 0 1 4.0%
T3a 24 40.0% 16 30.8% 6 24.0%
T3b 11 18.3% 4 7.7% 2 8.0%
T4 1 1.7% 0 0.0% 0 
T4a 1 1.7% 0 0.0% 0 
Pathological 
Stage 
Tx 0 0 4 16.0%
5 2 3.3% 4 7.7% 1 4.0%
6 13 21.7% 15 28.8% 7 28.0%
7 28 46.7% 29 55.8% 9 36.0%
8 5 8.3% 2 3.8% 5 20.0%
Gleason Grade 
9 12 20.0% 2 3.8% 2 8.0%
40-49 4 6.7% 3 5.8% 2 8.0%
50-59 19 31.7% 24 46.2% 8 32.0%
60-69 24 40.0% 22 42.3% 14 56.0% Age 
70-79 13 21.7% 3 5.8% 0  
Other 
information 
PSA values before and after 
prostatectomy; recurrent; vital status; 
seminal vesicle invasion; extension 
through capsule; etc. 
PSA value; Gland volume; 
extension through capsule; 
positive surgical margin; 
seminal vesicle invasion; 
recurrent; non-recurrent; 
etc. 
Selected transcript levels 
(PSA, Hepsin, MIC-1); 
percentage of various cell 
types from the section 
adjacent to the tissue 
profiled; etc. 
Non-Tumor Samples 
No. of Non-Tumor Samples 81 50 8 
Donor 18 0 0 
Features of Donor samples 
 <10 1 5.6%  
 10-19 4 22.2%  
 20-29 5 27.8%  
 30-39 1 5.6%  
 40-49 3 16.7%  
 
Age 
50-59 4 22.2%  
Patient Normal 63 50 8 
Features of NAT samples 
 40-49 4 6.3% 3 6.0% 0 
 50-59 20 31.7% 21 42.0% 4 50.0%
 60-69 26 41.3% 23 46.0% 4 50.0% 
 
Age 
70-79 13 20.6% 3 6.0% 0  
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 2.3.2. Classification approaches 
Three classification methods were used in this study, the Boosted Decision Tree approach 
(BDT)[167], Support Vector Machines (SVMs)[112, 113] and the Weighted Gene Voting 
(WGV) method[32]. The goal was to introduce the decision tree learning method based on C4.5 
algorithm and compare its performance with the other two commonly used, successfully applied, 
classification methods.  
C4.5 Decision tree learning (DT) 
The decision tree learning programs used in this study were C4.5 Release 8 (Quinlan, 
1993), which is a freeware, and its related commercial product C5.0/See5 Release 1.17 
(RuleQuest Research Pty Ltd., Australia).  
C4.5 uses the “divide and conquer” technique (also called recursive partitioning) to 
construct a decision tree from the training set. Each member of the training set belongs to a 
single class (for example benign or malignant). Each member also has one or more attribute-
value vectors where the values are mutually exclusive (for example, invasive or not invasive). 
For a continuous attribute such as the expression level of a gene or the serum level of a marker, 
cut offs are uses to construct mutually exclusive outcomes (e.g. > 5.0 and <= 5.0). To create a 
tree, an attribute is selected based on the “information gain” and the training set is split 
(partitioned) into subsets where all members of a subset have the same value for the given 
attribute. This process is applied recursively until all subsets contain members of a single class. 
A simplified set of rules defining each leaf (class) can further be derived after the tree is grown. 
These rules are not expressed as a tree structure and may be more attractive to the user [168]. 
Information gain [168] measures of how well a given attribute/gene separates the training set into 
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 subsets. It is defined as the expected reduction in entropy caused by partitioning the examples 
according to this gene.  
Gain (S, A) ≡ Entropy (S) - ∑ |Sv| Entropy(Sv) / |S|; 
v Є Values (A)    (1) 
Where A is a gene, Values (A) is the set of all possible values for attribute/gene A, and Sv is the 
subset of S for which attribute/gene A has value v. Entropy [168] in equation (1) represents the 
purity of samples in a subset and is defined as:  
Entropy (S) ≡ ∑i –pi log2 pi     i = 1, …, c  (2) 
The decision tree built from training examples will be used to predict the classification of new 
examples (in the “testing” set). When a new example comes into the tree, it starts to traverse the 
decision tree from the root node. At each node, the corresponding test is performed on it. The 
outcome of the tested attribute determines the branch on which the sample will descend to the 
next test/node. This process ends when a leaf is encountered and the classification of this leaf 
determines the predicted class of this example.  
The boosting approach 
The See5/C5.0 Release 1.17 (RuleQuest Research Pty Ltd., Australia) has implemented 
adaptive boosting based on the work of Rob Schapire and Yoav Freund[169]. Boosting is a 
general method in machine learning to improve the accuracy of any given learning algorithm 
(not just decision trees) by generating and combining multiple inaccurate classifiers/rules. Each 
training example is given a weight. In each trial, the boosting algorithm generates a classifier 
based on all the weighted training examples and assigns a new weight to each of them based on 
the classification results such that misclassified examples get more weight as the classification 
proceeds. Adjusting weight at each round forces the learning algorithm to focus on the different 
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 examples and thus generates different classifiers. At the end, all the classifiers are combined by 
voting according to their accuracies to create a compound classifier[169]. In this study, the 
number of trials used was increased from 0 to 50 with a pace of 5 trials each time. 
Support vector machines (SVMs) 
Gist software tool for support vector machine classification version 2.0.2 is used in this 
study. It is developed by William Stafford Nobel in the Department of Computer Science at 
Columbia University and by Paul Pavlidis in the Columbia Genome Center 
(http://microarray.cpmc.columbia.edu/gist/). 
An SVM attempts to computes a multi-dimensional plane (a hyper-plane) that separates 
all members of two different classes in the multidimensional microarray data set. Specifically the 
SVM computes a “maximal margin hyper-plane” that separates the two classes in the training set 
such that each training example has a maximum distance between it and the hyper-plane. When 
training examples are not linearly separable in the input space, i.e. SVM can’t find a maximal 
margin hyper-plane that can completely separate the classes in the input space, SVM uses a 
kernel function to map all the training examples to a higher-dimensional feature space where a 
maximal margin hyper-plane can be located and thus training examples can be linearly separated 
by it[112, 113]. In this study, only the simple dot-product kernel is used. In addition, soft-margin 
has been applied by tuning the diagonal factor (DF) to control the training error[113]. The range 
of DF was set to 0, 0.01, 0.1, 0.5, 1, 2, 5 and 10.   
Weighted gene voting (WGV) 
Weighted Gene Voting (WGV) is a method for binary classification first proposed by 
Golub et al. (1999)[32]. In WGV, genes are ranked based on a selection metric such as the 
signal-to-noise metric[32]. Then for the selected genes, each gene casts a vote for class 1 or 2. 
75 
 Finally, a class vote for each example calculates as the summation of all the votes from the 
selected genes.   
2.3.3. Feature selection 
For our feature selection criterion, we use the signal-to-noise (S2N) metric developed by 
Golub et al. (1999)[32]. Given “n genes” and “m tissue samples”, each of the m tissue samples is 
labeled either 1or 2 depending on the comparison at hand. (e.g. Tumor (1) v Donor Normal (2)). 
For each of the n genes, we calculate the mean, µ1 and µ2, and standard deviation, σ1 and σ2, 
for the samples labeled 1 or 2 respectively. The signal-to-noise metric is calculated as:  
S2Nij = (µij-µij) / (σij+σij); i = 1, …, n, and j = 1, 2; 
The S2N metric gives the highest and lowest scores for genes whose expression levels 
differ most on average in the two classes while also favoring those with small deviation in scores 
in respective classes. Genes are then ranked by S2N. The most positive and most negative genes 
are genes selected as the most differentially expressed, and therefore the top ranked, features 
used in this study. 
2.3.4. Experimental method 
Purposes of this study were to compare the effectiveness of the three classification methods 
(BDT, SVM, and WGV) across a series of data sets and to explore the classification tasks with 
gene expression data generated from human cancer specimens. The Experimental method can be 
described as follows (figure 2.1).  
The initial phase of the study (Figure2 1a) concentrated on the binary classification of 
Tumor and Non-Tumor samples in the PITT data set. As we described before, Non-Tumor 
samples in the PITT data set consist of Patient Normal samples and Donor Normal Samples. We 
applied each of the three classification methods (BDT, SVM, and WGV) to this comparison 
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 using a “leave-one-out” cross-validation (LOOCV) format (Figure2 1b). Initially, this was done 
against the entire feature set (~ 12,600 feature/sample). 
Returning to the initial data set, in the leave-one-out format, we used the S2N method (vide 
supra) to rank each feature (gene) for differential expression in the comparison of Tumor v Non-
Tumor samples (i.e. gene selection is also subjected to cross-validation). We then progressively 
re-applied the classification methods (in the same leave-one-out format) to data sets limited to 
the most differentially expressed features (genes) in the comparison (as determined by the S2N 
algorithm). This was done at various levels of stringency, resulting in data sets that represented 
the 2000, 1000, 500, 200, 100, 50, 20 and 10 most differentially expressed features in the 
comparison. At each level of stringency, equal numbers of the most up and down regulated genes 
were selected to compose the pre-selection features (e.g. the 2000 most significantly expressed 
genes contain 1000 most up regulated genes and 1000 most down regulated genes). The results 
of each classifier, at each level of pre-selection of features, were then compared (figure 2.1b).  
In the second phase of the analysis (figure 2.1a), Patient Normal samples and Donor Normal 
samples from the Non-Tumor category in the PITT data set were used separately to build 
classifiers with Tumor samples (in the PITT data set) separately. This gave us two types of 
comparisons: Tumor v Patient Normal and Tumor v Donor Normal. As in the phase 1, the three 
classification methods were first used to generate classifiers using the full feature (gene) set and 
a series of smaller feature (gene) sets selected for differential expression using the S2N metric in 
a LOOCV fashion. The Tumor v Patient Normal and Tumor v Donor Normal) classifiers were 
further investigated by using the PITT data set as a training set and two, previously published, 
independent data sets as test data sets. As in phase 1, the three methods were first used to 
generate and test classifiers using the full feature sets and a series of smaller feature sets selected 
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 for differential expression using the S2N algorithm. It is important to note that this time the most 
significantly expressed genes were selected using all training samples in the comparison because 
the performance of the classifiers was assessed by its ability to predict classes of independent 
samples (Figure 2.1c). 
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Figure 2.1 Depicts the experimental method in detail.  
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 Figure 2.1 legend: a) Illustrates the three phases of the experimental design. Four types of 
classifiers were built from three types prostate tissue samples in PITT data set. b) shows the 
procedures for the leave-one-out cross-validation (LOOCV) experiments when combining with 
feature selection. Two classes of tissue samples, class A and class B, are used to construct 
classifiers where class A has n tissue samples and class B has m tissue sample. When performing 
LOOCV using the full set of genes (all genes), a classifier (Class A v Class B) was built with 
(n+m-1) tissue samples and then used to predict the class membership of the tissue sample left 
out. This process was repeated (n+m) times until all tissue samples had been left out once. When 
feature selection is performed in combination with LOOCV, feature selection is performed using 
the (n+m-1) tissue samples to generate a series reduced feature sets consisting of a pre-defined 
number (2000, 1000, 500, 200, 100, 50, 20, 10) of most significantly expressed genes (i.e. 
feature selection is also subject to leave-one-out cross validation). Classifiers (Class A v Class B) 
are constructed use the reduced feature sets and used to predict the classification of the one left-
out tissue sample. This process is performed (n+m) times as each sample needs to be left out 
once. Prediction results for each left-out tissue sample are summarized to give the LOOCV 
results using the reduced feature sets. LOOCV results are shown in Figure 2.2c and Table 2.2) 
Shows the procedure of validating classifiers on independent data. The classifiers (Class A v 
Class B) are built from both the full feature set (all genes) and the reduced feature sets generated 
by feature selection procedure and tested on predicting the class membership of the tissue 
samples in the same test data set. Prediction results are summarized in Figure 2.2 and the best 
results are listed in Table 2.3.  
 
80 
 2.3.5.  Performance evaluation 
Four types of classifiers were generated for binary classification of the prostate specimens: 
a classifier for Tumor v Non-Tumor samples, a classifier for Tumor v Donor Normal samples, a 
classifier for Tumor v Patient Normal samples and a classifier for Patient Normal v Donor 
Normal Samples. Tumor samples are always considered as “positive” and the other type of tissue 
samples, Non-Tumor, Patient Normal, or Donor Normal, are “negative” samples in these 
comparisons. In the Patient Normal v Donor Normal comparison, Patient Normal is “positive” 
and Donor Normal is “negative”. The “positive” and “negative” assignments are arbitrary but 
necessary for measuring the performance of a classifier discussed in the following paragraph.  
The performance of each classifier was measured by examining how well it identified 
tissue samples belonging to its two classes in the training set itself while doing LOOCV or in the 
test sets since the class assignment of each tissue samples were known prior of learning. Using 
the classifier for Tumor v Non-Tumor as an example, each tissue sample can be categorized in 
one of four ways: the true “positives” (TP) and the true “negatives” (TN) are the Tumor and the 
Non-Tumor tissue samples, respectively, according to both the classifier and their true class 
assignments; the false “negatives” (FN) are Tumor tissue samples classified as Non-Tumor tissue 
according to the classifier; the false “positives” (FP) are Non-Tumor tissue samples classified as 
Tumor by the classifier. The number of samples in each category is reported for each of binary 
classifier. The overall performance is measured by the “Accuracy” of classification. Accuracy is 
calculated as Accuracy = (TP + TN) /Sum where Sum = (TP + TN + FP + FN). 
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 2.4.Results 
2.4.1. Tumor v Non-Tumor classification 
Table 2.2 shows the best leave-one-out cross-validation (LOOCV) results of the classifiers 
built from Tumor and Non-Tumor tissue samples in the PITT dataset using the three 
classification methods – BDT, SVMs and WGV. Feature reduction was also applied and cross 
validated. (LOOCV results at different levels of feature selection are given in Figure 2.2a.) 
Parameters of each method were tuned to get the best classification results. All classifiers gave 
comparable accuracies, between 0.74 and 0.8, while using reduced feature sets. The best 
LOOCV result was generated by boosted decision tree (BDT) method where 41 of the 60 Tumor 
samples and 72 of the 81 Non-Tumor samples were classified correctly.  
These results illustrate that Tumor tissue samples cannot be classified accurately in 
LOOCV when Non-Tumor samples were used as the “baseline” to build classifiers (since the 
best LOOCV result is 0.8 as discussed above). In addition, the poor performance of the 
classifiers for Tumor v Non-Tumor makes the validation on independent data sets less essential. 
We did not further investigate prostate tissue classification with this classifier. 
2.4.2. Tumor v Patient Normal classification and Tumor v Donor Normal 
classification 
Non-Tumor tissue samples were separated into two groups – Patient Normal samples and 
Donor Normal samples based on their tissue origins. Tissue samples in each group were then 
used to build classifiers against Tumor tissue samples. Thus two types of binary classifiers were 
generated – a classifier for Tumor v Patient Normal and a classifier for Tumor v Donor Normal. 
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 Table 2.2 LOOCV results of the four types of classifiers built by PITT data set using three methods. 
 
 
BDT: boosted decision tree; SVM: support vector machine; WGV: weighted gene voting; FP: false positive; FN: 
false negative; TP: true positive; TN: true negative; AC: accuracy; DF: diagonal factor. 
Classifiers Tumor vs. Non-Tumor 
Tumor v Patient 
Normal 
Tumor v Donor 
Normal 
Patient Normal v 
Donor Normal 
classification 
methods BDT SVM WGV BDT SVM WGV BDT SVM WGV BDT SVM WGV 
Parameters Boost 0 
DF 
0.1 NA 
Boost 
30 
DF 
0.5 NA 
Boost 
0 
DF 
0.1 NA 
Boost 
5 
DF 
0.1 NA 
Feature 20 50 100 20 200 1000 20* 50 100 500 200 100 
FP 9 21 19 13 21 18 1 1 1 4 0 1 
FN 19 15 16 16 16 17 3 0 1 1 2 4 
TP 41 45 44 44 44 43 57 60 59 62 61 59 
TN 72 60 62 50 42 45 17 17 17 14 18 17 
AC 0.80 0.74 0.75 0.76 0.70 0.72 0.95 0.99 0.97 0.94 0.98 0.94 
*: When the classification results are the same at different levels of feature selection, the smallest number of genes 
is reported. 
 
2.4.2.1. LOOCV results 
LOOCV results at each level of feature selection are given in Figure 2.2b and Figure 2.2c 
whereas the best results generated from each method are shown in Table 2.2. 
The classifiers for Tumor v Patient Normal did not perform well in LOOCV experiments. 
All three methods gave similarly low accuracies (< 0.8). The BDT classifier gave the highest 
accuracy of 0.76 when applied to the 20 most significantly expressed genes. 16 of the 60 Tumor 
tissue samples and 13 of the 63 Patient Normal tissue samples were misclassified as Patient 
Normal and Tumor respectively. SVMs gave the lowest accuracy of 0.7 (using 200 most 
significantly expressed genes. In aggregate, Tumor v Patient Normal classifier results were no 
better and actually even a little worse than the LOOCV results from the classifiers for Tumor v 
Non-Tumor.  
The classifier for Tumor v Donor Normal, however, yield significantly high accuracies in 
LOOCV study. All three methods gave accuracies above 0.9. Classifiers built by BDT had the 
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 lowest accuracy of 0.95 and the classifiers by SVMs gave the highest accuracy of 0.99 where 
only 1 Donor Normal tissue sample (and no Tumor samples) was misclassified.  
These results show that Tumor samples can be classified correctly in LOOCV when 
Donor Normal samples were used as “baseline” to create the classifiers. Patient Normal samples 
on the other hand were difficult to separate from Tumor samples regardless of classification 
method or degree of feature selection.  
2.4.2.2. Validation on independent data 
The two types of classifiers (Tumor v Donor Normal and Tumor v Patient Normal) built 
from the three methods were further validated on two independent data sets – the Singh data set 
and the Welsh data set. Although the classifiers for Tumor v Patient Normal had demonstrated 
poor prediction accuracy in LOOCV, we still attempted to validate the Tumor v Patient Normal 
classifiers on the independent data sets. The results were compared with those from the 
classifiers built on the Tumor v Donor Normal comparison (Table 2.3, Figure 2.2e, f, h and i). 
As we expected, the classifiers for Tumor v Patient Normal (Table 2.3 and Figure 2.2e) 
generated from all three methods did not give good accuracy on predicting the class membership 
of the Tumor and Patient Normal tissue samples in the Singh data set. The lowest accuracy is 
0.73 and is obtained by the classifier built by WGV. The highest accuracy was 0.84 by the 
classifiers built by SVMs where 11 of the 52 tumor tissue samples and 5 of the 50 Patient 
Normal tissue samples in the Singh data set were misclassified as Patient Normal and Tumor 
correspondingly. 
Significantly, in the original paper by Singh et al.[38], Tumor samples and Patient Normal 
samples in that data set had been reported to show significant differences in gene expression and 
were classified successfully (LOOCV accuracy was 0.95) by a nearest neighbor classifier. 
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 However, such two notably distinct types of tissue samples were inseparable by our classifiers 
built using the Tumor and Patient Normal tissue samples in the PITT data set regardless of the 
classification method employed. 
Table 2.3 Validation results of three types of classifiers built by PITT data set built by three methods on two 
independent data sets. 
 
 
Classifiers Tumor v Patient Normal 
Tumor v Donor 
Normal 
Patient Normal v 
Donor Normal 
Validation on Singh Data Set 
Classification 
methods BDT SVM WGV BDT SVM WGV BDT SVM WGV 
Parameters Boost 35 
DF 
1 NA 
Boost 
10 
DF 
0.01 NA 
Boost 
5 
DF 
0 NA 
Feature 200 200 20 10 20 100 10 20 500 
FP 10 5 24 0 0 0 0 0 0 
FN 13 11 4 0 1 0 2 4 0 
TP 39 41 48 52 51 52 48 46 50 
TN 40 45 26 0 0 0 0 0 0 
AC 0.77 0.84 0.73 1 0.98 1 0.96 0.92 1 
Validation on Welsh Data Set 
Classification 
methods BDT SVM WGV BDT SVM WGV BDT SVM WGV 
Parameters Boost 15 
DF 
5 NA 
Boost 
5 
DF 
0 NA 
Boost 
0 
DF 
0.1 NA 
Feature 1000* 50 100 10 10 50 10 10 100 
FP 0 0 0 0 0 0 0 0 0 
FN 1 1 1 0 0 0 0 0 0 
TP 24 24 24 25 25 25 8 8 8 
TN 8 8 8 0 0 0 0 0 0 
AC 0.97 0.97 0.97 1 1 1 1 1 1 
BDT: boosted decision tree; SVM: support vector machine; WGV: weighted gene voting; FP: false positive; FN: 
false negative; TP: true positive; TN: true negative; AC: accuracy; DF: diagonal factor. 
*: When the classification results are the same at different levels of feature selection, the smallest number of genes is 
reported 
 
On the other hand, the validation of the Tumor v Patient Normal classifiers on Welsh data set 
(Table 2.3 and Figure 2.2h) was very successful. Classifiers from all three methods gave the 
same high accuracy of 0.97. Only one Tumor tissue sample from the Welsh data set was 
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 misclassified and all Patient Normal tissue samples were classified perfectly as Patient Normal. 
This result is contradictory to the poor prediction results on Singh data set discussed above and 
was somewhat surprising.  
Welsh data set was also used by authors of the Singh data set to validate a nearest 
neighbor classifier for Tumor v Patient Normal tissue samples in the Singh data set. The 
prediction accuracy was also notable high (Accuracy was 86% using 16-gene model despite a 
10-fold difference in overall microarray intensity between these data sets.)[38]. However similar 
classifier developed using the Singh data set failed to predict the classes of Tumor and Patient 
Normal tissue samples in the PITT data set accurately (accuracy ~ 72%, data not shown).  
The finding that classifiers built on the PITT Tumor v Patient Normal and classifiers built 
on the Singh Tumor v Patient Normal both validate in the Welsh data set yet do not validate 
against each other’s data set suggests that there maybe a limitation in use of the Welsh data set 
for validation. The Welsh data set has good internal control and limited noise, but is rather small, 
containing 25 Tumor tissue samples and 8 Patient Normal samples and therefore may not 
represent all the characteristics of the Tumor and Patient Normal prostate tissue population. 
Thus, the prediction results on this data set may not provide enough information about the 
accuracy of Tumor v Patient Normal classifiers. 
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Figure 2.2 Bar charts on the comparisons of accuracies of the classifiers built by the three methods at 
different level of feature selection.  
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 Figure 2.2 legend: x axis is the number of genes used in common log scale (log 10); y axis 
represents accuracy. DBT: boosted decision tree, SVMs: support vector machines; WGV: 
weighted gene voting. Accuracies are represented by bars. The accuracy bars of the same type of 
classifiers built by the three methods using the same number of significant genes are grouped 
together. 
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 Since neither the Singh data set nor the Welsh data set have Donor Normal tissue 
samples, only the Tumor tissue samples were used to validate the performance of the classifier 
for Tumor v Donor Normal built by the three classification methods from PITT data set. 
Therefore, in Table 2.3, the true negative and false positive categories are empty and accuracies 
were calculated based on the classification results of Tumor tissue samples in the two data sets. 
The lack of Donor Normal tissue samples in the two independent test data sets limits the 
complete evaluation of the performance of this classifier. In particular, no information will be 
provided on the specificity of this classifier giving that specificity is measured by dividing true 
negatives with all “negative” samples. Here, the specificity of this classification is defined as the 
probability that a tissue sample is not classified as Tumor given that it is not a Tumor tissue 
sample (it is a Donor Normal tissue sample). However, we know of no other prostate cancer data 
set in the public domain that has Donor Normal tissue samples. LOOCV results of the classifier 
for Tumor v Donor built by PITT data set (reported above) can provide nearly unbiased error 
estimate. Furthermore, the Tumors are more difficult to classify and the classifiers’ performance 
on Tumor tissue samples is more interesting to us. We report the validation results in Table 2.3 
and Figure 2.2.  
The classifiers for Tumor v Donor Normal built with PITT data were very successful in 
predicting the classes of the Tumor tissue samples in Singh and Welsh data sets (Table 2.3 and 
Figure 2.2f, 2i). Both the classifier built by BDT and the classifier built by WGV perfectly 
classified all Tumor tissue samples while the classifier by SVMs misclassified one Tumor tissue 
sample in Singh data set. All the classifiers built by the three methods perfectly predicted the 
classification of all Tumor tissue samples in the Welsh data set. Compared with the validation 
results of the classifier for Tumor v Patient Normal discussed earlier, these results suggest that 
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 Tumor tissue samples in the two independent data sets are classified perfectly by the classifiers 
using Donor Normal as “baseline”.     
Both the results of LOOCV and results of validation on the two independent data sets imply 
that Donor Normal is a better “baseline” than Patient Normal. The Tumor and Patient Normal 
tissue samples in the PITT data set cannot be easily separated from each other in LOOCV study 
and the classifier built from these samples cannot predict the classes of the Tumor and Patient 
Normal tissue samples in the Sign data set. On the other hand, the Tumor tissue samples in the 
PITT data set are remarkably distinct from Donor Normal tissue samples in both the PITT data 
set and the two independent data sets. The Non-Tumor class is a pool of both Patient Normal and 
Donor Normal tissue samples and therefore the performance of the classifiers based on the  
Tumor v Non-Tumor comparison was significantly worse than the classifier for Tumor v Donor 
Normal but slightly better than the classifier for Tumor v Patient Normal (regardless of 
classification method).  
2.4.3. Patient Normal v Donor Normal classification      
Based on the results above, we postulated that Patient Normal tissue samples in the PITT 
data set are significantly different from Donor Normal samples in the PITT data set and a 
classifier for Patient Normal v Donor Normal would perform successfully. Classifiers for Patient 
Normal v Donor Normal were built by all three methods using 63 Patient Normal and 18 Donor 
Normal tissue samples in the PITT data set.  
The best LOOCV accuracies (Table 2.2 and Figure 2.2d) are all above 0.9 and classifiers 
built by BDT and WGV gave the same accuracy of 0.94. The best accuracy of 0.98 was 
generated by SVMs in which only two of the Patient Normal tissues were misclassified as Donor 
Normal and all Donor Normal tissues were perfectly identified.  
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 Results of validating the classifiers for Patient Normal v Donor Normal on two independent 
data sets were also reported in Table 2.3 and Figure 2.2g, 2j. Once again, since the Singh and 
Welsh data sets do not have Donor Normal tissue samples, the accuracies were measured by the 
classification results of Patient Normal samples only. While predicting the classification of 
Patient Normal tissues in the Singh data set, all classifiers gave similar, very high, accuracy 
above 0.9. The WGV classifier achieved the best prediction accuracy with all of the 50 Patient 
Normal samples in the Singh data set perfectly classified. All classifiers built from the three 
methods gave an accuracy of 1 (100%) when validating on the 8 Patient Normal tissue samples 
in the Welsh data set. 
These results confirm the distinction between Patient Normal and Donor Normal tissues in 
the PITT data set. Significantly, using the Donor Normal tissues as “baseline”, the classifiers 
built from PITT data set predict the classification of Patient Normal tissues in the two 
independent test data sets very well and as such suggests the Donor Normal tissues are different 
from all the Patient Normal tissues we tested (see more in Section 2.4.4).  
By combining these results with the results from the classifiers for Tumor v Donor 
Classification, we recognize that Donor Normal in the PITT data set is a unique type of Non-
Tumor prostate tissues that has remarkable distinctions from Tumor prostate tissues and Patient 
Normal. This makes classification tasks using Donor Normal as “baseline” highly successful. It 
is important however to remember that these results do not imply anything about the reason that 
Donor Normal and Patient Normal act as distinct entities (see more in Section 2.5). 
2.4.4. Classification of tissue samples from unseen classes 
Classification of tissue samples from unseen classes includes: predicting the classification 
of tissue samples from other organ using all the classifiers we tested in this study, predicting the 
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 classification of Donor Normal tissue samples using a classifier for Tumor v Patient Normal, 
predicting the classification of Tumor tissue samples using a classifier for Patient Normal v 
Donor Normal and predicting the classification of Patient Normal tissue samples using a 
classifier for Tumor v Donor Normal. (The first two prediction tasks are beyond the scope of this 
study.) The last two prediction tasks are particularly interesting to us as they can provide insight 
on the specificity of the Tumor v Donor Normal and the Patient Normal v Donor Normal 
classifiers, when Donor Normal tissues are absent from the independent test sets.  
We used the exactly same classifiers for Tumor v Donor Normal and for Patient Normal v 
Donor Normal in Table 2.3 to predict the class memberships of the Patient Normal tissue and 
Tumor tissue samples in the Singh and Welsh data sets correspondingly as those classifiers built 
by each method gave the best validation results. In another words, the exact parameters and 
reduced feature sets were used to construct the classifiers using PITT data set by each method 
that were then used to predict the classification of the tissue samples from an unseen class in the 
two independent data sets.  
Table 2.4 shows the prediction results. Most of the Patient Normal tissue samples in the two 
independent data sets were predicted as Tumor by the classifiers for Tumor v Donor Normal 
built by all three methods. Whereas most of the Tumor samples were put in the Patient Normal 
category by the classifiers for Patient Normal and Donor Normal. This result suggest that 
classifiers for Tumor v Donor Normal and for Patient Normal v Donor Normal were able to 
distinguish tissue samples from different patient origins as both the Tumor and Patient Normal 
tissue samples were mostly not predicted as Donor Normal. In addition, this result provides 
additional support on the uniqueness of Donor Normal tissues.   
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 Table 2.4 Results of the two types of classifiers built by PITT data set using three methods on the 
classification of tissue samples from unseen classes in independent data sets. 
 
 
Classifiers Tumor v Donor Normal Patient Normal v Donor Normal 
Tissue samples for 
prediction in each 
independent data set 
Patient Normal Tumor 
Singh Data Set 
Classification methods BDT SVM WGV BDT SVM WGV 
AC (from Table 2.3) 1 0.98 1 0.94 0.92 1 
Classified as Donor 
Normal 1 5 5 2 0 0 
Classified as Tumor 49 45 45 50 52 52 
Welsh Data Set 
Classification methods BDT SVM WGV BDT SVM WGV 
AC (from Table 2.3) 1 1 1 1 1 1 
Classified as Donor 
Normal 0 2 1 1 1 1 
Classified as Tumor 8 6 7 24 24 24 
BDT: boosted decision tree; SVM: support vector machine; WGV: weighted gene voting; FP: false positive; FN: 
false negative; TP: true positive; TN: true negative; AC: accuracy. 
 
2.4.5. Feature selection on classification accuracy 
We have observed in Table 2.2 and 2.3 that most of the best accuracies are obtained while 
performing classification using a small subset of significantly expressed genes instead of the full 
set of genes. Comprehensive investigation of the effect of feature selection on classification 
accuracy results in constructing Figure 2.2 where the classification results of each classifier at 
different level of feature selections are plot and compared. 
Performances of the classifiers built by the BDT method appear to be significantly affected 
by feature selection. Five of the ten results, the LOOCV accuracy of the classifier for Tumor v 
Non-Tumor (Figure 2.2a), the LOOCV accuracy of the classifier for Tumor v Patient Normal 
(Figure 2.2b), the accuracy of the classifier for Tumor v Patient Normal validating on Singh data 
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 (Figure 2.2e) and the accuracies of the classifier for Patient Normal v Donor Normal validating 
on both Singh and Welsh data (Figure 2.2 g and j), show significantly increase in accuracies 
along with the decrease of the number of significantly expressed genes used. The accuracy of the 
classifier for Tumor v Patient Normal validating on Welsh data, however, earns low accuracies 
when decreasing the number of significant genes used. Both the LOOCV accuracy and the 
accuracies of the classifier for Tumor v Donor Normal validating on both Singh and Welsh data 
are not affected by feature selection although the best LOOCV accuracy is gained using either 20 
or 50 most significant expressed genes. 
The performances of the classifiers built by the SVMs, on the other hand, have not been 
affected much by feature selection. Only the accuracies of the classifier for Patient Normal v 
Donor Normal validating on Singh (Figure 2.2g) and Welsh data (Figure 2.2j) significantly 
increased when decreasing the number of significant genes used. All other accuracies have not 
shown considerable trends along with feature selection. This finding agrees with other 
studies[113]. 
Finally, the accuracies of the classifiers built by WGV showed similar trends as those of the 
classifiers built by support vector machines. Most of the accuracies have not been affected by 
feature selection. The LOOCV accuracy of the classifier for Tumor v Patient Normal (Figure 
2.2b) and the accuracy of the classifier for Patient Normal v Donor Normal validating on Singh 
data (Figure 2.2g) decreased when reduce the number of significant genes used. The accuracy of 
the classifier for Tumor v Patient Normal validating on Welsh data (Figure 2.2e) increased 
significantly while decreasing the number of significant genes used. 
In the aggregate, the BDT appears to favor small subsets of significant genes; SVMs 
performs well regardless of the number of genes used; whereas the WGV approach functions 
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 badly when the number of significant genes used is too small (10 genes or 20 genes). It is hard to 
summarize a rule to predict the perfect number of genes for a given classification method. The 
number of genes used to achieve the best accuracies depends on the data set and individual 
classification method used. Significantly, the performances of the classifiers built by the three 
methods are not adversely affected if the number of genes used is reduced from 12,000 to 2,000 
or less. However, this feature selection dramatically decreases the complex city and cost of the 
classification task.  
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 2.5.Discussion 
The main goals of our work are to create highly accurate classifiers based on microarray 
gene expression data and make sound predictions on the classification of prostate cancer tissue 
samples. To this end, the classifiers for Tumor v Donor Normal and for Patient Normal v Donor 
Normal built from PITT data set performed very well in both leave-one-out cross validation 
studies and validation on independent data sets. These results were independent of the methods 
(BDT, SVM and WGV) used to build the classifiers. On the other hand, classifiers for Tumor v 
Non-Tumor (where Non-Tumor tissue samples consist of Patient Normal and Donor Normal 
tissue samples) and the classifiers for Tumor v Patient Normal built from PITT data set gave low 
accuracies in leave-one-out cross validation regardless to classification method. For comparison, 
the Tumor v Patient Normal classifiers were validated on independent data with the expected 
poor results. These results indicate that quality of data and type of baseline data employed is 
much more important than the specific classification method used, and is an important factor in 
microarray analysis of prostate cancer. 
It is important to note that the Tumor v Patient Normal comparison and the Tumor v 
Donor Normal comparison are fundamentally different. In the Tumor and Patient Normal 
classification, both the Tumor and Patient Normal samples are from the same patient population 
(prostate cancer patients undergoing prostatectomy) and from the same type of surgical 
specimens (prostates with cancer taken at surgery).[38-40] Donor Normal samples are from a 
different population (health organ donors) and specimen types (cancer free prostates taken at the 
time of organ harvest)[40]. The differences picked up by the classifiers for Tumor v Donor 
Normal built from the PITT data set may therefore be secondary to either biology or artifact 
(differences in processing or population) or both. That said, the classifiers for Tumor v Donor 
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 Normal proved capable of accurately separating Tumor from Non-Tumor samples in all three 
data sets containing Tumor and Patient Normal tissue samples. It is our belief that at least some 
of this separation may be due to biologic differences between prostate cancer and truly normal 
donor prostate (and, by extension, some biologic similarities between tumor and adjacent normal 
appearing tissue from a diseased gland). These distinctions in underlying population and tissue 
origins also contributed to the success of the classifiers for Patient Normal and Donor Normal 
built from PITT data set in predicting the classification of all the Patient Normal tissue samples 
in all three data sets.   
We have further investigated the possible causes for the poor prediction results of the 
classifiers built from PITT Tumor v Patient Normal data on the Singh data set. As mentioned 
briefly in the results section, we built classifiers on the Singh Tumor v Patient Normal data set 
using all three classification methods and evaluated them through the leave-one-out cross 
validation and against two independent data sets (PITT and Welsh data sets). All classifiers 
performed very well in LOOCV (accuracy ~ 95%) and against the Welsh data set but poorly 
(accuracy ~ 0.72) against the PITT Tumor v Patient Normal data. The significant LOOCV 
differences in Tumor v Patient Normal classifiers built on the PITT (accuracy ~ 70%) and Singh 
(accuracy ~ 95%) indicates there may be differences in the either the population, sampling, 
processing or a combination between the two data sets. 
These findings have implications for microarray analysis and prostate biology. Classifiers 
for Tumor v Patient Normal built on the Singh data using all three methods performed well in 
LOOCV, indicating that there were expression differences between Tumor and Patient Normal 
samples that can support a robust classification. Results from original Singh paper[38] also 
provided evidence for distinctions in gene expression between the two types of tissues in Singh 
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 data. Classifiers for Tumor v Patient Normal built on the PITT data performed poorly in 
LOOCV, indicating limited and fairly soft gene expression differences between sample types. 
Barring differences in laboratory technique or quality (which cannot be determined from the 
data, as no quality control data is provided) one could attempt to reconcile these differences 
based on potential difference in population, tumor grade or stage, or sampling.  Patient Normal 
samples could have been taken closer or further away from the tumor. In other studies several 
groups have reported molecular differences in normal appearing prostate immediately adjacent to 
tumor[45, 170]. It is also possible that the samples were taken from different anatomic lobes (i.e. 
posterior versus central) and therefore might reflect topographical variation in expression 
patterns because of different epithelium/stromal/smooth muscle ratios.  
Careful evaluation of the original papers, as well as discussions with the authors, 
indicates that though there were multiple, relatively small differences in samples (Table 2.1) and 
the way they were taken, processed, stored. It is very difficult to determine which if any of these 
factors are responsible for the significant difference in classifier performance. This appears to be 
another example for the growing consensus in the literature[93, 171] of importance of careful 
experimental design, tissue sampling, quality control and documentation of all aspects of 
microarray studies, not just statistical analysis. 
Another contribution of this study came from the simultaneous application of three 
classification methods. This approach helped to minimize any possible impairment on the 
classification results because of a bad classification algorithm. The results indicate that the C4.5 
based decision tree learning approach, if boosted, performed equivalently to the classification 
performance produced by more accepted microarray classification methods such as support 
vector machines and weighted gene voting.  
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 The decision tree based classifiers are of particular interest to the clinical application of 
microarray analysis because, unlike many classifiers, decision tree classifiers are easy to 
understand and the output - the learned decision trees and the induced rules sets - are remarkably 
easy to interpret. Decision trees are non-parametric, can incorporate numeric and categorical 
attributes, and are robust in the face of missing values. Furthermore, decision trees can be used to 
explore and reveal correlations and interactions between genes that exist in biologic systems and 
provide information on the relationship between attributes and classes. The C4.5 decision tree 
learning method[167] also aids in the selection of a small set of relevant genes by automatically 
selecting genes (on the basis of information gain) that are the most informative to the 
classification problem at hand. This property may make decision tree learning the optimal 
classification method in clinical applications of gene expression data. 
Despite their potential advantages, decision tree based classifiers have not been widely 
applied to the analysis of microarray data. Brown et al.(2000)[112] applied decision tree 
classifiers based on the C4.5 algorithm to the classification of genes and reported that results 
were inferior to those produced by Support Vector Machine classification. Zhang et al 
(2001)[115] introduced a decision tree based approach and claimed to be able to classify breast 
and colon cancer specimens successfully. However, the authors of that paper introduced 
selection bias while performing cross-validation after selection of the informative genes using 
the full data set. Therefore, the very high accuracies from cross validation are biased.   
Finally, it is important to note that it is the underlying gene expression, a function of both 
biology and experimental procedure that determines the classification performance. Differences 
in experimental design, specimen types, patient populations between different data sets, as well 
as the lack of consistent quality control documentation across the entire microarray experimental 
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 process remarkably affected the microarray results and as such provided the most significant 
difficulties in classification tasks. .  
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3. CHAPTER III Integration of microarray data sets with platform dependent solutions  
Presented as a Poster at Critical Assessment of Microarray Data Analysis 2003 Conference 
3.1.Abstract 
Comparison and integration of gene expression data generated at different institutions 
and across different DNA microarray platforms have become major tasks for many studies 
involving DNA microarray experiments. Accordingly, integration of information from several 
data sets of lung cancer gene expression profiling studies had become the major challenge of the 
Critical Assessment of Microarray Data Analysis 2003 conference (CAMDA’03). This study 
describes the analysis efforts attempted to integrate gene expression profiling results of lung 
cancer studies from two distinct research institutions using two generations of Affymetrix 
GeneChip® arrays. Results were presented on CAMDA’03 conference as a poster. In order to 
combine gene expression data, two data integration strategies were used in this study. One 
method integrates gene expression data using overlapped GenBank accession numbers or any 
other common identification from public databases across different DNA microarray platforms. 
The other method, in contrast, is a strategy specific for the Affymetrix GeneChip® arrays as it 
uses the probe-level matching information to achieve data integration. Integrated data was 
compared to examine whether these solutions are sufficient to achieve integrate between studies. 
We also discuss some of the issues relating to integrating diverse data sets. 
101 
 3.2.Introduction 
Gene expression profiling with DNA microarray based experiments have recently been used in 
molecular classification of cancers[33, 34] and prediction of clinical outcomes using clinical 
specimens[35, 36]. Usually, a number of studies on a particular type of cancer are conducted 
independently over years and/or at more than one institution because of the high cost of 
microarray experiments and limited availability of clinical specimens. As a result, multiple 
microarray data sets can be generated for the same cancer type and cover the same question in 
cancer biology. If integrated, these data sets could contribute significantly towards inter-study 
validation and the development of cancer biomarkers.  
However, integration of microarray gene expression data is not straightforward. 
Microarray gene expression data sets may be generated from different microarray platforms or 
different versions of arrays within the same platform. As reviewed in Chapter I, there exist a 
number of microarray platforms differing in probe deposition methods, number of probes per 
target, probe sequences and targets identified[2, 4, 25, 28]. Even within a single platform such as 
Affymetrix GeneChip® arrays, various versions of arrays or array sets differ in probe and target 
sequences making comparison between versions difficult. Consequently, the integration of 
information from different microarray dataset becomes a major challenge in many analyses using 
data from microarray experiments.  
HG_U95Av2 and HuGeneFL arrays were used to generate lung cancer data sets at two 
institutions (Table 3.1)[33, 35]. Both of them survey gene expression in human genomes; there 
are several major differences between them. First, the two arrays have different number of probe 
sets which represents different full-length genes. HuGeneFL is an early generation array which 
has 7,129 probe sets representing 5,600 full-length human genes. Most of the full-length genes 
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 on this array were selected from UniGene build 18 and the rest of them were from either 
GenBank or TIGR (The Institute for Genomic Research). HG_u95Av2, in contrast, has 12,600 
probe sets and monitors the expression level of approximately 10,000 full-length genes, all of 
which were selected from UniGene build 95. There is some overlap of the full-length genes 
represented by the two arrays. The degree of overlapped is discussed in Section 3.4.1. Second, 
the number of probe pairs in a probe set on each array is different. HuGeneFL uses 20 probe 
pairs in a probe set to represent a transcript in the human genome while HG_U95Av2 uses 16 
probe pairs instead. Furthermore, for a probe set representing the same transcript in human 
genome on the two arrays, the probes in this probe are not identical. These three major 
differences should be taken into consideration when attempting to integrate gene expression data 
generated from the two arrays.   
In this study, we have attempted to devise two strategies to integrate two lung cancer data 
sets generated using either HuGeneFL or HG_U95av2[33, 35] and examine whether these 
solutions are sufficient to achieve integrate between studies.  
3.3.Materials and methods 
3.3.1. Data sets 
Two data sets on lung cancer were used to plan two approaches for integrating gene 
expression profiling results from different generations of the Affymetrix GeneChip® arrays. One 
data set (Harvard)[33] was generated at Harvard using Affymetrix HG_U95Av2 arrays and the 
other (Michigan)[35] was generated at Michigan using Affymetrix HuGeneFL arrays. Table 3.1 
summarizes and compared these two studies including: the types of microarrays, patient 
demographic information, clinical variables, and processions presented in the original repots. 
Many fields in the table have no information from the original reports and therefore filled with 
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 “NA”. The “.cel” files from both data sets were downloaded for data integration and further 
analysis.  
Table 3.1. Comparison of the two lung cancer data sets for integration. 
 
 
 
  Harvard Michigan 
Microarray types HG_U95Av2 HuGeneFL 
No. of Transcripts on the array 12,600 7,129 
No. of full-length Genes represented 10,000 5,600 
UniGene Build No. 95 18 
Other Sequence Databases NA GenBank, TIGR 
DNA 
Microarrays 
Probe pairs 16 20 
Total number of patients in study 203 96 
Primary lung adenocarcinoma 127 86 
Normal 17 10 
Age (Median) 64 63.5 
Female 71 51 
Male 53 35 
Demographics 
Smoking 44 48 
Where is normal relative to tumor NA NA 
% tumor cells variable >70% 
Met static 12 NA 
Survival (average month) 37.5 29.5 
P53 accumulation NA See paper 
K ras mutation NA See paper 
Stage I 73 67 
Stage III 10 19 
Average Diameter Variable NA 
Clinical 
Variables 
Classification Variable Variable 
Surgery Variable NA 
Processing condition NA NA 
RNA quality Control Measure NA NA 
Processing 
Conditions 
Hybridization and scanning 
conditions Replicate NA 
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 3.3.2. Data integration strategies 
Two strategies were used to integrate data from the studies since the HGU95Av2 and 
HuGeneFL arrays contain different probe sets. Figure 3.1 schematically depicts the two 
methodologies.  
3.3.2.1. Integration based on GenBank accession number 
In the first approach (Method I) the two datasets were analyzed using Microarray Analysis 
Suite version 5.0 (Affymetrix Inc. Santa Clara, CA) and then integrated by matching the 
GenBank accession number of each probe set in the two arrays (Fig 3.1a). Only those transcripts 
with GenBank accession numbers represented on both array types were used for further analysis. 
3.3.2.2. Integration using the overlapped probes 
The second integration approach (Method II) integrates data by using probe-level 
matching information provided by Affymetrix (Fig 3.1b). Many probe sets in one array type, e.g. 
HuGeneFL, may share/match probes with a probe set on the other array type. Only probe sets 
sharing probes on both array types were used for data analysis and normalization with MAS5.0. 
The data sets obtained afterward has been integrated as they contain only gene expression data 
from probe sets with matched probes. These data were then subject to further analysis.  
Figure 3.2 presented details on how the integration was done by using overlapped probes. 
The probe matching information is provided in the Array Comparison File by Affymetrix Inc. 
(Santa Clara, CA). This file contains details about probe sets which shared matched probes on 
the two generations of Affymetrix GeneChip® arrays. For example, as depicted in Figure 3.2, 
the probe set A28102_at on the HuGeneFL array shares three matched probes with the probe set 
31726_at on the HG_U95Av2 array. The maximum number of matched probes is 16 because 
typical probe sets on the HG_U95Av2 array comprise 16 probe pairs and typical probe sets on 
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 the HuGeneFL array contain 20 probe pairs. Therefore, even at the maximum level of overlap 
some of the probes of a probe set on the HuGeneFL array do not match any probe of the 
overlapped probe set on the HG_U95Av2 array. On the other hand, not every probe sets on either 
of the two arrays has a match on the other array. 
 
Figure 3.1 Schematic representation of the two integration strategies.  
(a) Integration using GenBank accession number; (b) integration with probe-level matching 
information.
 
In order to accomplish integration, matched probes were first identified for a probe set in 
one array and its corresponding probe set with which it shares probes on the other array. Only the 
matched probes participated in the calculation of expression intensity values for the two probe 
sets; all other probe pairs with no matches were eliminated from data analysis by MAS5.0. If a 
probe set had no match at all, it was eliminated from data analysis. MAS5.0 software uses a 
“MASK” file to identify which probes for each probe set need to be eliminated from analysis 
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 [172]. Therefore, after identifying matched probes, for each probe set, an entry listing the probes 
for elimination was inserted into the MASK file of the particular array it belongs to (Figure 3.2). 
 
 
 
Figure 3.2 Integration using overlapped probes.  
 
3.3.3. High-level data analysis 
Using either integration approach, the two data sets were combined to create one larger data 
set. Hierarchical clustering[98] was applied on the integrated data. Within the integrated data set, 
Pearson’s correlation coefficients were calculated between data from Harvard and data from 
Michigan. Significance Analysis of Microarray (SAM)[109] was then used to determine if after 
integration data from Harvard and Michigan exhibit similar expression profiles by comparing 
differential gene expression of tumor versus normal samples and Stage I versus Stage II tumors. 
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 3.4. Results 
3.4.1. Integrated data sets 
Method I gave 5,987 overlapped transcripts across the two array types which account for 
83.98% of all transcripts on the HuGeneFL array (7,129) and 47.52% of all transcripts on the 
HG_U95Av2 array (12,600) respectively. Alternatively, method II yielded 6,167 overlapped 
transcripts corresponding to 86.51% of transcripts on HuGeneFL and 48.94% of transcripts on 
HG_U95Av2. Of these overlapped transcripts detected by either methods I and II, 4,671 of them 
were revealed by both methods, corresponding to 65.52% of all transcripts on the HuGeneFL 
array and 37.07% on the HG_U95Av2 array. Expression data from the 5,987 transcripts from 
method I and the 6,167 transcripts from method II were used for further analysis. In addition, 
several genes that were found to be significantly expressed in the original papers were eliminated 
by data integration (data not shown). 
3.4.2. Correlation coefficients of the integrated data 
Using integrated data from method I (5,987 transcripts), Pearson’s linear correlation 
coefficients of Harvard normal vs. Michigan normal, Harvard tumor vs. Michigan tumor, 
Harvard stage I tumor vs. Michigan stage I tumor, and Harvard stage III tumor vs. Michigan 
stage III tumor were 0.762, 0.805, 0.816, and 0.751 respectively (Table 3.2). The average of 
these Pearson’s correlation coefficients is 0.78. Expression data of Harvard stage III tumors vs. 
Michigan stage III tumors had the least correlation indicating the stage III tumor samples from 
the two studies may be significantly different. Using integrated data from method II, these 
correlation coefficients were improved significantly. The average Pearson’s correlation 
coefficient is 0.91. All four correlations reported were above 0.88 and the Harvard Stage III 
tumor vs. Michigan stage III tumor still gave the lowest correlation coefficient of 0.884 (Table 
3.2). 
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 Table 3.2 Pearson’s correlation coefficients within integrated data. 
 
 
Harvard vs. Michigan 
Integration 
Methods Normal vs. 
Normal 
All Tumor vs. 
All Tumor 
Stage I Tumor 
vs. Stage I 
Tumor 
Stage III Tumor 
vs. Stage III 
Tumor 
Average 
Method I 
(5,897) 0.762 0.805 0.816 0.751 0.784 
Method II 
(6,167) 0.896 0.936 0.937 0.884 0.913 
 
3.4.3. Hierarchical clustering of the integrated data 
Using the integrated data set from either method I or method II to perform clustering with 
all profiles from the two original studies, the Harvard and Michigan experiments separated into 
distinct clusters suggesting that some major underlying inter-institution variation in the two data 
sets cannot be eliminated by either integration methods used in this study. These variations are 
more significant than biological difference between tissue samples and therefore the major 
driving force for clustering is the inter-institution variation. On the other hand, within the clusters 
formed for profiles from each institute, tumor and normal samples were separated to distinctive 
clusters indicating that the biological difference was preserved even though different integration 
strategies were used (data not shown).  
3.4.4. Ability to detect differentially expressed transcripts after data integration 
After data integration using either method, the individual data sets, Harvard data set and 
Michigan data set, were used to determine if they exhibit similar expression profiles. Differential 
gene expression of tumor versus normal and Stage I tumor versus Stage III tumor were detected 
by SAM analysis. For each comparison, the lists of differentially expressed transcripts from 
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 either data set were compared and the number of overlapped transcripts for the 100, 50, 25, 10, 
and 5 most up- and down-regulated transcripts were listed in Table 3.3.  
Using either integration methods, for the comparison of tumor vs. normal, the maximum 
proportions of overlapped transcripts in all transcripts in the comparison was detected when 
comparing the 100 most up- and down-regulated, totally 200, transcripts. As the number of 
differentially expressed transcripts in the list decreases, the percentages of overlapped transcripts 
were also decreases. In another word, when increases the stringency of SAM analysis, the 
number of overlapped transcripts detected from integrated data sets decreases.  
Table 3.3 The number of differentially expressed genes overlapped in each comparison using integrated data 
from either method. 
 
 
# of Overlapped Differentially Expressed Genes (# 
of up genes / # of down genes) Comparisons Within the 
integrated data sets Methods 
Top 100 Top 50 Top 25 Top 10 Top 5 
I 80/200 (40%) 
36/100 
(36%) 
14/50 
(28%) 
4/20 
(20%) 
3/10 
(30%) Harvard 
Tumor vs. 
Normal 
Michigan 
Tumor vs. 
Normal II 97 /200 (48.5%) 
39/100 
(39%) 
13/50 
(26%) 
3/20 
(15%) 
1/10 
(10%) 
I 9/200 (4.5%) 
2/100 
(2%) 0 0 0 Harvard 
Tumor: 
Stage I vs. 
Stage III 
Michigan 
Tumor: 
Stage I vs. 
Stage III II 5/200 (2.5%) 
2/100 
(2%) 
1/50 
(2%) 0 0 
 
For the comparison of stage I tumor vs. stage III tumor, however, the lists of 
differentially expressed transcripts from Harvard data and Michigan data detected by SAM 
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 analysis were very different from each other. The gene lists did not overlap at all when the 10 or 
5 most up- and down-regulated transcripts were compared regardless of integration methods. 
Only several genes were overlapped when the 100 most up- and down-regulated transcripts 
(totally 200) were compared. These results indicate that although the Harvard and Michigan data 
sets demonstrate some level of overlap in differential gene expression, they are not identical.  
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 3.5.Discussion 
Results from this study demonstrated that integration of information from different 
datasets could be accomplished to some degree. Moderate to high correlation (0.75~0.94) can be 
achieved between gene expression profiles from the two original studies after integrating data 
from two generations of the Affymetrix GeneChip® arrays with either strategy proposed in this 
study. However, both the hierarchical clustering results and the low levels of concordances in 
detecting differentially expressed transcripts after data integration indicated the existence of 
major inter-institution variations which cannot be eliminated or controlled by integration 
strategies used. The inter-institution variation may be due to differences in patient demographics, 
tissues, sampling methods, experimental and analysis methods (Table 3.1). It is these potential 
sources of variation that must be addressed in future genomics and proteomic studies to allow 
inter-study comparisons and to produce high quality, highly annotated data sets for biomarker 
validation. Therefore, the complete integration of microarray gene expression datasets cannot be 
accomplished until all the variations in the process of microarray gene expression analysis have 
been identified and well controlled.  
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4. CHAPTER IV In vitro transcription labeling methods contribute to the variability of 
gene expression profiling with DNA microarrays 
Submitted to Journal of Molecular Diagnostics 
4.1.Abstract 
Considerable variation in gene expression data from different DNA microarray platforms 
has been demonstrated. However, no characterization of the source of variation arising from 
labeling protocols has been performed. To analyze the variation associated with T7-based RNA 
amplification/labeling methods, aliquots of the Stratagene Human Universal Reference RNA 
were labeled using three eukaryotic target preparation methods and hybridized to a single array 
type (Affymetrix U95Av2). Variability was measured in yield and size distribution of labeled 
products, as well as in the gene expression results. All methods showed a shift in cRNA size 
distribution, when compared to un-amplified mRNA, with a significant increase in short 
transcripts for methods with long IVT reactions. Intra-method reproducibility showed correlation 
coefficients >0.99, while inter-method comparisons showed coefficients ranging from 0.94 to 
0.98 and a nearly two-fold increase in coefficient of variation. Fold amplification for each 
method was positively correlated with the number of present genes. Two factors that introduced 
significant bias in gene expression data were observed: a) number of labeled nucleotides that 
introduces sequence dependent bias, and b) the length of the IVT reaction that introduces a 
transcript size dependent bias. This study provides evidence of amplification method dependent 
biases in gene expression data. 
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 4.2.Introduction 
Analysis of gene expression with DNA microarrays has allowed reclassification of 
tumors based on unique molecular profiles with potentially important prognostic and therapeutic 
implications[94, 107]. However, there are still significant hurdles for gene expression profiling 
to achieve routine acceptance within the clinical laboratory. A frequent criticism for the routine 
clinical use of this technology is the lack of concordance among results obtained using different 
array platforms[173].  
While it is believed that the major causes for platform-dependent differences in gene 
expression are due to variations in array design, probe deposition, probe sequence and gene 
annotation, very little attention has been paid to the bias introduced by the amplification and 
labeling reactions of different manufacturers. Linear, high fidelity amplification is critical as it 
ensures accurate replication of the size, distribution, and complexity of the initial mRNA 
population. Several studies have suggested that systematic biases are introduced by variations in 
amplification technique which could impact expression results regardless of the choice of array 
platform[64, 69]. These results challenge the common underlying assumption that representation 
of transcripts in a sample remains unchanged by the amplification and labeling protocols used 
prior to hybridization.  
The most widely used RNA amplification and labeling technique presently in use is the 
T7-based method developed by Gelder and Eberwine[61]. A growing number of T7 based 
amplification systems are now commercially available and most incorporate modifications from 
the original technique. The goal of the present study was to specifically test the effect of 
variations in amplification and labeling protocols on gene expression results. To achieve this 
goal, we compared three widely used, commercially available target amplification methods[2, 
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 73] to delineate the variation introduced by each one, and determine its potential impact on gene 
expression data. 
4.3.Materials and methods 
4.3.1. RNA sample 
The Universal Human Reference (UHR) RNA (Stratagene Corp. La Jolla, CA) was used for 
all amplification reactions. Aliquots of the total RNA samples were prepared according to the 
manufacturer’s protocol. Quality of the RNA was assessed by OD260/OD280 in a ND-1000 
Spectrophotometer (Nanodrop Technologies, Wilmington, DE) and by capillary electrophoresis 
with the Agilent 2100 Bioanalyzer (Agilent Technologies, Inc. Palo Alto, CA). Purification of 
mRNA was performed with the Oligotex Direct mRNA Mini Kit (Qiagen Inc. Valencia, CA) as 
suggested by the manufacturer. 
4.3.2. Target preparation methods 
Methods compared in this study will be described briefly in this section. For details readers 
are referred to the manufacturer’s manuals and selected references[2, 73, 174-176]. Table 4.1 
summarizes the major differences and similarities among the three target labeling kits. 
a. Affymetrix Eukaryotic Target Preparation 
Two in vitro transcription labeling kits compared in this study are used to prepare biotin 
labeled cRNA targets for Affymetrix GeneChip® arrays: the Enzo BioArray High YieldTM RNA 
Transcript Labeling Kit (Enzo) and the GeneChip® Expression 3’-amplification Reagents for 
IVT labeling (Affy). For first and second-strand synthesis, these two methods utilize reagents 
from Invitrogen Inc., and follow the same experimental steps. Hence, major distinctions between 
the two methods exist in the in vitro transcription (IVT) step. Twelve UHR RNA aliquots were 
labeled by each of the two methods and five were hybridized to arrays for each method. We also 
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 performed additional experiments using a modified version of the Affy method where IVT 
reactions incubated for only 4 hours at 37 oC (Affy4h).  
Table 4.1 Comparison of the target amplification and labeling methods. 
 
 
 CodeLink Affy Affy4h Enzo 
Starting Total RNA 1 µg 1 µg 1 µg 5 µg 
Reverse Transcription 
Reagents CodeLink ------------------------ Invitrogen ---------------- 
RT incubation 2 hours 1 hours 
2nd-strand cDNA 
synthesis Reagents CodeLink ------------------------ Invitrogen ---------------- 
2nd strand incubation 2 hours 2 hours 
Biotinylated 
Ribonucleotides Biotin-11-UTP 
Biotin-conjugated 
Uridine analog 
Biotin-CTP 
Biotin-UTP 
In vitro Transcription 
Incubation 14 hours 16 hours 4 hours 4 hours 
Purification and 
Fragmentation 
Reagents 
CodeLink ------------------------ Affymetrix ---------------- 
 
a.1 First-Strand and Second-Strand cDNA Synthesis--All reagents are from Invitrogen Corp, 
(Carlsbad, CA) unless otherwise specified. Recommended amounts of total RNA (Table 4.1) in 8 
µL Nuclease-free water were spiked with 2 µL diluted poly-A RNA control (Affymetrix, Santa 
Clara, CA), then incubated with 2 µL of 50 µM T7-Oligo (dT) 24 primer (Affymetrix, Santa 
Clara, CA) at 70oC for 10 minutes and cooled on ice. Poly-A RNA controls were diluted to 
appropriate concentrations immediately before performing the experiment in order to maintain 
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 the same proportionate final concentration of the spike-in controls to the total RNA. First-strand 
cDNA was synthesized by adding 4 µL 5X 1st-strand buffer, 2 µL 0.1M DTT, 1µL 10mM dNTP, 
1µL Superscript II reverse transcriptase and incubating at 42 oC for one hour. Second-strand 
cDNA was synthesized by adding 91µL of Nuclease-free water, 30 µL 5X 2nd-strand buffer, 3µL 
10mM dNTP, 1 µL E. coli DNA ligase, 4 µL E. coli DNA polymerase I, 1 µL RNase H and 
incubating at 16oC for two hours. 2 µL T4 DNA polymerase was added and the reaction was 
incubated at 16oC for 5 minutes. Reactions were stopped by adding 10 µL 0.5 M EDTA. Double-
stranded cDNA was purified using the Sample Cleanup Module (Affymetrix, Santa Clara, CA).  
a.1.1 Synthesis of Biotin-labeled cRNA with the Enzo kit--Purified double-stranded cDNA was 
used in the in vitro transcription reaction using the Enzo BioArray High YieldTM RNA Transcript 
Labeling Kit (Affymetrix, Santa Clara, CA) at 37oC for 4 hours in a 40 µL reaction volume, 
containing 4 µL of 10X HY reaction buffer, 4 µL 10X biotin-labeled ribonucleotides, and 4 µL 
10X DTT, 4 µL 10X RNase inhibitor mix, 2 µL 20X T7 RNA polymerase and variable amounts 
of RNase-free water.  
a.1.2 Synthesis of Biotin-labeled cRNA with the Affy kit--Purified double-stranded cDNA was 
used in the in vitro transcription reaction using the GeneChip® Expression 3’-amplification 
Reagents for IVT labeling kit (Affymetrix, Santa Clara, CA) at 37 oC for 16 hours in a 40 µL 
reaction volume, containing purified ds-cDNA, 4 µL of 10X IVT labeling buffer, 12 µL IVT 
labeling NTP mix, 4 µL IVT labeling enzyme mix and variable amount of RNase-free water. Ten 
additional labeling reactions incubating for only 4 hours were also performed (Affy4h method). 
a.2 Fragmentation and Hybridization for Enzo and Affy Protocols--One µL of purified biotin 
labeled cRNA was then analyzed for purity and concentration by ND-1000 Spectrophotometer 
and Agilent 2100 Bioanalyzer. For the cRNA prepared by Affy4h method, purified cRNA from 
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 two reactions were pooled together to achieve the required amount of cRNA for hybridization. 
15 µg of purified cRNA was incubated with the adequate amount of fragmentation buffer 
(Affymetrix, Santa Clara, CA) at 94 oC for 35 minutes. 1 µL aliquot was used to assess complete 
fragmentation by capillary electrophoresis.  
b. GE Healthcare CodeLink Expression System Target Preparation 
Twelve biotin-cRNA samples were prepared by the CodeLink method using the 
CodeLink Expression Assay Reagent Kit (GE Healthcare, Piscataway, NJ). All reagents used are 
from this kit unless otherwise specified. 1 µg of total RNA in 8 µL Nuclease-free water were 
spiked with 1 µL of working solution of bacterial control mRNAs and 2 µL diluted poly-A RNA 
control (Affymetrix, Santa Clara, CA), then incubated with 1 µL of T7-Oligo (dT) Primer at 
70oC for 10 minutes, and cooled on ice. First-strand cDNA was synthesized by adding 2 µL 10X 
1st-strand buffer, 4 µL 5mM dNTP mix, 1 µL RNase inhibitor, 1µL reverse transcriptase and 
then incubating at 42 oC for two hours.  
Second-strand cDNA was synthesized in a 100 µL reaction volume by adding 63 µL of 
Nuclease-free water, 10 µL 10X 2nd-strand buffer, 4 µL 5mM dNTP mix, 2 µL DNA polymerase 
mix,1 µL RNase H, and then incubating at 16 oC for two hours. dsDNA was purified using the 
QIAquik PCR purification kit (Qiagen Corp, Valencia, CA).  
In vitro transcription reaction was carried out by mixing purified dsDNA with 4 µL 10X T7 
reaction buffer, 4 µL T7 ATP solution, 4 µL T7 GTP solution, 4 µL T7 CTP solution, 4 µL UTP 
solution, 7.5 µL 10mM biotin-11-UTP (PerkinElmer Corp. Wellesley, MA), and 4 µL 10X T7 
enzyme mix, then incubating for 14 hours at 37 oC, final reaction volume was 40 µL. Biotin 
labeled cRNA products were purified with the RNeasy Mini Kit (Qiagen Corp. Valencia, CA). 
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 15 µg of cRNA from each sample were fragmented following the recommended procedures in 
CodeLink target preparation manual.  
4.3.3. Evaluation of amplification products 
cRNA yield for all methods was assessed in a ND-1000 Spectrophotometer (Nanodrop 
Technologies, Wilmington, DE). Fold amplification was calculated by dividing the total cRNA 
yield by the estimated mRNA content (2% of total RNA) in the initial starting total RNA of each 
reaction. mRNA/cRNA size distribution was obtained by capillary electrophoresis with the 
Agilent 2100 Bioanalyzer (Agilent Technologies, Inc. Palo Alto, CA), using the “Smear 
Analysis” function of the 2100 Expert software (Agilent Technologies, Inc. Palo Alto, CA). Six 
transcript size regions: 0~0.2kb, 0.2~0.5kb, 0.5~1.0kb, 1.0~2.0kb, 2.0~4.0kb and 4.0kb~max 
were defined in the electropherograms and then used to determine the percentage of area under 
the curve for each size interval. Small amount of rRNA contaminations, both 18s rRNA and 28s 
rRNA, was observed on electropherograms from mRNA and cRNA from the Enzo method. 
rRNA proportion was subtracted from the total area under the curve and from their 
corresponding regions when calculating the percentage of area under the curve. However, it is 
important to note that size distribution in the Agilent Bioanalyzer is relative to the fluorescence 
intensity and does not reflect the actual number of transcripts of a given size. Four individual 
mRNA samples were evaluated to determine the size distribution of un-amplified transcripts. 
4.3.4. Hybridization, washing, staining and data processing 
  Five cRNA samples from each method were hybridized to Affymetrix GeneChip HG-
U95Av2 arrays which contain 12625 probe sets representing approximately 10,000 full-length 
genes. Briefly, 15 µg of fragmented cRNA were mixed in a hybridization cocktail with control 
oligonucleotide B2 (Affymetrix, Santa Clara, CA), eukaryotic hybridization controls 
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 (Affymetrix, Santa Clara, CA), herring sperm DNA (Promega Corp. Madison, WI), Acetylated 
Bovine Serum Albumin(BSA) solution (Invitrogen Corp. Carlsbad, CA), 2X hybridization 
buffer--made from MES-free acid monohydrate(Sigma-Aldrich Corp. St. Louis, MO), MES 
sodium salt (Sigma-Aldrich Corp. St. Louis, MO), 5M NaCl (Ambion, Inc. Austin, TX), 0.5M 
EDTA (Sigma-Aldrich Corp. St. Louis, MO), molecular biology grade water, 10% Tween 
20(CalBiochem, San Diego, CA), and 10% DMSO (for Affy and Affy4h methods only) and 
variable amounts of water to a final volume of  300 µL. 200 µL of hybridization cocktail was 
hybridized on each array at 37 oC for 16 hours. Each array was then washed, stained with 
streptavidin-phycoerythrin in a GeneChip® Fluidics Station 400(Affymetrix, Santa Clara, CA) 
and scanned by a GeneChip® Scanner 3000 (Affymetrix, Santa Clara, CA) as recommended by 
the manufacturer. Quality Control (QC) parameters were derived from the MAS 5.0 algorithm of 
the GCOS software (version 1.1, Affymetrix, Santa Clara, CA). Numerical gene expression data 
were derived from the raw intensity files using two distinct algorithms: the MAS 5.0 and the 
MBEI algorithm from the dChip software (http://www.dchip.org)[177]. Gene expression data 
will be submitted to NCBI’s Gene Expression Omnibus. 
4.3.5. Analysis of gene expression data 
Present (P) and Absent (A) calls are based on the detection calls made by the GCOS 
software. For the purposes of this study, we defined that a transcript (probe set) is “truly” present 
in the UHR RNA if it is identified as “P” at least three times out of five replicates of any 
amplification labeling method.  
Data from MBEI PM-only model[177] of the dChip software were used for all the 
transcript lists analyses. The Avadis Pride software package v3.3 (Strand Genomics, Redwood 
City, CA) was used for annotation, filtering, and integration of gene expression data. Michael 
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 Eisen’s Cluster and TreeView software tools (http://rana.lbl.gov/EisenSoftware.htm)[98] were 
used to perform hierarchical clustering and view clustering results. Coefficient of Variance (CV) 
for each transcript across samples was calculated by dividing the standard deviation of its 
intensity values over the mean and expressed as a percentage (%CV).  
Two-class unpaired comparisons of gene expression data from two methods were 
performed with the Significance Analysis of Microarrays (SAM)[109] software tool 
v1.21(http://www-stat.stanford.edu/~tibs/SAM/). All gene expression profile comparisons with 
SAM were performed at a false discovery rate (FDR) of less than 0.03% (delta level of 3.0), 
except the comparison between Affy and Affy4h data, which was performed at an FDR of 0.32% 
(delta = 2.0). STATA software v8.01 (STATA Corp. College Station, TX) was used for all other 
statistical analysis including correlation studies, Mann-Whitney tests, analysis of variance and 
regression analysis. SigmaPlot v.8.0 (SSPS Inc. Chicago, IL) and Microsoft® Excel were used 
for all plots. 
For each “method A to method B” comparison of intensity values with SAM, transcripts 
that showed significantly increased values in method A over B were labeled as “affected by A”. 
Conversely transcripts significantly increased in method B, therefore decreased in method A, 
were labeled “affected by B”.  For the Enzo vs. Affy4h comparison, we calculated differences in 
Cytosine content in the target sequence of transcripts affected by these methods. The target 
sequence of a transcript is defined as the region interrogated by all probes in a probe set in the 
Affymetrix HG-U95Av2 array. Differences in cytosine content were calculated as the ratio of C 
to U. and expressed as G/A, thus reflecting the actual mRNA sequence. For the Affy vs. Affy4h 
comparison, transcript sizes reported correspond to the target mRNA sizes reported by the array 
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 manufacturer. Both transcript lengths and probe sequence information were obtained from the 
NetAffx website (www.affymetrix.com).  
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 4.4.Results 
4.4.1. cRNA yields 
More than 30 µg of cRNA were obtained with the Affy, Enzo and CodeLink methods in 
almost all reactions (Table 4.2). The Affy4h method yielded approximately 10 µg on average. 
The CodeLink method had the highest cRNA fold amplification and showed more variability in 
cRNA yields, which was mostly based on lot-to-lot differences of the amplification kit (Table 4.2 
Table 4.3). Lot-to-lot variability in amplification yield was not observed in the Enzo or Affy 
methods. 
Table 4.2 cRNA yield, fold amplification, and quality control parameters from the hybridizations to HG-
U95Av2 chips (Mean ±SD). 
 
 
 CodeLink Affy Affy4h Enzo p-value§
cRNA yield 
(µg)* 83.80±41.11 37.35±5.41 10.79±1.70 31.16±5.94 <0.0001
Fold 
Amplification* 4189.75±2055.73 1867.67±270.38 554.81±88.37 322.84±60.44 <0.0001
Median Array 
Intensity (raw) 128.60±46.31 109.00±10.65 150.40±11.94 207.08±47.18 0.0019 
Background 44.45±8.89 50.03±2.40 66.84±4.41 77.02±18.18 0.0005 
RawQ(noise) 1.57±0.28 1.76±0.13 2.18±0.09 2.53±0.49 0.0004 
% of P Calls 54.50±0.70 51.20±2.80 54.60±2.30 48.40±3.30 0.0026 
# of Present 
Genes 7476 7207 7455 6869 NA 
*: n=12. For all other rows, n=5. 
§: One-way ANOVA test with Bonferroni correction. 
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 Table 4.3 Amplification yields from each lot of the CodeLink kit. 
 
 
 
 
 
 
 
CodeLink Kit Lot I (n=6) Lot II (n=6) Lot I and II (n=12) 
Yield 48.29 ± 16.59 119.30 ± 20.44 83.80 ± 41.11 
Fold Amplification 2414.42 ± 829.52 5965.08 ± 1022.17 4189.75 ± 2055.73 
%CV 34.35 17.13 49.06 
4.4.2. Hybridization performance 
All hybridizations met quality control (QC) criteria as defined by the array manufacturer; 
however, some significant differences were noted (Table 4.2). Compared to hybridization results 
from Affy and CodeLink methods, the Enzo method had statistically significant higher 
background (one-way ANOVA: Affy vs. Enzo p-value=0.005; CodeLink vs. Enzo p-value= 
0.001), rawQ values (noise) (Affy vs. Enzo p-value=0.004; CodeLink vs. Enzo p-value= 0.001) 
and average median array intensities (raw) (Affy vs. Enzo p-value=0.002; CodeLink vs. Enzo p-
value= 0.012).  
There were no significant differences across samples in the 3’/5’ ratios of GAPDH, Lys and 
Phe (Table 4.4). However, the 3’/5’ ratios for β-Actin, Dap and Thr, were significantly higher in 
the samples labeled with the CodeLink method compared to Affy, Enzo and Affy4h methods (β-
Actin & Thr p<0.001 for all methods; Dap p = 0.004, 0.006, and 0.011 for each method 
respectively). Interestingly, control transcripts that showed increased 3’/5’ ratios are all nearly 
2kb long, while the controls not affected by this bias (GAPDH, Lys and Phe) are all less than 
1.5kb long. Additionally, rRNA sequences were detected in all but the Enzo labeling method 
(Figure 4.1). 
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 Table 4.4 (3’/5’) ratios (Mean  ± SD) for housekeeping genes and bacterial poly-A RNA spike controls. 
 
 
 CodeLink Affy Affy4h Enzo Transcript 
Length (kb) 
Housekeeping Genes 
GAPDH 1.16 ± 0.12 1.11 ± 0.06 1.07 ± 0.10 0.91 ± 0.05 1.27 
β-Actin 5.08 ± 1.73 1.44 ± 0.13 1.20 ± 0.08 1.10 ± 0.13 1.76 
Poly-A RNA Spike Controls 
Lys 3.04 ± 0.24 3.16 ± 1.46 2.97 ± 1.21 2.87 ± 0.58 1.00 
Phe 1.75 ± 0.22 1.65 ± 0.11 2.45 ± 0.56 2.45 ± 0.14 1.32 
Dap 5.85 ± 1.12 2.34 ± 0.40 3.11 ± 0.92 2.47 ± 0.95 1.82 
Thr 4.43 ± 0.36 2.02 ± 0.12 2.35 ± 0.22 2.37 ± 0.67 1.98 
 
 
 
 
Figure 4.1. Intensity values of the 3’, M, and 5’ probe sets for 28S and 18S ribosomal RNAs. 
The number (# / 5) on each column indicates the times this probe set is called “present” in the 
five hybridizations performed for each method. For example, the 4/5 of the “3’_at” probe set 
of18S rRNA in the Affy result (the left most bar) means that four of the five hybridizations 
detected this probe set as “present” in the RNA sample.  
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 The set of present genes, as defined in the methods section, consisted of 8,281 transcripts, 
equivalent to 65.76% of all probe sets on a HG-U95Av2 array. The Enzo method had the lowest 
number of present probe sets. There was a positive correlation (R2 =0.9553) between fold 
amplification and the number of present transcripts in samples from the Affy, Enzo, and 
CodeLink methods. Furthermore, this correlation is maintained as the stringency of the Present 
transcript definition goes from at least 3 of 5 replicates to 4 of 5 and 5 of 5 (data not shown). 
Interestingly, despite having relatively low fold amplification, the number of present probe sets 
in data from the Affy4h method is almost identical to the CodeLink method (Table 4.2). The four 
methods showed 83.3% agreement in present/absent calls for all transcripts interrogated by the 
HG-U95Av2 array (Figure 4.2). Of these, 6,183 (74.66%) were identified as present by all four 
methods. Only 2,098 were discordant between methods and, from the discordant set, less than 
10% (of all transcripts on the array) were identified as present by only one method. The set of 
present transcripts (8,281), based on our definition in the method section, comprise transcripts 
both identified as present by all four methods (6,183) and discordant between methods (2,098).  
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Figure 4.2 Concordance on present/absent transcript calls among the four methods studied.  
Total number of transcripts in the U95v2 array is 12,592. Complete agreement among methods is 
represented by a white background and further divided into present and absent calls. 
Disagreement among methods is shaded. 
 
4.4.3. Size distribution of cRNA products 
Table 4.5 shows the distribution of cRNA products for each method. These data are derived from 
the electropherogram profiles of the IVT products. All methods yielded cRNA with different size 
distributions when compared to the non-amplified mRNA in the Universal Human Reference 
RNA sample with the Enzo method being most similar. The most significant difference was seen 
in the abundance of transcript size between 0-200bp (p <0.001) and 200 to 500 bp (p <0.001, 
except Enzo p =0.014). Long incubation methods (Affy-14h and CodeLink-16h) produced higher 
abundance of short cRNA transcripts (<1000 nucleotides), while short incubation methods (Enzo 
and Affy4h) produced a higher percentage of longer cRNA transcripts (>2000 nucleotides). 
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 Table 4.5 Size distributions of mRNA in Universal Human Reference RNA and cRNA samples generated by 
the four labeling methods. 
 
 
Base pair UHR mRNA (n=6) 
CodeLink 
(n=6) 
Affy  
(n=4) 
Affy4h 
(n=10) 
Enzo  
(n=6) 
0~200 4.2 ±1.35 11.5 ± 1.03 10.4 ± 0.52 8.2 ± 0.97 6.9 ± 0.46 
200~500 4.5 ± 1.02 15.4 ± 1.30 14.0 ± 1.39 11.2 ± 1.06 7.1 ± 0.62 
500~1000 17.6 ± 9.11 26.3 ± 1.92 21.8 ± 1.53 21.4 ± 0.89 16.4 ± 0.85 
1000~2000 28.3 ± 10.40 25.6 ± 1.16 23.4 ± 1.22 25.1 ± 0.57 24.7 ± 0.96 
2000~4000 29.2 ± 13.38 15.1 ± 1.45 19.4 ± 1.04 22.2 ± 0.96 28.4 ± 0.60 
4000~max 16.0 ± 7.54 6.12 ± 1.88 11.08 ± 3.01 11.9 ± 1.77 16.5 ± 1.13 
Note: The transcript abundance in each region is represented as its percentage to the total 
distribution.
 
4.4.4. Reproducibility of gene expression measurements 
Pair-wise Pearson correlation coefficients of normalized gene expression measurements, 
within and between methods, were calculated using the set of present transcripts. Gene 
expression data showed excellent intra-method reproducibility and sensitivity, with correlation 
coefficients >0.990 for all methods (Table 4.6). The Affy and Affy4h methods had the highest 
inter-method correlation coefficient (r = 0.989), while the Enzo and CodeLink data correlate 
with each other the least (r = 0.949). With unsupervised hierarchical clustering, the arrays 
formed distinct clusters based on target preparation methods confirming that inter-method 
variability is greater than intra-method variability (data not shown). 
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 Table 4.6 Intra- and inter-method pair-wise correlation coefficients. 
 
 
 Affy CodeLink Enzo Affy4h 
Affy 0.9958    
CodeLink 0.9795 0.9916   
Enzo 0.9650 0.9494 0.9953  
Affy4h 0.9890 0.9703 0.9662 0.9962 
 
4.4.5. Variability of gene expression measurements 
Coefficients of variance (CV) for each present transcript were calculated across all 
replicates within a method (intra-assay) or across all four methods (inter-assay). As seen in 
Figure 4.3 a, all methods had average CVs of less than 12%, with Affy having the highest (10.45 
± 6.64%) and Affy4h the lowest (7.41 ± 4.81%). Inter-method variability was almost double of 
the intra-method (mean = 19.93 ± 9.87%). Figures 4.3 b-d show examples of the variability seen 
between methods for selected transcripts. CV plots for all transcripts in each method are 
presented in Figure 4.4. As has been shown in other studies, variability was higher in the low 
intensity region[85, 119]. 
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Figure 4.3 Variability in gene expression data.  
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 Figure 4.3 legend: a) Intra- and inter-assay %CV for all present transcripts. The solid line on 
each box represent the median %CV while the dashed line represents the mean %CV. b) example 
of two transcripts with high intensity values in hybridization result showing no change across 
methods. c) example of one transcript with low intensity values showing difference between 
Affy vs. Affy4h comparison. d) example of low expressor affected by the Enzo method in the 
Enzo vs. Affy4h comparison. 
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Figure 4.4 Intra- and inter-assay variations among all methods studied.  
Average %CV data were plotted as a function of log average intensity value for each present 
transcript. In each plot, every black dot represents a transcript; a trend line (grey) depicts the 
moving average of %CV of every 100 transcripts. For better visualization values >60% CV are 
not shown. 
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 Paired comparisons between all methods with the SAM algorithm revealed significant 
changes in transcript measurements, showing that cRNA targets prepared by the four studied 
methods have significant, reproducible, and consistent differences (Table 4.7). Since all 
experiments started with the same total RNA and were hybridized to the same array type, these 
differences are introduced by the target preparation (amplification) method. For each “method A 
to method B” comparison of intensity values with SAM, transcripts that showed significantly 
increased values in method A over B were labeled as “affected by A”. Conversely, transcripts 
significantly increased in method B were labeled “affected by B”. The comparison between Enzo 
and Affy4h methods had the highest number of “affected” transcripts; while the comparison 
between Affy and Affy4h had the lowest even at a less stringent level. For all comparisons, each 
method accounted for approximately half of the affected transcripts. 
Table 4.7 SAM analysis results from paired comparison of all methods. 
 
 
Method A Method B FDR (%) 
Number of 
Affected 
Transcripts (%§) 
Affected in A 
(%§) 
Affected in B 
(%§) 
Affy CodeLink 0.0202 1633 (19.7) 864 (10.4) 769 (9.3) 
Affy Affy4h 0.3187* 2029 (24.5) 1335 (16.1) 694 (8.4) 
Affy Enzo 0.0109 5070 (61.2) 2577 (31.1) 2493 (30.1) 
CodeLink Affy4h 0.0151 3090 (37.3) 1445 (17.4) 1645 (19.9) 
CodeLink Enzo 0.0140 4976 (60.1) 2407 (29.1) 2569 (31.0) 
Affy4h Enzo 0.0082 5085 (61.4) 2585 (31.2) 2500 (30.2) 
*: Delta for this comparison was set at 3.0, all others at 2.0.  
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 Since there are multiple factors that could contribute to the observed inter-method 
differences, we performed two focused comparisons that allowed us to isolate the sources of 
variation: a) the Enzo vs. Affy4h comparison was used to analyze the effect of double nucleotide 
labeling, and b) the Affy vs. Affy 4h comparison was used to analyze the effect of long in vitro 
transcription reaction time. From all the methods studied, Affy and CodeLink are the most 
similar in terms of workflow; however, comparison between these two methods still showed 
affected transcripts that could not be explained by the variation sources discussed above.  
4.4.6. Sources of variation 
4.4.6.1. Dual labeling 
The Enzo method uses double nucleotide labeling (biotin-CTP and biotin-UTP) while 
others use one (Table 4.1). Samples labeled with this method had higher average un-normalized 
fluorescence intensity values than all other methods (Table 4.2). As seen in Table 4.6 for the 
Enzo/Affy4h comparison, 61.4% of all transcripts have significantly different gene expression 
values, and are therefore affected by the method-dependent variation.  
We hypothesized that if this method-dependent variation is a direct result of the double 
nucleotide labeling, then the transcripts that show higher gene expression values with the Enzo 
method will have a higher Cytosine content in the transcript sequence interrogated by the probe 
set, since this nucleotide is only labeled by this method. This was expressed as the G/A ratio of 
the target transcript sequence as defined in the Methods section. The average G/A ratio of 
transcripts showing elevated expression in Enzo data was 1.166 ± 0.485, which is significantly 
higher than those of transcripts increased by the Affy4h method (0.773 ± 0.305; Mann-Whitney 
test: z = -32.477 p <0.00001). When transcripts that are affected significantly by the two 
methods are categorized according to their G/A ratio, we found that 93.7% of transcripts with 
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 ratios >2.0 show significantly higher values with the Enzo method and 84.70% of genes with 
ratios <0.5 show higher values with the Affy 4h method (Figure 4.5). 
 
 
 
Figure 4.5 The G/A ratio of the affected transcripts from SAM analysis of the Enzo vs. Affy4h comparison.  
Enzo and Affy4h affected transcripts (totally 5,085) were divided into groups based on their G/A 
ratios which were obtained from the target sequence information provided by array manufacture. 
In each group, the number of affected transcripts by each method and the corresponding 
percentages of total number of affected transcripts in this group were obtained. The percentage 
of affected transcripts of each method in each group was plotted as a function of the G/A ratio. 
 
 
4.4.6.2. Incubation time 
Given that the Affy and Affy4h methods only differ in the length of IVT incubation time 
(Table 4.1), comparison of these two methods provides an insight on how this factor affects gene 
expression data. In this comparison, 24.5% of all present transcripts are significantly different 
between Affy and Affy4h methods with a delta of 3.0 (FDR= 0.3187%).  
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Figure 4.6 Transcript lengths of the affected transcripts from SAM analysis of Affy vs. Affy4h comparison.  
Affected transcripts from SAM results were grouped based on their transcript lengths. In each 
interval, the number of affected transcripts and their percentage in the total number of affected 
transcripts in this interval were gathered. The proportion of affected transcripts of each method 
in each interval was plotted as a function of transcript length. Please note only the transcripts 
shorter than 1.5kb were of interest to this analysis. 
 
Based on the transcript size shift observed with long IVT reactions, we hypothesized that 
transcripts with significant higher expression values in samples labeled with a long (overnight) 
IVT are more likely to be short transcripts. The analysis of 3’/5’ ratios of control genes shown 
above revealed that the 3’ end of transcripts > 1.5 kb was preferentially amplified by at least one 
of the long incubation methods (Table 4.4). Therefore, we investigated if genes < 1.5 kb would 
be preferentially amplified by a long-IVT labeling method. Figure 4.6 shows the percent of 
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 transcripts <1.0 kb that are selectively increased in the Affy method in comparison to the Affy4h. 
These data show an inverse relationship between transcript length and the percentage of 
transcripts whose expression values are increased by the long IVT. Linear regression analysis 
shows an R2 of 0.9291, indicating a strong association between the increase of transcript length 
and the decrease of the proportion of long-IVT affected transcripts. This association could not be 
found when a comparison of both long IVT methods (Affy/Codelink) was done (Figure 4.7). 
 
 
 
Figure 4.7 Percentage of affected transcripts by each method in the Affy vs. CodeLink comparison (long 
IVT), grouped by transcript length.  
Data were plotted using the same strategy described in the legend for Figure 4.6 No correlation 
with transcript length was found in this comparison. 
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 4.5.Discussion 
 This study demonstrates specific biases in gene expression data introduced by 
commercially available T7 RNA polymerase based amplification reagent kits and protocols. 
Although T7 amplification is generally regarded as linear, several studies have shown 
differences in gene expression between amplified cRNA (single or double round) and non-
amplified mRNA[64, 69, 70, 133, 151]. Our results corroborate and extend those obtained in 
other studies, and show that gene expression results can show biases that are dependent on the 
number of labeled nucleotides in the amplification kit or in the length of IVT reaction, which 
translates to a transcript size-dependent bias.  
Most researchers judge labeling kit for DNA microarrays based on their performance in 
yielding sufficient labeled cRNA for hybridization. However, our results suggest that attention 
should be paid to the number of biotinylated ribonucleotides used for labeling at the in vitro 
transcription step. When comparing single vs. double nucleotide labeling with normalized data, 
we found that approximately 30% of the present genes had substantially higher gene expression 
values in Enzo (double nucleotide) compared to Affy4h (single nucleotide), suggesting the data 
sets generated from methods using two labeling nucleotides are not directly comparable to data 
sets derived by using a single labeling nucleotide. It has been shown previously that 
incorporation of biotin-CTP is not as efficient as biotin-UTP.[73, 178] Our results are in 
agreement with these findings, since we found differences when the G/A ratio was higher than 2, 
indicating that at least 2 incorporated biotin-CTPs per biotin-UTP are necessary to significantly 
increase the amount of fluorescent signal per transcript. However, given the complexity of the 
labeling process, and the hybridization reaction, it is unclear if the biases introduced by the 
number of labeling molecules can be corrected by a normalization method.  
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 We also demonstrate that the distribution of transcripts shifts towards shorter cRNA 
products in protocols with long IVT incubations, suggesting enhanced amplification of short 
transcripts. This is further corroborated by the fact that short transcripts were more likely to be 
increased in cRNA samples from long IVT labeling methods. Interestingly, Spiess and 
collaborators reported a similar cRNA size shift with long IVT incubation, but suggested that 
degradation of cRNA molecules by T7 RNA Polymerase accounted for this observation.[156] 
However, in our results long incubations consistently gave higher yields, which contrasts with 
their decrease in cRNA yield after 5h. Furthermore, in their description of exonuclease activity 
of T7 RNA polymerases, Sastry and Ross indicated that this activity is only unmasked in 
paused/arrested transcription complexes and that the kinetic balance during normal transcription 
was balanced towards polymerization[179]. We speculate that the degradation and/or decrease in 
IVT yields seen by Spiess and others [151, 156] with IVT reactions exceeding 4h, could be a 
result of paused transcription complexes due to depletion of reaction components. New IVT kits 
that are designed for longer incubation times seem to overcome this problem. Although the 
degree of amplification correlated with the increase in short cRNA transcripts, we were unable to 
assess the role of enzyme concentration between protocols with identical incubation times 
because the kit manufacturers would not provide this proprietary information.  
In this study, the number of transcripts identified as P in a sample, was directly related to 
the degree of amplification achieved in all methods but one (Affy 4h). This suggests that 
transcripts actually present in a sample are not always amplified successfully, which contributes 
to the variability within and between assays. In fact, as seen in other studies[119], variability in 
gene expression measurements was most pronounced in the low fluorescence intensity range, i.e. 
in the low expressor transcript range, as would be expected if low abundance transcripts are not 
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 efficiently amplified each time. It is interesting to note that the Affy 4h method, which used 
pooled reactions due to low fold amplification, yielded similar P calls as the CodeLink platform, 
which showed the highest fold amplification. These results suggest that multiple labeling 
reactions may be more effective at amplifying low-expressor transcripts, because more 
transcription initiation events may occur with multiple short-term incubations. Further testing of 
this hypothesis is currently underway in our laboratory.  
Intra-method variability reflects random errors created during the performance of a 
specific method, while inter-method variability comprises both random experimental errors and 
systematic biases. In the present study, all methods provided low intra-method CVs, but inter-
method variability was considerably higher. Average CV across any two methods ranged from 
15.65% to 20.44% approximating the average %CV across all methods of 19.93%. Other studies 
have reported correlation coefficients for the CodeLink and Affymetrix platforms between 0.59 
to 0.79[119, 128, 180]. In our study, we obtained higher correlation coefficients between these 
two platforms, which could reflect the fact that all samples were hybridized to the same array 
type, therefore isolating only the variability contributed by the labeling method.  
Another significant difference observed between labeling methods was under 
representation of 5’ probes from genes larger than 1.5 kb with the CodeLink method. This 
phenomenon was observed by Baugh et al[69], and was demonstrated to be related to inefficient 
reverse transcription. Indeed, when comparing the CodeLink method against all others, which 
share a common RT step, the former requires a longer incubation period (2h vs. 1h) that may 
lead to depletion of dNTPs and early termination of reverse transcription reactions yielding 5’ 
truncated cDNA products. It is also possible that IVT further contributes to 5’ under-
representation when the T7 RNA polymerase fails to transcribe full-length transcripts. It is likely 
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 that the majority of gene expression results are not affected by this phenomenon, since most 
probes in current array designs are 3’ biased, but this factor should be taken into account for 
probes that interrogate the 5’ region of selected transcripts.  
In summary, our results indicate that individual amplification methods significantly bias gene 
expression data, despite the fact that they are all derivatives of the T7 RNA polymerase based 
linear amplification. We have shown that part of this variability can be explained by: the number 
of biotinylated nucleotides used in the labeling reaction and the length of the in vitro 
transcription reaction. These biases are not corrected by intensity based normalization techniques 
such as the invariant set normalization method[177], and therefore can generate discordant 
results even with the same sample. As shown recently, concordance between different platforms 
has improved substantially thanks to advances in gene annotation and array design[130]  and 
high reproducibility among laboratories can be achieved when the same protocols and array 
platforms are employed[121, 181]. Our results emphasize the importance of standardized target 
preparation methods in order to optimize gene expression analysis and achieve a consistency 
compatible with clinical application of this technology. These findings should be taken into 
account when comparing data from different platforms, and in standardizing protocols for 
clinical applications. 
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5. CHAPTER V Conclusions and future prospects 
5.1.Conclusions 
The goal of this thesis work is to help improve bioinformatics support and quality assurance 
(QA) for DNA microarray based gene expression profiling, with the goal of molecular diagnosis 
implementation of DNA microarrays as diagnostic and prognostic tools in clinical pathology 
laboratories. Rigorous quality assurance and quality control (QA/QC) have been applied in the 
clinical laboratories as a critical component to guarantee the delivery of high-quality test results 
by controlling the variance and detecting measurement errors. For DNA microarray based gene 
expression profiling, QA and QC can be achieved through standardizing both the technology and 
experimental procedures. Work in this thesis provides insight into the problems existing in the 
experimental procedure associate with gene expression profiling.  
The most important conclusion that can be drawn from observations in this dissertation is 
that significant levels of variations can be introduced into microarray gene expression data either 
by tissue sampling or by the target preparation method and that these biases often overwhelms 
the most powerful statistical analysis. Variations introduced by tissue sampling have been shown 
to interfere significantly the accurate classification of tissue specimens from cancerous and 
disease free donor prostate and this principle almost certainly extends to all organ systems. For 
the classification of prostate tissue specimens using classifiers built on microarray data, results 
show the selection of the tissue baseline; normal prostate tissue specimens from prostate cancer 
free donors versus normal appearing prostate tissue from prostate cancer patients. In addition, 
results from this dissertation showed that the decision-tree learning algorithm can be successfully 
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 applied to the classification of cancer using microarray data although even the best analysis 
could be significantly undermined by experimental biases such as these discussed above. 
DNA microarray allows the high-throughput gene expression profiling of any biological 
system by simultaneously surveying the expression level of tens of thousands of transcripts in 
massively parallel fashion and across many cellular conditions. Gene expression data from DNA 
microarray based experiments have both a massive data volume and exceptionally high 
dimensionality and, as a result, it becomes a major challenge to discovery biologically 
meaningful gene expression patterns from such data sets. It is not hard to understand why 
algorithm design and application became a major task in the application of DNA microarray 
technology for gene expression profiling. Few studies had been done on classification using 
decision-tree learning at the time the study in this dissertation was conducted. Results in this 
thesis show that the decision-tree learning algorithm performed as well as, if no better than, 
several popularly used classification algorithms on partitioning prostate tissue specimens using 
solely microarray gene expression profiling data. However, unlike the popular analysis methods 
of the time, decision-tree learning algorithm created a classifier in the form of a tree structure, 
which could be used to suggest potential underlying relationships between genes or potential 
linkage within pathways; these features have made the decision-tree learning algorithms 
attractive for classification tasks using microarray data. Despite the success of the decision-tree 
learning algorithm, however, the performance of all three classification methods was clearly 
impaired by the limited quality of the microarray gene expression data sets themselves.   
Gene expression data from DNA microarray based experiments should delineate the 
composition and the relative abundance of each transcript in a transcriptome and this should be a 
function of the biological events happening at the time cells or tissues were harvested. However, 
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 noise and biases at various levels have been observed in microarray gene expression data and 
have significantly interfered with the accurate discovery of unique patterns of gene expression in 
a cell or tissue specimen. In many cases, the noise and bias introduced have been much larger 
than the biological signals themselves. This has been a major obstacle for the clinical application 
of DNA microarray technology as a diagnostic and prognostic prediction tool for clinical 
application.  
Recently efforts have been focused on identifying possible sources of variations by 
comparing microarray gene expression profiling results generated from different microarray 
platforms, various institutions, and multiple laboratories. DNA microarray platform, tissue 
sample, laboratory and array replication are the major sources recently identified which can 
introduce significant levels of variations in microarray gene expression data[120, 121]. RNA 
labeling, hybridization, data acquisition, and data analysis methods, if standardized, have also 
been proven to significantly improve the reproducibility of gene expression profiling between 
datasets produced on different array platforms and across different laboratories[120, 121]. 
Significantly, however, no study has been performed to formally investigate the level and source 
of these variations.    
T7 RNA polymerase based in vitro transcription labeling method is the most popularly 
used RNA labeling method. Past works have proven the linearity of this methodology and 
pointed out the potential for biases introduced by RNA amplification. However, no studies had 
systematic evaluated the significance of those biases or investigated their source. Results from 
the second aim of this dissertation demonstrated, for the first time, that significant levels of 
variations can be introduced into microarray gene expression data by several RNA labeling 
methods even though they are all derivatives of the T7 RNA polymerase based method. More 
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 importantly, statistically significant associations have also been established between the 
variations observed and their possible sources. Specifically, variations in the number of 
biotinylated nucleotides used in labeling have been shown to be responsible for the alteration of 
gene expression pattern of approximately 30% transcripts presented on a microarray. 
Furthermore, the incubation time of the in vitro transcription has been shown to significantly bias 
the gene expression pattern of short/small transcripts significantly. The observed 
variations/biases introduced into the experimental data set cannot be eliminated or controlled by 
applying advanced normalization algorithms such as the invariant set normalization, indicating 
data from experiments using target preparation methods with different number of labeling 
nucleotides or IVT reaction time may not be directly comparable.  
Furthermore, although results reported were from the comparison of three particular 
methods/kits these observations can be generalized to other RNA labeling methods. First, these 
results show that the variations introduced by RNA amplification and labeling methods are 
significant. The average coefficient of variance of all transcripts on the array across all three 
methods is approximately 0.2 (Figure 4.3 and 4.4). For each paired SAM analysis, a large 
number of present transcripts were significantly altered/biased (20%~60% of all present 
transcripts on the array) (Table 4.7). Since the three methods are all derivatives from the T7 
RNA polymerase based in vitro amplification approach, greater levels of variations may be 
expected in microarray gene expression data if RNA labeling methods used are fundamentally 
different from each other.  
Secondly, the association between the number of biotinylated nucleotides and biased 
expression pattern of transcripts is not unique to the labeling methods used in this study. When 
comparing microarray data from RNA labeling methods that differ with the number of labeling 
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 nucleotides, results may not be directly comparable. This is because the number of labels on each 
target molecule (cRNA or cDNA) varies when the number of labeling nucleotides changes. 
Depending on DNA microarray platform used, this variation may be or may not be controllable 
by normalization or other algorithms. For Affymetrix GeneChip® arrays, no easy solution is 
expected as the probe sets are designed with high redundancy and hybridization of targets to 
each probe is not yet a fully understand procedure, but for arrays incorporating one probe per 
transcript, solutions or approximations may be made. The bottom line is that caution should be 
taken when attempting to compare gene expression data if the labeling methods use different 
number of labeling nucleotides.  
Third, observations from this dissertation also suggest results from RNA labeling 
methods using T7 RNA polymerase based in vitro transcription is different and may not be 
comparable directly if the length of IVT reaction is not appropriately controlled. Optimum IVT 
reaction times are 4~5hours based on the studies on hand in this dissertation in Chapter IV.  
Past work has shown that tissue sampling is an important source of variations in DNA 
microarray gene expression profiling. In this dissertation, results show that tissue sampling 
affected the performance of classifiers built using microarray gene expression data. When 
classifiers built on gene expression profiles of normal appearing tissues adjacent to prostate 
tumor and profiles of prostate tumors were not able to classify correctly prostate tumors from 
other institutions. On the other hand, if using the profiles of prostate specimens from prostate 
disease free organ donors to build the classifier instead, classifiers performed well on 
distinguishing prostate tumor specimens, indicating that biases induced were as great as even the 
most profound biologic signals. In addition, results from the attempt of integrating lung cancer 
data from different generations of the Affymetrix GeneChip® arrays demonstrated how 
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 variations from all sources (tissue sampling and handling, patient demographic information, 
experiment methods, analysis methods, etc. Table 4.1) dwarfs the “cancer” relevant biological 
signal, causes specimens to cluster by institution instead of biology and makes difficult, if not 
impossible, the integration of microarray data sets from different institutions if appropriate QA 
and QC are not utilized. Most importantly, these findings highlight the importance of 
correct/appropriate tissue sampling in applying DNA microarray gene expression profiling in 
cancer research and possible clinical application.  
Lastly, observations and conclusions from this dissertation emphasize the importance of 
standardized target preparation methods and tissue sampling in order to optimize gene expression 
analysis and achieve a consistency compatible with clinical application of this technology. These 
findings should be taken into account when comparing data from different platforms, and in 
standardizing protocols for research and clinical applications. 
5.2.Future prospects 
 
The ultimate goal is to achieve rigorous quality control and quality assurance by 
standardization of both the DNA microarray technology and the experimental procedure so that 
good quality and comparable gene expression profiling results can be created at each individual 
laboratory. Moreover, these high quality data sets can eventually be shared and made available 
for meta-analysis. Once standardized, DNA microarray technology will become a powerful tool 
for research use and for diagnosis and prognosis in clinical laboratories. However, because 
biases induced by experimental procedure often cannot be “controlled” by later analysis, if data 
is to be shared or compared, standardization cannot be done in one laboratory or a single 
institution. Both the research community and the DNA microarray related industry should work 
together toward accomplishing this goal. Every result and each raw data set will contribute to the 
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 overall efforts and bring us closer to the ultimate goal of transparent sharing of gene expression 
data sets. Therefore, at the end of this dissertation, two types of future prospective work are 
proposed: (1) work towards to improving comparability of existing microarray gene expression 
profiling data sets, (2) work towards furthering experimental standardization of gene expression 
studies. 
5.2.1. Developing algorithms to approximate, control or eliminate variations 
introduced by the number of labeling nucleotides  
Many previously published studies used RNA amplification and labeling methods with two 
labeling nucleotides while the majority of current studies use methods with one single labeling 
nucleotide. The significant levels of variation due to the number of labeling nucleotides (as 
demonstrated in this thesis), therefore, becomes a hurdle for the comparison and integration of 
microarray gene expression results generated recently with data from the past two years. 
A possible solution to this problem is to develop algorithms which can simulate and control 
for the events occurring at hybridization and, at the same time, take into account of the number 
of labeling molecules on a target molecule. Before such an algorithm can be developed, more 
analysis need to be done on the effect of the number of labeling nucleotides on other types of 
DNA microarray which may have different probe length and use different labeling dyes. These 
may all contribute to the overall variations observed across different data sets and will be used to 
develop important parameters in the approximation/correction algorithm. 
5.2.2. Cross-platform comparison and integration of prostate gene expression data 
generated with standardized target preparation method 
As target amplification and labeling methods have been demonstrated to introduce 
significant level of variations into microarray gene expression data (Chapter IV), cross-platform 
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 comparison and integration studies should be cautious in the use of multiple target preparation 
methods. Therefore, the data set that was generated in our laboratory using prostate tissue 
specimens from both tumor patients and disease-free organ donors is very useful in this work. 
The uniqueness of this data set is that targets for hybridization were all prepared with one RNA 
labeling method. Three types of arrays were used: the CodeLink oligonucleotide arrays from GE 
HealthCare; the HG_U95Av2 arrays and the HG_U133A arrays from Affymetrix.  
The objectives of this proposed study are as follows. First, variations due to the 
differences between DNA microarray platforms will be measured and characterized. Three 
paired comparison can be made: CodeLink array vs. HG_u133A array, CodeLink array vs. 
HG_U95Av2, and HG_U133A array vs. HG_U95Av2 array. Previous studies reported the 
correlation of gene expression data from CodeLink arrays and Affymetrix GeneChip® arrays is 
from 0.5 to 0.79[118, 119, 128]. Most of these studies did not control for the variation introduced 
by target preparation methods. Results from our data sets are expected to show better 
concordance of gene expression data from the two platforms. These comparisons will help to 
investigate further the possible sources of the observed variations.  
We expect to use this data set to study a data integration strategy with matched sequences 
and matched probes across different platforms. Previous studies from other groups have shown 
that cross-platform concordance of microarray gene expression data can be improved by using 
probes with matched sequences[182]. Variations from target preparation methods and other 
sources were not controlled and therefore the levels of improvement may be less than optimum. 
The data set we have generated is unique and valuable because it was truly with very well 
controlled experiments to minimize possible variations and used a single target preparation 
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 method. Comparison and integration results from this data set should reflect more closely the 
real level of improvement possible by using sequence matched probes.  
5.2.3. Developing an optimal method for target amplification and labeling 
An optimal target preparation method would preserve 100% the integrity, composition, and 
relative abundance of each transcript in a transcriptome. Results from this dissertation show that 
that the Affy 4h method, which used pooled reactions due to low fold amplification, yielded a 
similar number of “present” transcripts as the CodeLink platform which showed the highest fold 
amplification. These results suggest that multiple labeling reactions may be more effective at 
amplifying low-expressor transcripts, because more transcription initiation events may occur 
with multiple short-term incubations. Further testing of this hypothesis is currently underway in 
our laboratory.   
5.2.4. Future works related to other sources of variation in DNA microarray based 
gene expression profiling 
In this thesis, tissue sampling and target preparation methods have been investigated as 
sources for the variations in microarray gene expression results. There are many other ones left 
unstudied.  
For example, the probe design for different DNA microarray platform may affect the 
microarray data if probes are not optimized to hybridize with their intended target molecules. 
The issues with probe design are whether redundancy should be applied and the optimal probe 
length with or without redundancy. Controversial results regarding these two issues have been 
reported recently[28, 183, 184]. Large scale, systematic studies need to be carried out to 
investigate this problem.   
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 Hybridization is a critical step in microarray experiments (Figure 1.2a). Current protocols 
typically use 18 to 24 hours at hybridization and assume that this length of incubation is long 
enough for hybridization reactions to reach equilibrium. However, a study by Sartor et al.[185] 
recently carried out a study to investigate the effect of increasing hybridization time (from 18 
hours to 42~66 hours) on gene expression data using two-channel long oligonucleotide 
microarrays. Their results show that hybridization results from prolonged hybridization yielded 
more genes detected as present on the array, higher signal-to-noise ratio, and better 
reproducibility compared to results from 18-hour hybridization. These results suggested that 
hybridization reaction does not reach to equilibrium, as assumed, at 18 hours and, consequently, 
gene expression data from such hybridization will not reflect faithfully the level of expression of 
transcripts in a transcriptome. Specifically, as there will be high proportion of nonspecific 
hybridization before reaching equilibrium, some genes presented in the transcriptome may not be 
detected as present in microarray data sets and the fold change of the differentially expressed 
genes may be underestimated. The study summarized here demonstrates the variations 
introduced by hybridization on a specific type of DNA microarrays. It is likely that variation 
from the length of hybridization is not unique to the two-channel long oligonucleotide array used 
in that study. Other studies had also presented some preliminary results support this 
observation[23]. However, few studies thoroughly investigate the extent and source of variations 
introduced by hybridization. Furthermore, variations associated with hybridization time may 
vary with target concentration. Therefore, target concentration should also be taken into account 
when such studies are designed.  
In summary, we have proposed several possible prospective studies to extend the 
observations and results from this thesis. These future studies will help to improve 
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 standardization of experimental procedures, provide better integration of microarray data sets 
which have been generated, and improve our understanding of the sources of variation in DNA 
microarray data.  
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APPENDIX A 
 
 
 
Differences in gene expression in prostate cancer, normal appearing prostate tissue 
adjacent to cancer and prostate tissue from cancer free organ donors 
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Decision tree learning-based characterization of the global effects of cocaine abuse on gene 
expression in the rat brain 
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ABSTRACT  
Motivation: This study aims to 
characterize the global changes in gene 
expression across the rat brain due to an 
acute dose of cocaine. Microarray gene 
expression data were generated from 
cocaine-treated and untreated tissue 
samples from five regions of the rat 
brain. A decision tree learning method 
was applied to this data to learn 
plausible models of the interactions 
among the brain regions.  
Results: Our approach to normalization 
and filtering of the original dataset 
provides a useful methodology for 
successful application of decision tree 
learning to this novel gene expression 
dataset. The popular decision tree 
learning program C4.5 learned a highly 
accurate (97.53% average prediction 
accuracy from cross-validation) and 
human-understandable model from the 
normalized and filtered data. The 
learned model  depicted a global change 
in gene expression among three brain 
regions in response to an acute dose of 
cocaine. The learned global pattern was 
verified independently using a different 
normalization procedure and 
visualization. The rule sets were studied 
carefully and the genes covered by each 
rule were annotated based on Gene 
Ontology terms. 
Contact: chmst40@pitt.edu
Supplementary Information: The 
normalized dataset and the Gene 
Ontology annotations of the genes 
covered by each rule are available at 
http://www.pitt.edu/~chmst40/ratdata/. 
 
Key words: Decision Tree Learning, 
Cocaine Abuse, Descriptive Generalized 
Models, Gene Expression Analysis, 
Normalization. 
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 INTRODUCTION  
One of the major public health problems 
in the United States stems from the 
abuse of psychostimulant drugs, such as 
cocaine, amphetamine and their 
derivatives. A critical property of these 
drugs is that they tend to be addictive, 
that is, when administered in acute 
doses, their usage entails repeated usage. 
Cocaine and similar drugs induce the 
expression of immediate early genes 
which activate several networks of 
biochemical pathways in brain neurons 
(Hope, 1998; Torres and Horowitz, 
1999). These affected neurons locate in 
different brain regions and belong to 
different brain systems but synaptically 
converge on a common set of 
mesocorticolimbic neurons (Torres and 
Horowitz, 1999). The complexity of this 
system has made it difficult to map gene 
expression to addictive behaviors. 
Recently developed high-throughput 
microarray technology, however, allows 
the expression of thousands of genes to 
be monitored simultaneously and thus 
has the potential to enable the study of 
drug abuse at the genomic scale. This 
capability may provide a new way to 
understand the global changes in the 
gene expression patterns in brain due to 
drug abuse. Specifically, we can identify 
patterns of gene expression that 
correspond to cocaine exposure. 
A number of popular methods 
exist to identify higher order patterns in 
gene expression data. These methods can 
be usefully classified as being 
“supervised” or “unsupervised”. 
Unsupervised methods, such as 
clustering (Eisen et al., 1998) and self-
organizing maps (Tamayo, et al., 1999), 
seek to identify patterns in the gene 
expression data without the use of prior 
knowledge. Such methods are useful in 
basic data discovery and often find 
unique and novel groupings in the data 
but often do not reproduce known 
groups. Supervised methods, such as the 
decision tree learning method used in 
this study, on the other hand, incorporate 
informative specimen labels and 
knowledge about the dataset beyond the 
gene expression data. For example, a 
supervised method might be told which 
subjects had a given disease and which 
had not, and it would use that 
information to classify gene expression 
patterns. Supervised methods are likely 
to find gene expression patterns that 
correlate with the external labels, in this 
case the disease or lack of the disease. 
Decision tree learning (Quinlan, 
1986) is a commonly used technique to 
derive plausible descriptive models from 
training examples that can used to 
classify test examples whose 
classification is unknown. A primary 
advantage with respect to clustering 
methods and other supervised learning 
methods is that the predictive models 
obtained from decision tree learning 
method are human-understandable rules 
and therefore, enable characterization of 
general trends within the training 
dataset.  Decision tree learning has been 
applied in the past to gene expression 
data (Brown et al, 2000), but with 
limited success. 
In this paper, we describe an 
approach to normalization and filtering 
of a novel gene expression dataset that 
enables the learning of highly accurate 
decision rules to characterize gene 
expression obtained from normal tissue 
as well after treatment with an acute 
dose of cocaine. The analysis of this 
initial set of experimental data aims to 
understand the global effects of cocaine 
across the brain, using rat as the model 
animal. The popular decision tree 
learning program C4.5 was used to learn 
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 a highly accurate decision tree, and then 
generate set of production rules (using 
the C4.5rules program) that describe a 
generalized model for discriminating 
between cocaine-treated and untreated 
brain. This model describes the global 
effect of cocaine in the rat brain and 
implicates the interaction among the 
regions in rat brain due to cocaine abuse. 
 
METHOD  
The Cocaine Dataset 
Forty male Sprague Dawley rats, twenty 
naïve and twenty sensitized with an 
acute dose of cocaine were used in the 
experiment. From the naïve and 
sensitized cohorts, pools of total RNA, 
from five brain areas: the Amygdala 
(AMY), Caudate Putamen (CPU), 
Nucleus Accumbens (NA), Prefrontal 
Cortex (PFC) and Ventral Tegmental 
Area (VTA), were used as the substrates 
for cDNA synthesis (see Figure 1 for 
spatial distribution of the brain regions). 
Region specific tissue from twenty 
animals was required to procure 
sufficient high-quality mRNA for the 
microarray experiments. It was also 
hoped that pooling tissue from twenty 
animals would also dampen the possible 
effect of inter-individual differences in 
gene expression at baseline or following 
treatment. We therefore had ten samples 
for analyzing differences in gene 
expression using commercially available 
Rat Genome U34A (RG-U34) array set 
from Affymetrix, Inc, Santa Clara, CA. 
There are totally 8799 probe sets 
on the RG-U34A array derived from all 
full-length or annotated genes (~7000) 
as well as thousands of EST clusters. In 
this paper, we will use “gene” as the 
general term referring to the genes and 
ESTs on the microarray chip. The results 
of gene expression analysis using the 
Affymetrix Micro Array Suite 4.0 
software from Affymetrix, Inc., Santa 
Clara, CA, are expressed as several 
parameters representing both qualitative 
as well as quantitative information for 
each gene represented on the arrays. An 
important quantitative measure of gene 
expression is represented by the Average 
Difference parameter. The Average 
Difference is a relative indicator of the 
level of expression of a transcript, and is 
used to determine the changes in 
expression of a given gene.  For each 
gene, there are ten Average Difference 
data points corresponding to its relative 
expression level in cocaine-treated and 
untreated tissue samples from five brain 
regions. Thus, there were 87990 data 
points available for analysis, divided as 
follows - 8799 genes x 2 conditions x 5 
regions.  
 
Figure 1. Schematic representation of some of 
the neurotransmitter systems in the rat brain 
sagittal section. AMY = Amygdala; CPU = 
Caudate Putamen; NA = Nucleus Accumbens; 
PFC = Prefrontal Cortex; VTA = Ventral 
Tegmental area. The schema is derived from 
page 55 of the Rat Nervous System volume 1: 
Forebrain and Midbrain (Paxinos, 1985).   
 
Overall Methodology  
Our methodology used for analysis of 
this dataset is depicted in Figure 2. The 
Average Difference values from 8799 
genes, from ten samples were merged 
into one data file, referred to as the raw 
data (Figure 2a, Step 1). Using this data, 
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Figure.2. Our method for learning models for the cocaine dataset. (a) A flowchart for the possible steps to 
perform the decision tree learning. A brief explanation is given to each step. (b) The seven experiments we 
performed by applying different combinations of the steps shown in (a). The * indicates that the sequence 
of performing normalization and filtering is not critical for deriving the result. 
 
the decision tree learning program C4.5 
learned an extremely inaccurate model 
(Figure 2b, Experiment1). The default 
settings were used for all runs of C4.5, 
as changing the parameters did not 
significantly improve the prediction 
accuracy of the learned models. The raw 
data was subsequently normalized and/or 
filtered prior to decision tree learning 
(Figure2a, steps 2 and 3; Figure2b, 
Experiments 2 to 7).  Experiment 7 
yielded a highly accurate model from 
normalized and filtered datasets, with a 
small number of rules within the rule set. 
The gene expression pattern implicated 
by this model was observed and 
validated visually by using GeneSpring 
4.1. The genes covered by each rule 
were annotated on the basis of TIGR Rat 
Gene Index. The software tools used in 
this study are listed below: 
• C4.5 Release 8 publicly available at 
http://www.cse.unsw.edu.au/~quinla
n/ was used for decision tree 
learning.  
• GeneSpring software version 4.1 
from Silicon Genetics, Redwood 
City, CA, was used to normalize the 
raw data and perform gene clustering 
using spearman correlation. The 
gene tree was used to validate the 
decision tree learning result.  
• TIGR (The Institute for Genomic 
Research) Rat Gene Index release 
Version 6.0 is publicly available at 
http://www.tigr.org/tdb/rgi/index.ht
ml. This index provides the source of 
gene ontology annotation.  
 
Decision Tree Learning 
Training examples are represented as the 
gene expression values for each brain 
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 region for each gene (i.e. five values in 
this dataset), followed by the brain 
tissues’ classification, i.e. normal 
(untreated) or cocaine (cocaine-treated). 
Two examples are shown below, where 
each of the five relative expression 
values is separated by commas, followed 
by the target class (NORMAL or 
COCAINE):  
 
0.949,1.143,0.691,0.242,1.316,COCAINE. 
1.006,1.789,0.718,0.783,2.121,NORMAL. 
 
Given such training examples, 
we apply C4.5 to learn a decision tree 
classifier that comprises of region-wise 
tests of expression values that best 
discriminates examples of cocaine-
treated class from the normal brain tissue 
samples. The decision tree is built 
incrementally by applying an entropy-
based measure called “information gain” 
to determine which attribute (gene 
expression in a particular brain region 
such as Amygdala) is most informative 
in terms of discriminating between the 
target classes (i.e. normal vs. cocaine). 
This most informative attribute is then 
placed as the first test at the root of the 
decision tree, with branches labeled 
according to its values. The training data 
are then sorted along the branches. For 
each branch, the next most informative 
attribute that best discriminates among 
the subset of training data along that 
branch, is then chosen as the attribute 
whose values will be tested. The process 
continues until there are no more 
training examples that need to be 
covered (classified) along each branch. 
The leaf nodes contain labels of the 
target class, and represent the 
classification of the conjunction of 
features (<attribute, value> pairs) along 
that unique path from the root attribute 
of the decision tree. The most general 
classifier and the smallest decision-tree 
that does not over-fit the training data is 
used for prediction (Quinlan, 1993). 
 
Data Normalization  
A normalization procedure is first 
applied to the data (8799 x 10) by using 
GeneSpring 4.1. To normalize in the 
context of DNA microarrays means to 
standardize your data to be able to 
differentiate real (biological) variations 
in gene expression levels and variations 
due to the measurement process. 
Normalizing also scales the data so that 
you can compare relative gene 
expression levels (GeneSpring, 2001). 
Here, each sample was normalized to 
itself first, and then each gene was 
normalized to itself across all the ten 
data points.  
 The normalization of each 
sample to itself (also called per sample 
normalization or normalized per sample 
in this paper) intends to remove the 
differences in amount of exposure 
between samples, so different samples 
are comparable to one another. The 
median of all measurements in a given 
sample X is set to 1, and all other values 
scaled accordingly. The formula used is:  
 
(the signal strength of gene A in sample X) 
(the median of all of the measurements taken in sample X) 
 
The normalization of each gene 
to itself (also called per gene 
normalization or normalized per gene in 
this paper) accounts for the difference in 
detection efficiency between spots. It 
also allows you to compare the relative 
change in gene expression levels, as well 
as display these levels in a similar scale 
on the same graph. The formula used is: 
 
 
 
(the signal strength of gene A in sample X) 
(the median of every measurement taken for gene A 
throughout all of the samples) 
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 The mean value of all gene 
expression data, for one given sample or 
gene, is commonly used in normalization 
since mean is correlated with standard 
deviation of that data. However in our 
dataset, there are no repeat 
measurements available for each sample. 
Moreover, the data points for a given 
gene are obtained from tissues across 
different rat brain regions. It is not 
meaningful to determine the standard 
deviation from this gene expression data, 
for a given sample or gene, and 
consequently the mean value of that data 
is not reliable. Under this condition, the 
median value of the data is less subject 
to outliers and therefore more 
representative of the overall expression 
level for all the expression data for a  
given sample or gene. Therefore, the 
median value was used for normalization 
instead of mean value in this study.  
 
Filtering 
The filtering procedure took advantage 
of a qualitative feature in the Affymetrix 
expression data files called the Absolute 
Call Metric (Affymetrix Inc., 2000). 
Using the Absolute Call we could 
eliminate transcripts that were reported 
to be absent (A) or only marginally 
present (M) as detected by the 
technology. The filter was designed to 
select only genes reported to be present  
(P) in all 5 brain regions under both 
cocaine-treated and normal brain 
conditions. After applying this filter to 
the original data, we obtained 1917 
genes that are present in all ten 
experiments. 
Schadt et al. (2000) have argued 
that filtering of genes on the basis of 
Absolute Call can be associated with 
some risk as genes with “absent” or 
“marginal” expression may be 
informative. However, the goal of our 
study was to detect differences in global 
expression pattern in cocaine exposed 
and naïve rats. Therefore, the 3140 genes 
(36% of the 8799 genes on the chip) that 
were “absent” in all samples are clearly 
not informative for our purposes. This 
left 42% of genes which were called 
“present” in between 1 and 9 of the 
samples (22% were expressed in all ten 
specimens and therefore included by the 
filter). Because of the large quantitative 
variation induced by these partially 
expressed genes, and uncertainty of how 
to represent “absent” genes in our 
model, we decided to focus on the 1917 
genes that were expressed in all samples. 
 
RESULTS AND DISCUSSION 
Prediction Accuracy   
Table 1 depicts the dramatic 
improvement in the prediction accuracy 
of the classifier due to our method as 
described in Figure 2. TP and TN refer 
to the true positive rate (sensitivity) and 
true negative rate (specificity); FP and 
FN refer to the false positive and false 
negative rate. The accuracy of each 
classifier is calculated as the percentage 
of training examples that are classified 
accurately (the number of correct 
predictions/ the number of examples 
predicted * 100). As reported in this 
table, the true positive rate (TP) for 
cocaine class prediction increased to 
98.85% in both Experiment 5 and 7. The 
accuracy of the classifiers for classifying 
the training examples increased to 
98.36% and 98.88% respectively.  
Experiment 5 and 7 yielded the most 
accurate models. The datasets used in 
these two experiments were both 
normalized sample-wise but, in 
Experiment 7, the data were also
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 Table.5.1. Comparison of the prediction accuracy of models generated by running C4.5 against different 
datasets. TP: true positive rate; FP: false positive rate; TN: true negative rate; FN: false negative rate; AC: 
accuracy. The experiment numbers are identical to those of Figure2b.  
Datasets TP (%) FP (%) TN (%) FN (%) AC (%) 
Experiment 1. raw data (8799 genes, no 
normalization and no filtering) 45.49 17.14 82.86 54.51 64.18 
normalized data (8799 genes in each dataset) 
Experiment 2. normalized per sample 
data 87.2 24.7 75.3 12.8 81.25 
Experiment 3. normalized per gene 
data 70.2 32.37 67.63 29.8 68.92 
Experiment 4. normalized per sample 
and per gene data 87.16 26.51 73.49 12.84 80.32 
normalized and filtered data (1917 genes in each dataset) 
Experiment 5. normalized per sample 
then filtered data 98.85 2.13 97.86 1.15 98.36 
Experiment 6. normalized per gene 
then filtered data 19.67 6 94 80.33 56.83 
Experiment 7. normalized per sample 
and per gene then filtered data 98.85 1.1 98.9 1.15 98.88 
Table 5.2. Results from a ten-fold cross-validation on the training set consisting of 3834 examples (1917 
genes x 2 classes). TP: true positive rate; FP: false positive rate; TN: true negative rate; FN: false negative 
rate; AC: accuracy. 
Times TP (%) FP (%) TN (%) FN (%) AC (%) 
1 98.44 3.12 96.88 1.56 97.66
2 97.92 1.04 98.96 2.08 98.44
3 96.35 2.08 97.92 3.65 97.14
4 93.75 1.04 98.96 6.25 96.35
5 97.92 2.6 97.4 2.08 97.66
6 97.4 1.04 98.96 2.6 98.18
7 98.44 3.65 96.35 1.56 97.4
8 98.44 2.08 97.92 1.56 98.18
9 97.92 3.65 96.35 2.08 97.14
10 97.4 3.12 96.88 2.6 97.14
Average 97.4 2.34 97.66 2.6 97.53
 
normalized gene-wise prior to the 
decision tree learning. This indicates that 
per sample normalization makes a 
significant difference in prediction 
accuracy in learned models. The model 
learned from Experiment 7 was selected 
as it has the smaller set of rules (17 
rules) compared with the model learned 
from Experiment 5 (37 rules).  
 
Cross-validation  
To test the robustness of the selected 
model, a ten-fold cross-validation is 
performed, wherein 10 separate runs of 
C4.5 were made using each time 90% of 
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 the relative expression data from 1917 
genes as training examples; and the 
remaining 10% as the test set of 
examples. The results with this cross-
validation were very encouraging (> 
97% accuracy on each test set). These 
results described in Table 2 lead us to 
believe that there are distinguishable 
patterns across the five brain regions in 
response to cocaine that can be modeled 
as a decision tree. Examples that are 
misclassified by a good model can also 
point us toward genes whose expression 
patterns lie in the boundary areas of the 
two classes, that is, those patterns that 
are not entirely describable as belonging 
to one class versus the other.  
 
Production Rule Model  
The production rules generated by 
C4.5rules program were carefully 
studied (Figures 3 and 4). All the rules 
for a single class appear together and the 
class subset (the group of rules for a 
single class) is ordered according to 
prediction accuracy of the rule; while the 
rule numbers are based on when they 
were generated. As in Figure 3, all the 
rules for the NORMAL class are listed 
first; then are the rules for the 
COCAINE class. The rules are applied 
to each case in the test dataset one by 
one in the listed order until the case is 
covered by a rule. The first rule that 
covers the case will be taken as the 
operative one since that is the rule with 
highest classification accuracy. During 
generation of the decision-tree, all 
training examples classified by any 
existing rule are removed from 
consideration; hence each rule in the 
rule-set will cover at least one training 
example not covered by other rules.  
Each production rule comprises 
of a left-hand side and a right-hand side. 
The left-hand side can contain tests for 
values of up to five attributes that are 
normalized gene expression values in 
five brain tissue samples. The right-hand 
side contains a classification, which is 
the name of a target class such as 
COCAINE or NORMAL. For example, 
Rule 25 in Figure 3 can be interpreted as 
follows. The left-hand side of the rule 
contains tests for values of two attributes 
which are normalized gene expression 
values in brain tissue from the Amygdala 
and Prefrontal Cortex; while the right 
side is a class name namely COCAINE. 
A test case that satisfies the left side of 
this rule is classified as COCAINE. The 
program also predicts that this 
classification will be correct for 99.7% 
of unseen cases that satisfy this rule’s 
left-hand side. This implies that 
whenever this rule is used to classify an 
unseen test case that has not been 
classified by any of the more accurate 
rules for that class, there is a 99.7% 
chance that the classification is accurate. 
Rule 17, the most generalized 
rule in the rule set that covered 1227 
genes without any misclassification 
described a pattern of global effects on 
gene expression in the five different 
brain regions under cocaine treatment 
(Figure 4). This pattern showed that 
genes are up regulated in Amygdala and 
simultaneously down regulated in the 
Prefrontal Cortex and to some extent in 
the Ventral Tegmental Area. We verified 
this pattern by the result of a clustering 
study on gene expression of the 1917 
genes using GeneSpring 4.1.  
Prior to the clustering study, the 
raw data was firstly normalized sample-
wise. Then the relative expression value 
of each gene in cocaine treated samples 
was divided by that in normal sample, 
from each brain region. These 
normalized relative expression data of a 
gene indicated the fold change in gene 
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 expression between the cocaine treated 
samples   and   normal   samples  
 
 
Figure.3. The set of rules obtained by providing 
all 3834 training examples to C4.5 and 
subsequently invoking C4.5rules to create rules 
from the learned decision tree. These rules 
provide a plausible, generalized model learned 
from the training data. The program 
automatically finds the values for normalized 
expression levels across one or more brain 
regions that in combination are predictive of 
cocaine-treated tissue or normal tissue. Each rule 
can be used to classify a certain number of 
training examples to a certain degree of accuracy 
(indicated in square brackets). The boxed rules 
did not misclassify any training example. See 
Figure 1 legend for abbreviations. 
 
 
Figure 4. Coverage of training examples (genes 
described by their expression values tagged with 
the type of tissue) by each of the rules in the 
learned rule set in Figure 3. Consider for 
example Rule 25, which was used 46 times in 
classifying the training cases. All of the cases 
that satisfied the rule’s left-hand side did in fact 
belong to class COCAINE, so this rule did not 
misclassify any example (Wrong = 0). The 
advantage of including this rule in the set of 
learned rules is indicated as 24 (24|0) – this 
means that if the rule were omitted, 24 cases now 
classified correctly by this rule would be 
classified incorrectly, and 0 cases now 
misclassified by this rule would be correctly 
classified by the subsequent rules and the default 
class; the net benefit of retaining the rule is thus 
24 = 24 – 0. Other rules could be interpreted 
similarly. (Quinlan, 1993). The confusion matrix 
(Kohavi and Provost, 1998) is shown at the 
bottom of the figure with 1.1% of examples 
incorrectly classified. The boxed rules are 
corresponding to the same rules in Figure 3. 
 
 
from each brain region. This dataset was 
filtered as described in the METHOD 
Section. This filtered dataset was 
therefore referred as the fold change 
dataset. A gene tree was built from the 
fold change dataset by using the gene 
clustering function provided by 
GeneSpring 4.1. Similarity was 
measured by spearman correlation; 
separation ration was set to 0.5; and the
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 Figure 5. Visualization of the 1917 genes present in all ten samples. Red indicates up-regulated genes and 
blue indicates down-regulated genes. The expression of these genes are shown in the following order row-
wise alternating between cocaine-treated and normal tissue; from Amygdala, Caudate Putamen, Nucleus 
Accumbens, Prefrontal Cortex and Ventral Tegmental Area.  The pattern of global effects of more than half 
of the genes being over-expressed in Amygdala; and simultaneously under-expressed in the Prefrontal 
Cortex and to some extent in the Ventral Tegmental Area is clearly visible and is described by Rule 17 in 
Figure 3. 
 
minimum distance was adjusted to 
0.001. The gene tree obtained for 
visualization (Figure 5) depicted the 
same pattern described by Rule 17 and 
provided a strong evidence for the 
existence of that global effect.  
Apart from the model, we listed 
and annotated genes covered by each 
rule using Gene Ontology terms  from 
the TIGR Rat Gene Index. The Gene 
Ontology annotation provides insightful 
information for a gene categorized as: 
the cellular component a gene belongs 
to, its molecular function, and the 
biological process associated with the 
gene (The Gene Ontology Consortium, 
2000). The Gene Ontology based 
annotation of the genes covered by each 
rule and the normalized dataset are made 
available publicly at 
http://www.pitt.edu/~chmst40/ratdata/ .  
We also studied many of the 
genes obtained from the rules that do not 
misclassify any of the training examples 
(the boxed rules in Figure 3). Many of 
the genes covered by these rules are 
implicated in signal transduction 
mechanisms. For example, the HPC-1 
gene covered by Rule 30 was up 
regulated in both Amygdala and Caudate 
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 Putamen. HPC-1 antigen may play a role 
in neurotransmitter release from nerve 
terminals by associating with omega-
CgTX-sensitive N-type calcium channel 
and synaptotagmin (Yoshida et al., 
1992). This reinforces the general belief 
that several signal transduction pathways 
are activated from the receptor/cell 
surface to the nucleus and back that 
regulate the behavioral circuits in the 
brain leading to the kinds of response 
seen in animals exposed to drugs.  
 
CONCLUSIONS  
Methods for visualization and analysis 
of large, high throughput gene 
expression datasets remain an important 
area of research. In this paper we present 
such a method based on classical 
supervised machine learning. In 
particular, we have successfully used the 
well known decision tree learning 
program C4.5 to analyze global effects 
of acute cocaine exposure in the rat 
brain. The program was able to generate 
highly accurate, human-understandable 
rules that could distinguish cocaine 
exposed and naïve rat brains on the basis 
of gene expression data and which were 
consistent with Spearman correlation 
based statistical clustering analysis on 
differently normalized gene expression 
data from a same set of genes.  
Our methodology of 
normalization and filtering ensured the 
success of decision tree learning. The 
importance of normalization and 
filtering however, is not unique to 
decision tree learning or this study, it is a 
critical step first step in analysis of all 
large gene expression data sets no matter 
which analytic approach is used. 
In order to develop suitable 
treatment options for drug abuse, science 
will need to establish whether the effects 
of drugs such as cocaine are due to local 
or global changes in gene expression 
across the various brain regions. Our 
experiment establishes one such 
interaction among the Amygdala and the 
Prefrontal Cortex that could be very 
useful in this understanding.  The 
Amygdala region of the brain is typically 
associated with fear and emotion 
(Agglenton, 2000); while the Prefrontal 
Cortex is associated with long-term 
memory, planning and multi-tasking 
(LeDoux, 1996). The simultaneous 
down-regulation of more than a 
thousand genes in the PFC region and 
up-regulation of the same genes in the 
Amygdala is a likely contributor to 
reinstating drug-seeking behavior due to 
short-term reward or stimulus. Previous 
studies have implicated both 
dopaminergic as well as non-
dopaminergic systems as being involved 
in drug abuse and addiction (Lucas et al., 
1997; Bhat and Baraban, 1993). This 
study suggests that there are strong 
global effects of interaction among brain 
regions due to the exposure to a drug. 
Treatment measures designed to 
counteract these global effects might be 
more successful than those that consider 
only local effects of drug exposure. 
In conclusion, we have demonstrated 
that the decision tree learning method 
can accurately learn from microarray 
gene expression data and can generate a 
human-understandable model that can be 
used for prediction. The model learned 
from the gene expression data of rat 
brain with or without cocaine treatments 
describes a global change of gene 
expression due to acute cocaine 
treatment. This model provides evidence 
for the existence of global effects of 
cocaine in the rat brain, implicates the 
interaction of different brain regions 
under cocaine treatment, and gives 
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 insightful information for the treatment 
of drug abuse. 
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